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Abstract 
Due to ever increasing pressure for pharmaceutical companies to characterise and 
patent the polymorph landscape of new APIs, it is important that as many forms as 
possible are identified in the early stages of drug development. Novel polymorph 
screening techniques are required to expand the scope of traditional solution-phase 
methods, and access highly metastable or difficult to nucleate solid forms. This work 
exemplifies a modern polymorph screen, using a wide variety of experimental and 
computational methods to comprehensively characterise the polymorph landscape of 
mexiletine hydrochloride. Instead of the six forms described in previous literature, this 
screen revealed seven: an enantiotropic pair of anhydrous polymorphs that are stable 
at different temperatures, one anhydrous metastable form, three families of 
isostructural channel solvates, and a fourth solvate of unknown structure. Two new 
channel solvates, and new routes to three known forms were discovered by 
crystallising mexiletine within drug-mimetic supramolecular gels. As gelation was 
often turned off when a new polymorph crystallised within the gel, these changes in 
solid form are likely driven by strong interactions between the drug and gelator. The 
crystallisation of high temperature stable Form 2 from a gel at room temperature is a 
particularly striking example of the powerful stabilising effect of these tailored 
supramolecular gels. A complementary study into the gel-phase crystallisation of 
diatrizoic acid showed that the drug followed the same two-step crystallisation regime 
as the gelator, leading to the formation of two novel drug-gelator salt solvates. These 
results suggest that the polymorph landscape of the gelator has influenced the drug 
crystallisation, which may provide a new avenue of inquiry for the design of 
supramolecular gelators for pharmaceutical crystallisation. From this work, it is clear 
that supramolecular gels are a valuable tool for pharmaceutical polymorph screening. 
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1. Introduction 
1.1  The solid-form landscape of small molecules 
Famously defined by McCrone in 1965, the term polymorph refers to “a solid 
crystalline phase of a given compound resulting from the possibility of at least two 
different arrangements of the molecules of that compound in the solid state”.1 The 
term was first coined by Mitscherlich in 1822, during his study of the solid forms of 
various inorganic salts.2 The first example of polymorphism in an organic molecule 
was benzamide, reported by Liebig and Wohler in 1832.3 This compound has three 
known forms, which sequentially crystallise from solution in order of increasing 
thermodynamic stability.4 The first crystal structure of benzamide was recorded in 
1959, belonging to the stable form,5 but the other metastable structures were not 
determined until 20056 and 2007,4 following the development of more efficient X-ray 
diffraction techniques.   
Other landmark discoveries in this field include the first reports of conformational,7 
disappearing8 and concomitant9 polymorphs, and increased understanding of the 
thermodynamics of polymorphism10, 11 and the phase transitions between forms.12 The 
application of polymorphism to pharmaceuticals13 was a further catalyst that rapidly 
increased interest in this topic. Ground-breaking cases including ritonavir,14, 15 
aspirin16-18 and the litigation surrounding Zantac’s polymorphism19, 20 led to the 
development of a wide range of modern theories, practices and applications of 
polymorphism.  
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In addition to anhydrous, crystalline polymorphs, there are a wide range of other 
structures that make up the solid-state landscape of a compound. If the molecules are 
arranged without any long-range order, the structure is described as amorphous.21 Due 
to a lack of structural order, amorphous forms are significantly higher in energy than 
their crystalline counterparts. Coupled with very low intermolecular interactions 
within the structure, these properties make amorphous forms extremely soluble.22 All 
other solid forms fall under the umbrella of crystalline, multi-component systems 
(Figure 1.1). There has been significant debate in the literature regarding the 
classification of multi-component systems, particularly in the context of 
pharmaceutical regulation.23 Neutral multi-component crystals are termed solvates if 
one of the components was used as a solvent during the crystallisation. If the solvent 
is water, these structures are termed hydrates. When neither component is a solvent, 
multi-component crystals are called co-crystals.24 Solvates, hydrates and co-crystals 
can exhibit different stoichiometries and degrees of interaction between the 
components. In some cases, the second component is an integral part of the structure 
with strong interactions between molecules, and a precise stoichiometry. In others, 
termed inclusion compounds, the components do not interact strongly and do not have 
a defined stoichiometry. One component is often accommodated in voids or channels 
within the crystal structure of the other and in some cases, the guest component is 
highly disordered. These two arrangements lead to very different physical properties.25 
In any of these multi-component systems, if the component molecules are formally 
charged, the structure is described as a salt. Ionic co-crystals, also known as co-crystal 
salts, are subtype of charged multicomponent crystals in which a cation, anion and 
another neutral molecule crystallise together.26, 27 All types of multicomponent crystal 
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can also exhibit polymorphism, and there is therefore a very diverse landscape of 
possible forms to explore for a given compound.24  
 
Figure 1.1: Proposed classification system for pharmaceutical solid forms by Grothe et al. 
Reproduced from reference 24 with permission. Copyright 2016, American Chemical Society. 
1.2  Crystallisation Mechanisms 
It is widely agreed that crystallisation occurs via two main steps: nucleation and 
growth. Nucleation refers to the aggregation of molecules into an ordered cluster large 
enough to overcome the tendency to re-dissolve. This step constitutes the spontaneous 
formation of a new phase, and therefore must occur under non-equilibrium conditions. 
In solution crystallisation, this means that the solution must be supersaturated.28 There 
are two types of nucleation. Primary nucleation occurs where there are no crystals of 
the product initially present in the solution. It can be divided into two categories: 
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homogeneous, where nucleation is not influenced by the presence of added solids, and 
heterogeneous, where the rate of nucleation is increased by the addition of foreign 
particles. In practise, the former is rare due to the large energy barrier to spontaneous 
nucleation. Secondary nucleation is initiated by the presence of crystalline seeds in the 
solution.29 
Classical nucleation theory assumes that nuclei are formed by the combination of 
individual molecules, one by one until the cluster reaches the critical radius (Figure 
1.2). However, this model ignores the possibility that multiple sub-critical clusters 
may combine in order to form the nucleus, or that multiple molecules may incorporate 
at once.28, 29 Two-step nucleation theory provides a more comprehensive model in 
which the molecules first aggregate into disordered, liquid-like clusters analogous to 
a colloid. In the second, rate-determining step, these clusters then rearrange to produce 
an ordered, crystalline nucleus (Figure 1.2). This model has since been supported by 
theoretical calculations, computation and experiments.28, 30 
 
Figure 1.2: Classical and two-step nucleation pathways: (a) supersaturated solution; (b) ordered 
sub-critical cluster of solute molecules, proposed by classical nucleation theory; (c) liquid-like cluster 
of solute molecules, proposed by two-step nucleation theory; (d) ordered crystalline nuclei; (e) solid 
crystal. Reproduced from reference 28 with permission. Copyright 2009, American Chemical Society. 
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Once a stable nucleus has formed from a supersaturated solution, a macroscopic 
crystal begins to grow by continuously incorporating molecules from the solution into 
the lattice. There are several factors that influence crystal growth: the rate of diffusion 
within the solution, the rate of adsorption onto the surface of the crystal, and the 
surface energy of the crystal. Crystal growth occurs by the continual deposition of 
solute from solution into a loosely bound adsorption layer on the crystal surface, in 
which molecules are free to move over the surface of the crystal, before binding into 
the crystal lattice where attractive forces are highest.31, 32 Therefore, the kinetics of 
crystal growth are controlled by which step is slower, the transport of molecules 
through solution to the face of the crystal, i.e. diffusion, or the incorporation of these 
molecules into the lattice, i.e. adsorption. Which of these is the slower, rate-
determining step depends on the degree of supersaturation of the surrounding 
solution.33 The morphology of the resulting crystal is controlled by its surface energy, 
as well as the kinetics of long-range transport processes within the solution. The 
equilibrium morphology of a crystal is the shape with the lowest possible surface 
energy and therefore, the minimum Gibbs free energy. This morphology can be 
derived from the classical Wulff construction although in reality, equilibrium 
morphologies are observed rarely, and the kinetically controlled growth morphology 
is more common.34   
Classical nucleation theory states that the dominant factors determining the rate of 
crystal nucleation are temperature, interfacial tension, and degree of supersaturation. 
The importance of supersaturation indicates that there is a link between the solubility 
of a polymorph and its rate of nucleation.29 The most thermodynamically stable 
polymorph has the lowest solubility in the surrounding liquid. Plotting the solubility 
curves of a compound’s polymorphs reveals whether the system is enantiotropic or 
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monotropic (Figure 1.3).  Two polymorphs are monotropic if their solubility curves 
do not cross each other. In this case, the one with lowest solubility is most stable. 
Conversely, the system is enantiotropic if the solubility curves cross at a transition 
temperature, Tr, lower than the melting point of the two polymorphs. In this case,  the 
relative stability of the two polymorphs depends on the temperature and concentration 
of the solution.35  
 
Figure 1.3: Solubility curves for a monotropic and an enantiotropic system. 
This stability relationship means that, due to its lower solubility, a supersaturated 
solution of a given concentration will be most supersaturated with respect to the 
thermodynamic form. Thus, the critical nucleus size will be lower and the rate of 
nucleation will increase.29 However, nucleation is a kinetic process, so in practise, this 
statement is not always true.36 In fact, Ostwald’s rule of stages says that a chemical 
system does not necessarily tend towards equilibrium, but towards the metastable state 
closest in energy to its current form. Therefore, crystallisation of the thermodynamic 
form occurs in steps via a series of metastable forms, with each step inducing a 
minimal change in free energy.37, 38 This behaviour has often been observed 
experimentally.39-41  
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Solubility curves can also be helpful to understand the conditions under which 
nucleation is possible (Figure 1.4). 
 
 
 
 
 
 
 
 
 
Figure 1.4: Schematic solubility and supersolubility curves for one crystal form. 
Spontaneous primary nucleation is only possible in the labile zone. The number of 
nuclei formed corresponds to the proximity of the experimental conditions to the 
boundary of the labile zone (Figure 1.5). Few nuclei are formed close to the boundary, 
whereas many can be formed if the system is more supersaturated. Nucleation stops 
when the concentration crosses the supersolubility curve, and crystal growth then 
occurs in the metastable zone. Once sufficient solute has been incorporated into 
crystals, the system enters the stable zone where the crystal and solution are in 
equilibrium, and no further transformation occurs. The thermodynamic stability of the 
target polymorph dictates the most effective strategy for its production. Crystallisation 
of a thermodynamically stable form requires the system to remain at, or close to, 
equilibrium at all times. Few nuclei are formed by concentrating the solution just over 
the supersolubility limit, and the crystals are then allowed to grow slowly by gradual 
cooling of the solution, ensuring a lot of time is spent in the metastable zone. These 
are referred to as “thermodynamic conditions” and produce few, large crystals (Figure 
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1.5). Conversely, metastable forms are produced under “kinetic conditions”, in which 
the system is far from equilibrium. In this method, the solution is highly 
supersaturated, producing many nuclei of the kinetic form, and then crash cooled, 
limiting the time in the metastable zone and preventing a transition into the 
thermodynamic form. These conditions typically produce a larger number of smaller 
crystals (Figure 1.5).42, 43 In any crystallisation experiment, Ostwald ripening can take 
place after the first crystals have formed. In this process, smaller crystals dissolve and 
the solute molecules incorporate into the existing larger crystals, causing them to grow 
further, and often favouring the production of the thermodynamic form. This process 
reduces the surface energy of the system and therefore its overall free energy.44  
 
Figure 1.5: Thermodynamic vs. kinetic crystallisation. 
Although there are numerous theories to describe the driving forces behind crystal 
growth and polymorphism, less is understood about the formation of solvates. A recent 
computational study suggests that the key criterion for solvate formation is the 
presence of a solute-solvent affinity, in excess of the solute-solute and solvent-solvent 
affinities. The affinity between solute and solvent does not have to be particularly 
high, so long as it is greater than the others. Even solvent-phobic molecules can be 
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encouraged to form solvates if this results in a decrease in Gibbs potential, due to an 
increased packing efficiency or high atmospheric pressure.45 
1.3  Characterising solid form 
As with any problem of structure determination, single-crystal X-ray diffraction 
remains the gold standard.46 However, significant challenges are encountered in 
growing diffraction-quality crystals. Most common approaches to growing large 
single crystals involve crystallising the substance very slowly.47 Clearly this method 
is unsuitable for metastable polymorphs because they will transform into a more stable 
structure over time.48  
A more widely applicable method is powder x-ray diffraction (PXRD), which 
provides a unique fingerprint of a polymorph without demanding the growth of single 
crystals. This technique is appropriate for metastable forms as any crystallisation 
procedure can be applied, and the experimental run-time is relatively short, meaning 
that metastable forms have less time to transform.48-51 In addition to the identification 
of different polymorphs, PXRD can also be used to quantitatively determine the degree 
of crystallinity and the composition of mixtures. This technique is particularly useful 
in the pharmaceutical industry because drug formulations are typically mixtures.52  
Spectroscopic analyses such as infra-red (IR) and Raman give information on the 
chemical nature and environment of molecules in a crystal. They benefit from being 
non-destructive and highly sensitive to changing intermolecular interactions such as 
hydrogen bonds. However, their resolution is often insufficient to distinguish between 
polymorphs. If two polymorphs are distinguishable by spectroscopy, valuable kinetic 
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information can be gained by monitoring the spectral changes that correspond to the 
transition between forms.48, 50, 51, 53 
Solid-state NMR (SS NMR) facilitates a more quantitative analysis. Although 1H 
SS NMR is not feasible due to extreme line-broadening caused by homonuclear 
coupling, 13C, 15N and 31P SS NMR allow precise compositional analysis of mixtures 
and can be used to distinguish between polymorphs. This technique can even be used 
to characterise an API within the final dosage form.54-57  
The relative stability and transitional behaviour of a polymorphic system can be 
characterised using thermal techniques, predominantly differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA). TGA records changes in 
the mass of a sample with heating. It is useful for characterisation of solvates and 
hydrates, as the mass deficit corresponds to the proportion of solvent originally 
incorporated in the crystal. Sublimation and decomposition can also be identified by 
a much larger mass loss. DSC measures the difference in power required to maintain 
a sample and a standard at the same temperature, which can be used to identify phase 
transitions within the sample, including melting, crystallisation, glass transitions, 
crystal-crystal transformations, and desolvation. These transitions appear as peaks in 
the DSC thermogram and the area under these curves corresponds to the enthalpy 
change of the transition. DSC is the predominant method used to establish the 
thermodynamic relationships between polymorphs.48, 50, 51, 58, 59 
Hot-stage microscopy is often used in conjunction with thermal analyses and offers 
a quick and simple route to both the production and characterisation of polymorphs 
that are accessible by a change in temperature.60, 61 Temperature cycling can be used 
to identify solvates, transition temperatures, stability relationships and crystallisation 
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kinetics, giving physical context to the thermodynamic data obtained by DSC. 
Similarly, structural information such as crystal habit and dimensions can be gained 
from observation of the crystals under crossed polarisers.48, 50, 51  
1.4  Polymorphism in Pharmaceuticals 
The polymorphs of a compound can display different physical and chemical 
properties including heat capacity, density, hardness, crystal habit, colour, thermal 
phase transitions, solubility, dissolution rate, stability and hygroscopicity.62 In a 
pharmaceutical context, the majority of active pharmaceutical ingredients (APIs) are 
produced using some kind of crystallisation process, so controlling polymorphism is 
of particular importance to drug development. The uncontrolled emergence of a new 
solid form can significantly impair the processing, manufacture, storage, 
administration and efficacy of the drug as a result of different physical and chemical 
properties.63, 64 Changing the solid form of an API can also be used to improve the 
performance of a formulation.65 Modern drug candidates are often poorly 
water-soluble,66 so using a different polymorph can overcome this problem without 
having to change the chemistry of the molecule.67 Some drug polymorphs have been 
shown to display more than a four-fold increase in solubility compared to the least 
soluble form,68 and amorphous forms can offer even more.22  
A classic example showing the importance of polymorph control in 
pharmaceuticals concerns the HIV-protease inhibitor ritonavir, marketed by Abbott in 
1996 (Figure 1.6). During development only one polymorph, the structure now termed 
Form I, was known. After two years on the market, Form II was discovered when the 
capsules began to fail quality assurance tests due to decreased solubility. The large 
difference in solubility between these two forms derives from a difference in crystal 
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packing.14 The molecule adopts a different conformation in each form, and they are 
therefore termed “conformational polymorphs”.69 In Form I, the amide bonds are 
arranged in a trans conformation whereas in Form II they are cis. Due to a stronger 
hydrogen-boding network, the cis structure is more stable, and therefore less soluble. 
However, this form is extremely difficult to nucleate because it is preceded by an 
unfavourable conformation in solution, which explains how it remained undiscovered 
throughout the entire drug development process.15 Due to the high thermodynamic 
stability of Form II, once it did nucleate, all samples of Form I began to transform into 
Form II, and this process was irreversible due to the formation of seeds of Form II 
throughout the manufacturing facility.8 These difficulties resulted in the product being 
withdrawn from the market and reformulated, at an extremely significant cost and with 
widespread disruption to the treatment of HIV patients.14 In 2003, a high-throughput 
polymorph screen of ritonavir identified five solid forms, three of which were 
previously unknown. It was also shown that a new solvate could easily be converted 
to the disappearing polymorph, Form I.70 These results show the importance of 
thoroughly polymorph screening any new API before releasing it to market, to ensure 
the most desirable solid form is used, and any stability problems have been addressed.  
 
Figure 1.6: (a) The structure of ritonavir, and (b) crystals of Form I and II of ritonavir. Image (b) was 
adapted from reference 15 with permission. Copyright 2001, Springer Nature. 
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Ritonavir was the first example of this phenomenon to occur whilst a product was 
on the market, and it rapidly drew attention to the topic of drug polymorphism. As a 
result, significantly stricter regulations were implemented surrounding the production 
of polymorphic pharmaceuticals, and companies are now required to exhaustively 
screen the solid-form landscape of all potential drugs.71, 72 Due to the Hatch-Waxman 
Act, which allows generic drug companies an expedited application process when 
reproducing a previously approved product,73 pharmaceutical companies face 
significant pressure to legally protect their inventions. Given the increased regulatory 
requirements surrounding solid forms, it has become common practise for companies 
to patent not only the drug substance itself, but its individual solid forms. These patents 
can be extremely valuable, and infringement cases surrounding the polymorphism of 
competing formulations are common.74  
In addition to the increased interest in drug polymorphism, there has also been a 
more recent focus on the use of co-crystals75 and amorphous forms76 to improve the 
properties of a pharmaceutical formulation. Novel drug candidates frequently suffer 
from poor water solubility,66 so using a co-crystal77-79 or amorphous form22, 80 offers a 
route to improving the bioavailability of an API when none of its polymorphs have 
suitable properties. Traditionally, poor water solubility was overcome by formulating 
the API as a salt, so the use of other solid forms offers an alternative for molecules 
with no ionisable groups.25, 81, 82  
A key method of increasing the bioavailability of poorly water-soluble drugs is to 
generate and maintain a supersaturated solution of the drug within the GI tract, a 
concept commonly described as the “spring and parachute” approach. The high 
solubility of the amorphous form generates a rapid increase in supersaturation of the 
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API, and this is termed “the spring”. Excipients are then used to prevent crystallisation 
and maintain the supersaturated solution for long enough to allow the drug to be 
absorbed, and this is termed “the parachute”.83 This model can also be adapted to 
explain the increased solubility of pharmaceutical co-crystals (Figure 1.7). The co-
crystal first dissociates into amorphous or nanocrystalline drug clusters, which exhibit 
extremely high solubility and provide “the spring”. These clusters then transform into 
crystalline states of increasing thermodynamic stability, according to Ostwald’s rule 
of stages. These transformations result in a gradual reduction in solubility, which 
maintains the supersaturated solution for as long as possible and allows more time for 
the drug to be absorbed. 84  
 
Figure 1.7: Dissolution profiles for a crystalline (pink) and co-crystalline (red) drug, showing the 
spring and parachute effect that is responsible for the greater solubility of co-crystalline 
pharmaceuticals. Reproduced from reference 84 with permission. Copyright 2011, American 
Chemical Society. 
The first co-crystalline drug, Entresto, was launched by Novartis in 2015.85 Since 
then, the FDA have developed new regulations regarding pharmaceutical co-crystals 
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that classify them as equivalent to a polymorph of the API for regulatory purposes.86 
This change has made the approval of co-crystalline drugs significantly easier and has 
encouraged the development of many of these formulations.87, 88 Co-crystals 
containing multiple APIs are also emerging, and function as dual-purpose 
formulations89 that have shown superior performance in early clinical trials.90  
Amorphous drugs are thermodynamically unstable, and whilst this can be 
extremely beneficial for improving the solubility of an API, it also means they have a 
tendency to transform into a much less soluble crystalline polymorph.  Therefore, 
amorphous drugs must be stabilised in order to ensure their properties remain constant 
throughout their shelf life. Stabilisation methods typically rely on the physical 
separation of drug molecules, which prevents them aggregating to form a crystal. 
Typical methods include the formation of solid dispersions with an inert matrix, 
coating the amorphous particles in a thin layer of an inert polymer, and adsorbing the 
amorphous material onto a porous substrate.91-94 The presence of a secondary 
amorphous material, whose molecules are strongly bound to the drug by 
intermolecular interactions, can also provide a barrier towards recrystallisation by 
preventing the drug molecules from aggregating together. These are termed 
co-amorphous forms.95, 96 Due to their inherent instability, there are very few drugs 
formulated as a pure amorphous API, but stabilised amorphous formulations are 
common and set to increase.97 
Due to the direct relationship between the solid-form landscape of an API and its 
pharmaceutical properties, manufacturability, shelf life, patentability and financial 
value, there has been significant research into the understanding and control of 
pharmaceutical solid form. The end goal of this research is to predict and control the 
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solid form of a new API. Achieving this goal would ensure that a new pharmaceutical 
product contains the most desirable polymorph, and that the formulation is optimised 
to overcome any shortcomings in the properties of that solid form. A key area of 
research towards this goal concerns new polymorph screening techniques, which can 
be used to characterise the solid-form landscape of an API accurately and efficiently. 
1.5  Traditional Polymorph Screening Techniques  
The aim of any polymorph screen is to thoroughly explore the solid-form landscape 
of the target compound by recrystallisation under as many conditions as permitted by 
the available time, material and resources.98 By varying experimental conditions, the 
speed of crystal nucleation29 and growth32 can be controlled, and the resulting crystals 
should represent a range of thermodynamic and kinetic products, ensuring the most 
suitable form can be selected for the desired application. 
Solution crystallisation is the most common technique used in polymorph 
screening, due to its experimental simplicity. Typical solution-phase methods include 
cooling crystallisation, evaporation, and anti-solvent addition.99 Although the nature 
of the solvent is often the dominant factor in determining the outcome of a 
crystallisation,100-103 other parameters can also be varied to generate different solid 
forms, including the drug concentration, crystallisation temperature, the rate of 
cooling, evaporation or anti-solvent addition, the pH, and whether the system is 
agitated during crystallisation.104-107 As a general rule, slow crystallisations involving 
mild conditions are more likely to yield a thermodynamically stable form, whereas, 
rapid crystallisations involving harsh conditions are more likely to produce metastable 
solid forms.99 Metastable structures can be converted to the stable form by slurrying 
in an inert solvent via the process of solvent-mediated polymorphic transition. This 
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mechanism involves three consecutive steps. First, the metastable form dissolves in 
the solvent until its concentration exceeds the solubility limit of the stable form. At 
this point, the stable form spontaneously nucleates from solution and then begins to 
grow. The growth step occurs concurrently with dissolution and continues until the 
metastable form has completely transformed. This process can be used to transform a 
wide range of solid forms including polymorphs, solvates and salts, and can also be 
used to crystallise amorphous forms. As such, it is commonly used in polymorph 
screening to assess the stability of a particular form.108, 109 
Mechanochemistry, or “chemical reactions that are induced by the input of 
mechanical energy”, is another common technique for the production and 
interconversion of specific polymorphs (Figure 1.8). Although the definition 
encompasses reactions in any state of matter, the most common application of this 
method involves solid reagents.110 There are two major mechanochemical techniques 
used in pharmaceutical solid form screening: neat and liquid-assisted grinding. On a 
small scale, these processes can be carried out in a mortar and pestle. In neat grinding, 
the pure solid reagents are ground together, whereas liquid-assisted grinding involves 
the addition of a small volume of solvent, which increases the rate of reaction by 
increasing the conformational freedom of the molecules and the opportunity for 
collisions between components.111 On a larger scale or for greater efficiency, a ball 
mill can be used to undertake these reactions. There are a wide range of parameters 
that can be varied to change the polymorph obtained by mechanical grinding, 
including the stoichiometry of starting materials, the temperature, the volume and type 
of solvent, the grinding time, frequency and force, and for ball milling, the size, shape 
and composition of the ball.112-115 
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Figure 1.8: Forms I and II of the caffeine-anthrailic acid co-crystal produced by liquid-assisted 
grinding, originally published by Madusanka et al.115 Image adapted from reference 110 with 
permission from The Royal Society of Chemistry. 
Thermal techniques are crucial in polymorph screening, both for the 
characterisation and discovery of new solid forms. DSC and hot stage microscopy can 
be used to identify crystal-to-crystal transitions.116 If the system is enantiotropic, there 
are two forms that are thermodynamically stable at different temperatures. The high 
temperature stable form can be obtained by heating the low temperature stable form 
above its transition temperature. If the system is monotropic, only one polymorph is 
thermodynamically stable at all temperatures. In this case, heating a metastable 
polymorph at any temperature will generate the stable form.36 Thus, heating each 
known polymorph can be a valuable method of discovering new forms. Sometimes, 
the same crystal can be used for subsequent characterisation of the new polymorph but 
often, molecular reorganisation causes the crystal to crack.117 A better-quality crystal 
can be grown using solution-phase methods at a temperature above the crystal-to-
crystal transition temperature.107 The applicability of this method is limited by the fact 
that the boiling point of the solvent must exceed the transition temperature so the 
solvent does not boil off.  
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If no suitable solvent can be found, sublimation provides an alternative method to 
access high temperature stable polymorphs (Figure 1.9). Approximately two thirds of 
all organic compounds display a direct transition from the solid to gas phase upon 
heating.118 For these compounds, the vapour can recrystallize as a different 
polymorph. The polymorphic outcome of this crystallisation predominantly depends 
on the sublimation temperature. Other important factors include the heating rate, 
pressure, the presence or absence of solvent vapour, and the distance and temperature 
gradient between the sublimation and crystallisation surfaces.99, 119  
 
Figure 1.9: Apparatus used to selectively crystallise the two polymorphs of succinic acid both under a 
nitrogen atmosphere and in the presence of solvent vapour. Reproduced from reference 119 with 
permission. Copyright 2012, Elsevier. 
In general, metastable forms are favoured by lower crystallisation temperatures, as 
the gas crystallises immediately upon contact with the cool surface, which kinetically 
traps the metastable structure.37 Often, crystals grown by sublimation do not contain 
solvent because the sublimation temperature exceeds the boiling point of the solvent. 
This technique can therefore offer a route to pure forms of a compound that typically 
exists as a solvate. However, crystals formed by sublimation often have many defects 
and can be of low quality due to the high temperature causing increased molecular 
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motion. A slow growth rate and an extremely clean crystallisation surface (to decrease 
nucleation) can help to grow fewer, better-quality crystals.120 For compounds that do 
not sublime, crystals can also be grown from the melt by controlled heating and 
cooling. As with sublimation, the polymorphic outcome is strongly influenced by the 
heating and cooling rate. Rapid cooling can kinetically trap metastable polymorphs, 
whereas slow cooling allows time for the molecules to reorganise into the 
thermodynamic form.121 Cooling too quickly can entirely prevent the self-assembly of 
molecules into a defined crystal lattice and generate an amorphous form.122  
Incorporation of these thermal techniques into the polymorph screen of an API can 
provide insight into the relative stability of the known polymorphs and facilitate the 
discovery of further high-energy forms. This knowledge is important to minimise the 
risk of an unwanted change in polymorph later in the product lifetime. Solvated forms 
are also common in pharmaceutical development, where the pure API has undesirable 
properties. It is therefore important to include experiments targeting these forms in a 
comprehensive polymorph screen. The stability of a solvate is dependent upon its 
environment therefore, changing its environment can bring about a change in solid 
form. For example, a solvate may be the most thermodynamically stable form whilst 
in contact with its solvent, but once removed from the liquor, the structure could 
become highly metastable, causing it to transform. Important variables in solvate 
stability include the nature and concentration of solvent in the environment, the 
temperature, pressure, and for hydrates, the relative humidity.123 Solvated and 
anhydrous polymorphs can be interconverted by varying these parameters to either 
add or remove solvent from the structure. 
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The most obvious method of hydrate formation is crystallisation from water,124 but 
this is not always possible due to poor water solubility. An alternative method is to 
crystallise a metastable polymorph from an organic solvent and to expose it to water 
vapour to initiate a transformation to the more stable hydrate. This transition can 
sometimes be reversible, in which case the anhydrate is re-formed by heating the 
hydrate to remove water.125 Solvate formation is an analogous process and can be 
achieved directly by crystallisation from the desired solvent. Other forms can also be 
transformed into a solvate by slurrying in the solvent or exposure to its vapour.126 
Solvent molecules can be removed from solvates and hydrates by heating the material, 
exposing it to reduced pressure or decreasing the relative humidity. Depending on how 
the solvent is incorporated into the crystal structure, the desolvate may sometimes 
retain the structure of the solvate (Figure 1.10). These structures are often highly 
metastable due to the loss of stabilising intermolecular interactions with solvent 
molecules, and the introduction of voids within the structure.127 It is common for 
desolvates to retain a structure analogous to that of the solvate,128 but this is not 
necessarily the case, and they can adopt completely different packing arrangements. 
Desolvation, especially when done very quickly, can also generate amorphous forms 
when the crystal structure permanently breaks down following the removal of 
stabilising solvent molecules.129  
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Figure 1.10: Crystallisation of desolvated forms of methyl cholate that bear a structural resemblance 
to their solvated analogues. Reproduced from reference 128 with permission. Copyright 2017, 
American Chemical Society.  
A pharmaceutical polymorph screen typically incorporates a selection of 
experiments from each of these areas to address all aspects of the solid-form landscape 
and give a reliable estimation of the API’s behaviour under a range of conditions. The 
most simple and reliable experiments are often selected to give a comprehensive 
characterisation using as little time and material as possible. However, there is a range 
of more sophisticated crystallisation techniques that can be used to access highly 
metastable or difficult to nucleate solid forms that may not be accessible using 
traditional methods. As these modern methods develop, it is likely they will become 
more common in industry, widening the scope of current polymorph screening 
methodology.130 
  
23 
 
1.6  Modern Crystallisation Techniques  
In the pharmaceutical industry, the most favourable of an API must be identified as 
quickly as possible to minimise delays in marketing the product. For this reason, it is 
important to develop efficient polymorph screening techniques. The largest 
development in this field has been the advent of automated, high-throughput screening 
techniques. Although they are predominantly applied to the discovery of novel 
polymorphs, these methods can also be used to characterise a wide range of solid forms 
including salts, hydrates, solvates and co-crystals. A high-throughput crystallisation 
system typically consists of hardware and software that is used for the design of 
experiments, handling of materials, execution of crystallisation protocols, 
characterisation of results, and analysis of data.131 They typically rely on the same 
solution-phase crystallisation techniques as traditional polymorph screening, but 
high-throughput systems can rapidly access a larger parameter space using less 
material. This method is significantly more efficient and can generate a wider range 
of solid forms.132 The small sample size required for high-throughput screening makes 
it particularly suitable for the early stages of pharmaceutical development. However, 
the wide range of accessible parameter space means a large library of data can be 
generated for the target API, allowing the successful crystallisations to be optimised 
and scaled up for subsequent stages of development.133-135  
In addition to solution-phase methods, there are several alternative techniques to 
control the polymorphic outcome of a crystallisation. Based on the suggestion that 
different polymorphs form structurally distinct nuclei,136 many techniques focus on 
controlling the nucleation step of the crystallisation. Homogeneous or soluble 
additives can promote, impede or inhibit the nucleation of a particular form, and 
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determine which polymorph is produced.137 Polymorph selection can be achieved by 
a range of different mechanisms, and more than one is generally observed in each 
crystallisation. Common mechanisms include influencing the structure of a pre-
nucleation cluster, stabilising a particular nucleus once it is formed, and promoting the 
growth of one crystal face over another in order to influence the resulting crystal habit 
(Figure 1.11).138, 139 The strength of interaction between the solute and the additive is 
a key factor in determining its ability to influence nucleation.  The additive must be 
able to disrupt the formation of solute clusters and therefore requires a strong 
interaction with the solute. Often, this interaction is achieved by mimicking a 
structural feature of the solute in the additive.140 In addition to polymorph selection, 
additives can also be used to influence the habit, solvent content and stereochemistry 
of a crystal, all of which are extremely important in determining the physical and 
chemical properties of the resulting material.141, 142 
 
Figure 1.11: Schematic diagrams to show the adsorption of various face-selective, soluble additives 
onto a crystal. (a) The specific adsorption of ions of low molar mass additives, (b) the unspecific 
adsorption of polyelectrolytes and, (c) the specific adsorption of block copolymers with a short 
polyelectrolyte block. Reproduced from reference 139 with permission from The Royal Society of 
Chemistry.  
25 
 
As well as homogeneous systems, the addition of heterogeneous impurities has 
been shown to offer polymorph control via selective nucleation of a specific form. 
Seeding a supersaturated solution with crystals of the target form is a well-known 
method of polymorph control that is commonly used in large-scale manufacture. The 
polymorphic purity of the seeds is an extremely important factor in determining the 
success of this technique, as a small trace of an unwanted polymorph can induce 
crystallisation of that form.143 This problem is particularly serious if the seeds are 
introduced unintentionally, as was the case with ritonavir.15 However, simply adding 
seeds to any crystallisation is not sufficient to generate the desired polymorph reliably 
and with high purity. Instead, the conditions must be tightly controlled to ensure that 
the secondary nucleation rate of the desired form exceeds the primary nucleation rate 
of any unwanted forms.144 In addition to seeding with crystals of the solute, the same 
effect can be produced using a different compound that is isostructural with the desired 
polymorph.145  
A range of other heterogeneous additives can also be used to initiate nucleation and 
exert control over the polymorphic outcome of a crystallisation. Most commonly, 
these additives are insoluble polymer beads (Figure 1.12). The ability of the polymer 
to initiate nucleation is determined by the complementarity of the surface and the 
solute. Hence, the nature of the polymer is tailored to the structure of the solute and 
the crystallisation conditions. This specificity requires the use of large libraries of 
chemically diverse polymers, often accessed using combinatorial synthesis.146, 147 
Studies report the use of this method for polymorph-selective crystallisation of various 
drug compounds, even accessing a previously unknown form of cabamazepine.146-148 
Some homogeneous additives that were successful in controlling nucleation can 
subsequently be polymerised to produce effective heterogeneous additives, and this 
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can simplify the process of identifying useful polymers.149 Phase-selective nucleation 
has also been observed using other additives including porous frameworks and 
functionalised glass surfaces. Once again, the polymorphic outcome is directed by the 
surface chemistry of the substrate.150, 151 
 
Figure 1.12: Form II, the metastable orthorhombic polymorph of acetaminophen growing from 
isotactic polypropylene beads. Reproduced from reference 147 with permission. Copyright 2002, 
American Chemical Society. 
When using a heterogeneous additive, whose crystalline structure complements 
that of the solute, the energy barrier to nucleation is lowered due to a reduction in the 
interfacial free energy required to form a new solid phase. The product grows as a 
crystalline film on top of the substrate, and this process is termed epitaxy.152 
Polymorph selection can be achieved using this method because interaction with the 
substrate promotes ordering of molecules within a pre-nucleation cluster. This 
behaviour is thought to derive from one of two mechanisms. Either the lattice 
parameters of the substrate could match those of one polymorph of the solute, or a 
topological feature on the surface could mirror those of a specific solid form. Either 
mechanism would lead to preferential growth of the polymorph whose structure 
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matches that of the surface.153, 154 If a chiral surface is used as a template, it is even 
possible to achieve enantioselective crystallisation.155 
Instead of incorporating an additive into the crystallisation, it is also possible to 
influence nucleation and control polymorphism by physical methods. 
Nonphotochemical laser-induced nucleation is used to induce crystallisation by 
exposing a supersaturated solution to laser light. This method is most commonly 
applied to small organic molecules, and although the exact mechanism is unknown, it 
is thought that molecules within existing pre-nucleation clusters align with the applied 
electric field, which reduces the entropic barrier to crystallisation.  The pre-nucleation 
clusters corresponding to each polymorph may also have different polarisabilities, 
which means they will align differently with the electric field, and thus the polymorph 
with best alignment will crystallise preferentially. This theory is supported by the fact 
that the resulting polymorph is dependent on the polarisation of the incident light.156  
Another common strategy is to carry out the crystallisation in a confined space. A 
glass capillary can serve as a simple crystallisation vessel in which traditional 
solution-phase techniques can be carried out in a small volume (Figure 1.13). Often, 
these confined crystallisations are used to produce metastable solid forms, which may 
not be accessible using other methods. There are two mechanisms behind this effect. 
Firstly, the small volume limits convection and provides a quiescent environment in 
which the nucleation rate is low. As a consequence of reduced nucleation, the 
supersaturation increases and permits nucleation of metastable solid forms. At this 
elevated concentration, Ostwald ripening is suppressed, as there is sufficient solute to 
allow the growth of multiple forms without the stable form progressing at the expense 
of the others.157, 158  
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Figure 1.13: Capillary grown crystals of a novel polymorph of nabumetone, Form II.  Reproduced 
from reference 158 with permission. Copyright 2002, American Chemical Society.  
A recent study reports a novel confinement technique in which an inert oil is used 
to encapsulate a nanolitre-sized droplet of a concentrated analyte solution. The oil 
coating leads to slow, controlled evaporation of the solvent and a very gradual increase 
in concentration, up to the point of supersaturation. Due to the very limited droplet 
size, nucleation is reduced, and both of these factors promote the growth of 
high-quality single crystals (Figure 1.14). This technique has been used to crystallise 
fourteen structurally diverse substrates, most notable of which are the crystallisation 
of the agricultural fungicide dithianon, which was previously thought to be 
“uncrystallisable”, and the discovery of a thirteenth polymorph of ROY, which was 
not predicted by any simulation. The extremely low mass of analyte required for each 
crystallisation makes this technique well-suited to high-throughput screening, which 
allows a wide parameter space to be accessed using very little material.159 
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Figure 1.14: Encapsulated nanodroplet crystallisation of ROY: (a) solution of solvated analyte under 
oil, (b) evaporative solvent loss to supersaturation, (c) onset of crystal growth, and (d) crystallisation 
complete. Adapted from reference 159. Use permitted under the Creative Commons Attribution 
License (CC BY-NC-ND 4.0). 
Microemulsion crystallisation is a similar technique in which droplets are used for 
confinement. However, in this case the thermodynamic form can be crystallised 
preferentially. Within the small volume of an emulsion droplet, the supersaturation 
will decrease significantly with the formation and growth of a nucleus, which leads to 
a minimum in the free energy, Fmin, at a particular radius, rmin. If the crystallisation 
conditions are tightly controlled to ensure Fmin is below kBT (kB = Boltzmann constant, 
T = temperature) for only the stable polymorph, then any viable nuclei above size rmin 
will correspond to this form, and only the stable form will grow (Figure 1.15).160 
Selective crystallisation of the thermodynamic form of various organic molecules has 
been reported using this method, including the antibiotic drug isoniazid.161-163 Aside 
from microemulsions, small liquid droplets produced by techniques such as inkjet 
printing can also offer polymorph control. However, these droplets are typically on 
the picolitre scale and are therefore too large to give thermodynamic control, like in a 
microemulsion. In this case, the metastable polymorph is produced most often due to 
size limitation of the growing nucleus.164 
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Figure 1.15: Representative plots of free energy vs. nucleus size for systems crystallizing from (a) 
bulk solution and (b), (c), (d), a 3D nanoconfined solution. Adapted from reference 160 with 
permission. Copyright 2011, American Chemical Society. 
A similar effect can also be achieved by nanoconfinement within a range of porous 
structures such as polymer gels, mesoporous silicas, controlled pore glass, 
self-assembled polymer matrices and etched plastics. The properties of the pores can 
be tuned to preferentially deliver either stable or metastable crystal forms. Systems 
with pore dimensions close to the radius of a critical nucleus can crystallise one 
polymorph preferentially because the nuclei of each form differ in size. Similarly, the 
large surface area of these materials offers significant opportunity for heterogeneous 
nucleation using the pore walls, which can be functionalised to favour one particular 
form. Finally, at the nano scale, the relative stability of a given polymorph has been 
shown to depend on the size of the crystal and thus, limiting the crystallisation volume 
can lead to polymorph selectivity.165, 166 
Patterned self-assembled monolayers (SAMs) allow the formation of a highly 
specific microenvironment, with tightly controlled dimensions and chemical 
31 
 
functionality. These factors allow control over the nucleation and growth of a 
crystallising substance. A SAM consists of an organic monolayer, which is 
spontaneously adsorbed onto a surface in an organised array. Each molecule contains 
a head-group, which anchors it to the surface, and a tail-group, which is functionalised 
to interact with the solute.152 Often, long-chain thioalkanes are attached to a gold 
surface to form a SAM, via a sulphur-gold covalent bond.167 In these systems, 
polymorph control occurs by a range of mechanisms. The pattern, density, and size of 
structural features on the surface of a SAM, in addition to the chemical functionality 
of the tail groups, can all be tuned to alter the way in which the solute interacts with 
the surface. As a result, the structure of pre-nucleation clusters and post-critical nuclei, 
the local supersaturation within surface features, the rate of nucleation, and the 
orientation and dimensions of growing crystals can all be adjusted to facilitate control 
over polymorphic form. This technique is particularly valuable because it allows the 
production of many identical crystals (Figure 1.16).152, 168-171  
 
Figure 1.16: Ordered 2D arrays of calcite single crystals grown on patterned, self-assembled 
monolayers. Reproduced from reference 169 with permission. Copyright 1999, Springer Nature. 
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In addition to the development of more efficient experimental techniques such as 
high-throughput screening, there has also been significant effort towards the 
improvement of theoretical techniques such as crystal structure prediction. Crystal 
structure prediction aims to calculate the crystal structure of a molecule, starting from 
its chemical structure. There are many different approaches, but the most common is 
to calculate the lattice energy of all possible crystal-packing arrangements. The one 
with the lowest energy is the most likely crystal structure, and any arrangements with 
comparable energies are possible polymorphs. This strategy includes three main steps: 
firstly, building a three-dimensional model of the molecule from its chemical 
structure, secondly, calculating all possible close-packed structures and finally, 
calculating the lattice energy and physical properties of each of these structures to 
determine which are most likely.172 The wide range of alternative methods to achieve 
crystal structure prediction were displayed in the most recent CCDC Blind Test, which 
received the largest number of entries to date.  All five target structures were 
successfully predicted despite being extremely challenging targets, which is testament 
to the significant progress that has been made in this field.173  
In the pharmaceutical industry, accurate crystal structure prediction would be an 
extremely useful tool to support experimental polymorph screens by suggesting 
whether a molecule is likely to be polymorphic and if so, which experimental 
conditions are required to access those forms.174, 175 Whilst there has been some 
progress towards this goal, particularly in calculating the likelihood that a stable form 
has been missed by an experimental screen,176 computational methods struggle to 
model flexible molecules, high Z′ structures and multi-component systems, and 
continue to predict more forms than can be found experimentally.177 One reason that 
not all predicted forms crystallise experimentally is that they do not nucleate under 
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standard conditions. To combat this, a templating approach can be used in which the 
crystallisation is seeded using a crystal of a different compound, whose packing is 
isostructural with the predicted form. This method has been used to discover new 
forms of carbamazepine178 and tolfenamic acid,179 which shows that the combination 
of experimental and computational techniques can be extremely powerful. Current 
pharmaceutical polymorph screens typically utilise this combination of theory and 
experiment,180-182 but as crystal structure prediction becomes increasingly advanced, 
it is likely that computational methods will play a larger role, as shown by the 
increasing development of in-house CSP methodologies by large pharmaceutical 
companies.183  
1.7  An Introduction to Supramolecular Gels 
Gels are applied in many fields, including medicine, food and materials science, 
finding diverse applications from simple commercial products such as shampoos and 
shower gels to high-tech, stimuli-responsive gels. The widespread use of these 
materials derives from their unique physical properties. Sitting on the boundary 
between a liquid and a solid, gels are able to support their own weight but can also 
flow or deform under stress.184 The term “gel” was defined by Flory as “a two 
component, colloidal dispersion with a continuous structure with macroscopic 
dimensions that is permanent on the time scale of the experiment and is solid-like in 
its rheological behaviour”.185, 186 Gels are composed mostly of a fluid phase, supported 
by a solid-like network, formed by the aggregation of gel-forming or gelator 
molecules. The fluid phase is most often a liquid, including water, organic solvents 
and ionic liquids, which produce hydrogels,187 organogels188 and ionogels,189 
respectively. Alternatively, gels can contain a gas, which are called aerogels.190 These 
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are not to be confused with xerogels, which are formed by the removal of solvent from 
a gel by evaporation.191, 192  
Gels are traditionally polymer-based,193-198 but more recently, supramolecular or 
low molecular weight gelators have come to the fore.188, 199-201 Supramolecular gels 
are formed through the self-assembly of gelator molecules into one-dimensional 
fibres187 or scrolled sheets202 (Figure 1.17). These molecular architectures are termed 
the primary structure of the gel187 and can often be modelled by the supramolecular 
motifs in the crystal structure of the gelator.203, 204 Indeed, a recent study has shown 
that successful gelators typically produce high aspect-ratio crystals, suggesting that 
molecules preferentially assemble into one-dimensional supramolecular 
architectures.205 These molecular aggregates come together to form nanoscale fibrils, 
which entangle to give the three-dimensional gel network: the secondary and tertiary 
structures of the gel, respectively (Figure 1.17).187 This network immobilises the 
solvent by surface tension, producing a solid-like material despite the very high 
dilution of the system.206 It is extremely difficult to characterise the secondary and 
tertiary structures of a gel because of their small size and dynamic nature. Their 
properties are therefore approximated from the bulk properties of the material, using 
techniques such as rheology, electron microscopy, spectroscopy and calorimetry.207 
Supramolecular gels have found applications in diverse fields by virtue of their 
tuneable properties, reversibility, and response to external stimuli.201, 208-213  
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Figure 1.17: The primary, secondary and tertiary structure of a supramolecular gel. Reproduced from 
reference 187 with permission. Copyright 2004, American Chemical Society. 
Supramolecular gelation is promoted by uni-directional non-covalent interactions 
between molecules, which drive the formation of one-dimensional fibres. In a 
technique akin to crystal engineering, structural motifs that self-assemble into known 
supramolecular synthons can be incorporated into gelator molecules to tune gelation 
behaviour.214, 215 These synthons are based on a variety of non-covalent interactions 
including halogen bonding,216-218 halogen-halogen interactions,219, 220 π-stacking,221-
223 and coordination interactions,224-226 but by far the most common is hydrogen 
bonding. Amides and ureas are commonly used building blocks that form low 
molecular weight gels due to their strong, directional hydrogen bonds.227 In 
amide-based gelators, molecular stacking is driven by NH···O=C hydrogen bonds.228-
232 Incorporating an extra NH group to produce urea-based gelators typically 
strengthens this interaction, resulting in stronger gels.233, 234 Urea groups form 
intermolecular hydrogen bonds between the carbonyl oxygen in one molecule, and the 
two NH groups in another. This interaction encourages linear stacking of molecules 
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into the so-called α-tape arrangement, which promotes the formation of one-
dimensional fibres and encourages gelation (Figure 1.17).235, 236 By increasing the 
number of amide or urea groups in a molecule, this interaction can be strengthened, 
meaning bis-ureas and bis-amides are often better gelators than their mono-
functionalised equivalents.233, 234, 237-240 An anti-parallel arrangement of urea groups 
has been shown to further enhance the gelation behaviour of bis-ureas. The 
arrangement of the urea groups is influenced by the structure of the linking group that 
connects them. In a homologous series of alkyl-linked bis-ureas, gelation was shown 
to alternate with the number of methylene groups in the linker (Figure 1.18). 
Odd-membered chains did not gel, whereas even-membered chains did, because the 
linker ensured that the urea groups were anti-parallel.241 
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Figure 1.18: Alternating gel (even n) and sol (odd n) formation in a series of alkyl-linked bis-urea 
gelators. Reproduced from reference 241 with permission from The Royal Society of Chemistry.  
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Whilst structure-property correlations of the gel-forming groups have been widely 
studied, less is known about the impact of the linking groups or the peripheral 
functionality known as end-groups. In urea-based gelators, intermolecular hydrogen 
bonds can be promoted over intramolecular ones by the incorporation of a methylene 
group between the urea and the end-group (Figure 1.19). The addition of the methyl 
group reduces steric hindrance around the carbonyl oxygen atom, which encourages 
the formation of the α-tape arrangement, known to support gelation.242  
 
Figure 1.19: Structure of the gelators investigated by Offiler et al.242 
Similar behaviour has been observed in a series of N-aryl-N′-alkyl urea gelators, in 
which intramolecular hydrogen bonding between the aryl group and the urea group 
inhibited gelation by disruption of the α-tape motif (Figure 1.20).243  
 
Figure 1.20: Structure of the gelators investigated by Piana et al.243 
Finally, a detailed study into the gelation behaviour of three structurally related bis-
urea compounds highlighted the importance of both the structural and electronic 
features of the linkers and end-groups (Figure 1.21). π-π interactions between the 
central aromatic groups were reinforced by the presence of an electron-withdrawing 
nitrogen atom in the ring. Further functionalisation of the central ring with methyl 
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groups also improved gelation behaviour by promoting an interlocked packing 
arrangement that supports a more favourable hydrogen-bonding motif.244  
 
Figure 1.21: Structure of the gelators investigated by Baddeley et al.244 
Whilst the structural and electronic properties of the molecule are both extremely 
important, its solubility and supramolecular interactions with solvent molecules also 
play a key role in determining its success as a gelator, and these characteristics have 
also been taken into consideration throughout most structure-property correlations.245 
Despite these studies, the discovery of low molecular weight gelators remains 
predominantly serendipitous. Until the effect of each structural component on the gel-
forming ability of a molecule can be fully understood, it will remain impossible to 
achieve the rational design of a supramolecular gelator.  
The most common method used to identify a supramolecular gel is visual 
inspection. Termed the “inversion test”, a gel is defined by the ability to hold its shape 
in an upturned vial. Although this test is the easiest and quickest method of identifying 
gel formation, its lack of sophistication presents significant drawbacks. The size, shape 
and composition of the container all affect the ability of a gel to resist inversion, which 
can lead to inconsistent results. A weak or partial gel with a very low yield stress may 
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give a false negative result, and similarly, this technique cannot distinguish between a 
gel and a suspension or viscous liquid.246 It is more reliable to identify a gel based on 
its rheological properties. Gels are viscoelastic and display both an elastic storage 
modulus, G′, which corresponds to “solid-like” behaviour and an elastic loss modulus, 
G′′, which corresponds to “liquid-like” behaviour. Gels are usually solid-like and 
therefore can be identified by a value of G′ approximately an order of magnitude 
greater than G′′. Similarly, when a small stress is applied, the storage modulus (G′) of 
a gel should be invariant with frequency (Figure 1.22). The magnitude of G′ gives an 
indication of the relative strength of a gel, which can be further quantified by 
measurement of the yield stress. This term refers to the point at which the gel begins 
to flow under the applied shear forces. At this point, the material has liquefied and G′′ 
will become larger than G′. A large yield stress therefore corresponds to a stronger 
gel.186, 206 The potency of a gelator can be characterised by measurement of the critical 
gelation concentration (CGC), defined as the lowest concentration of gelator that 
results in a stable gel. The lower the CGC, the more potent the gelator. The critical 
gelation temperature (Tgel) is an analogous quantity that describes the maximum 
temperature at which a gel is stable, above which it dissolves.247  
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Figure 1.22:  Typical rheological behaviour of a supramolecular organogel: 4 % wt 12-hydroxystearic 
acid in dodecane. · = G′, ○ = G′′, ▴ = η*. Reproduced from reference 206 with permission. Copyright 
2000, American Chemical Society. 
1.8  Gels as Selective Crystallisation Media 
Since the late 19th century, gels have been as crystallisation media. Termed 
gel-phase crystallisation, this technique is used for the study and modification of 
solid-state materials. Traditionally, this method was used for growing large single 
crystals for X-ray diffraction. A particularly common example is the use of silica and 
agarose hydrogels to grow diffraction-quality single crystals of proteins, a technique 
still in use today.248-250 Gel-phase crystallisation first arose from the observation of 
concentric circles of solid silver chromate, formed when silver nitrate was dropped 
onto a potassium dichromate-containing gel. This pattern, now referred to as 
“Liesegang rings”, derives from the periodic precipitation of a weakly soluble salt in 
a process akin to an oscillating chemical reaction.251, 252 From this point, early gel-
phase crystallisations primarily involved inorganic metal salts in silica or agarose gels, 
and were often used to study the mechanism of chemical reactions, and to explore 
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alternative crystallisation media.253 In these techniques, the use of a gel-phase 
crystallisation medium produced higher-quality crystals because the rigid network of 
fibres decreased diffusion in the liquid phase, limiting the rate of nucleation and 
promoting the slow, controlled growth of single crystals.254, 255  
More recently, this method has been applied to polymorph-selective crystallisation. 
In this case, the interaction between the gel and the solute may also be important. The 
gel can act as a high-energy surface to encourage crystallisation via heterogeneous 
nucleation. As with traditional solid substrates, the surface can be tuned to favour the 
production of a particular polymorph, and can even lead to epitaxial growth in which 
a structural feature of the gel fibre is transferred to the growing crystal.256 An example 
of this gel-solute interaction is the preferential formation of vaterite, the metastable 
form of calcium carbonate, when crystallised from a chitosan hydrogel. Carbonate 
anions formed hydrogen bonds to the chitosan polymer in a periodic array, which acted 
as a template to encourage the formation of vaterite crystals.257    
One advantage of polymeric gels is that they are very sturdy and can withstand 
having solutions diffused into the gel network or being stored for a long time. Both of 
these properties make them suitable for crystallisation experiments, which can take 
several weeks. A common format for gel-phase crystallisation involves the formation 
of a gel column into which a supersaturated solution can be diffused. A different 
solution can be diffused into either end of the column, in a technique termed 
counterdiffusion, which is often applied to protein crystallisation. This method allows 
the controlled mixing of two solutions, or a solution and an anti-solvent, to limit 
nucleation and encourage the growth of high-quality single crystals (Figure 1.23).258 
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Figure 1.23: Protein crystals grown by capillary counterdiffusion: (a) membrane protein PSIIcc 
from Pisum sativum, (b) hydantoin racemase from Sinorhizobium meliloti, (c) PDZ domain of the 
mammalian PSD95 protein and (d) PurE. Reproduced from reference 258 with permission. Copyright 
2009, Elsevier. 
In this technique, polymorph selection is possible by varying the concentration of 
solute along the column. The polymorph-selective crystallisation of paracetamol has 
been reported using this technique. Paracetamol has three forms: monoclinic Form I, 
which is thermodynamically stable, orthorhombic Form II, which is metastable, and 
an uncharacterised Form III, which is highly metastable. Form I is currently used in 
tablet formulations, but it requires an excipient to bind the tablets as the crystal lattice 
has a low compressibility. Form II would be much easier to formulate into tablets due 
the presence of slip planes in the crystal structure, which increase compressibility. 
Therefore, a crystallisation technique to selectively produce high-quality crystals of 
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Form II is of great interest to industry. When a solution of paracetamol was diffused 
into a pre-formed column of silica gel, a concentration gradient was formed along the 
column due to more rapid evaporation of solvent from the surface of the column 
compared to the bulk. This concentration gradient caused selective nucleation of 
Forms I and II at different heights along the column, allowing easy separation of the 
two polymorphs.259 
An alternative method of polymorph selection using polymeric gels is to tune the 
size and properties of pores within the gel network to encourage nucleation of a 
particular form. Studies report the polymorph-selective crystallisation of aspirin, 
paracetamol, carbamazepine and ROY within polymeric microgels whose well-
defined pores ranged from angstroms to nanometres. The solute preferentially 
partitions into the gel pores, which leads to an increased concentration, stronger solute-
solute interactions, and therefore an increased likelihood of cluster formation. The 
structure of these pre-nucleation clusters is directed by interactions with the polymer 
chains. The solute molecules adopt a specific arrangement to maximise favourable 
interactions with the polymer, which therefore reduces the entropic barrier to 
formation of the polymorph whose structure is most similar to the cluster.260, 261 A 
similar effect was observed when crystals of the amino acid L-asparagine 
monohydrate were grown in biopolymer hydrogels of agarose, carrageenan and 
gelatin. In this case, striking differences in habit were observed from crystallisation 
within the different gels (Table 1.1). Polymer-solute interactions were thought to be 
responsible for this effect, although it was difficult to be specific given the diversity 
of functional groups in these gelators.262 
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Table 1.1: Asparagine monohydrate crystal morphologies observed from gel and solution. 
Reproduced from reference 262 with permission. Copyright 2006, American Chemical Society. 
 
A particularly impressive result deriving from the interaction between solute and 
gel has been reported for the crystallisation of sodium chlorate in an agarose hydrogel. 
Agarose is chiral in both its primary and tertiary structures. Sodium chlorate is achiral 
in terms of its molecular structure, but crystallises in a chiral space group, giving rise 
to d and l forms. Typically, the ratio between these forms is 1:1, but crystallisation 
within the gel alters the distribution due to interaction with the helical agarose fibres. 
The exact ratio depends on experimental parameters such as temperature and 
solvent.263 Development of a gel capable of selectively crystallising pure enantiomers 
from a racemic compound would be extremely valuable to the pharmaceutical 
industry, given that many drugs are chiral and the properties of each enantiomer can 
vary significantly.264 
45 
 
In addition to using known gelators such as silica or agar, it is also possible to 
design or modify the polymer structure to enable specific gel-solute interactions and 
encourage heterogeneous nucleation. For example, surface-modified nanocellulose 
organogels have been used for the crystallisation of a group of poorly water-soluble 
antibiotics. Cellulose contains many alcohol groups, which can be used as a handle for 
surface modification. Attaching long alkyl chains to the cellulose polymer leads to a 
gel with a hydrophobic surface. The hydrophobic drug molecules are drawn to these 
surfaces, and this attraction increases the local drug concentration and encourages 
nucleation (Figure 1.24). In this case, gel-phase crystallisation led to a variety of 
changes in the API solid form, including amorphisation of a previously crystalline 
product, a change in crystal habit, a change in polymorphism, and the formation of a 
novel solvate.265, 266  
 
Figure 1.24: Schematic representation of the function of surface-modified nanocellulose organogels in 
pharmaceutical crystallisation. Reproduced from reference 265 with permission from The Royal 
Society of Chemistry. 
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1.9  Supramolecular Gels as Pharmaceutical Crystallisation Media 
Recent interest has turned to the use of supramolecular gels as crystallisation media 
by virtue of their reversibility and tunability. The use of small-molecule gelators 
allows the structure of the fibres to be modified more easily, so they can bind to a 
growing crystal through non-covalent interactions. Once bound, they can promote 
crystallisation of a particular solid form through preferential heterogeneous 
nucleation, or by inhibiting the growth of a certain crystal face.267 In 2004, Estroff et 
al. reported the first gel-phase crystallisation using a supramolecular gelator (Figure 
1.25). Calcite crystals were grown in the resulting hydrogel and their morphology was 
found to be dependent upon the time spent in the gel. Carboxylic acid groups on the 
gel fibres bind to Ca2+ ions in the calcite, facilitating polymorph-selective 
crystallisation by heterogeneous nucleation.268  
 
Figure 1.25: The ion-binding gelator published by Estroff et al.268 
A recent study has shown that the presence of a solute can affect the nucleation of 
gel fibres. This effect is determined by the concentration of each component in the 
system. Typically, there is little interaction between the two components, and the self-
assembly processes of the gel and the crystal have little effect on each other. Under 
the right conditions, nucleation of the crystal and gel occur simultaneously, the 
interaction between solute and gel impairs fibre formation and gelation is suppressed. 
Given that it is not currently possible to predict when or how a gel will form, these 
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conditions are likely to be system-specific and discovered through trial and error. Even 
if nucleation of the crystal and gel do occur simultaneously, the kinetics of each 
process is often very different, which leads to the formation of one phase before the 
other.269  
As described in section 1.4, solid form-selective crystallisation is of great interest 
to the pharmaceutical industry, where the solid form of a drug can have a significant 
impact on its physical and biological properties. As a result, the gel-phase 
crystallisation of pharmaceuticals is becoming an increasingly active field of research. 
Supramolecular gel-phase crystallisation is particularly well-suited to the 
pharmaceutical industry because the gels are often reversible, which means they can 
be handled in liquid form and easily be incorporated into a high-throughput screening 
methodology. The addition of anions has been a common method of modifying the 
physical properties of supramolecular gels for some time.270 Both a strengthening and 
weakening effect has been observed, based on the nature of the gel and the anion. One 
theory suggests that the anion-strengthening effect depends on the Hofmeister series, 
with chaotropic or “salting-in” ions favouring gelation.271 However, anion-induced 
weakening of the gel is more common, and is thought to derive from a disruption of 
the supramolecular interactions that support gelation. The addition of anions, even in 
non-stoichiometric quantities, can cause complete dissolution of the gel, or a less 
significant weakening, which is visible as a reduction in the yield stress and elastic 
and viscous moduli (Figure 1.26).241, 272-274 A gel-strengthening effect can also be 
induced by the incorporation of cations that are capable of acting as a template for the 
self-assembly of gel fibres, such as the co-ordination of silver ions to a pyridyl 
ligand.275, 276  
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Figure 1.26: Influence of different anions (0.1 equiv. of anion added as their NBu4+ salts) on the 
storage modulus (G′) of a 1 % wt bis-urea gel. Reproduced from reference 241 with permission from 
The Royal Society of Chemistry. 
Anion-induced weakening is particularly common in urea-based gels, given that 
strong urea-anion hydrogen bonds have been exploited in supramolecular chemistry 
for some time.277 A key example of this behaviour is the development of switchable 
bis-urea gels applied for the crystallisation of pharmaceuticals. A variety of APIs were 
used in this study, chosen because they cover a wide range of chemical functionality, 
and are either polymorphic, form hydrates or have unusual crystal packing. Rheology 
studies showed that the addition of acetate ions, in the form of tetrabutylammonium 
(TBA) acetate, strongly weakened the gel. Addition of one molar equivalent of TBA 
acetate was enough to completely dissolve the gel without affecting the crystals within, 
allowing them to be retrieved by a simple filtration (Figure 1.27). The majority of 
crystallisations yielded the same solid form as from solution, apart from the drug 
piroxicam, which produced a different polymorph in one particular gel. Other key 
results include the habit modification of carbamazepine, an alteration in the 
supersaturation level required to induce nucleation for carbamazepine and aspirin, and 
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preferential crystallisation of the thermodynamic form of a model urea compound. 
Although little control over solid form was observed in this study, the anion-
switchability of these gelators offers a valuable mechanism for the retrieval of crystals 
from gels. This method is much more gentle than heating or hydrolysis, which are used 
to remove traditional, polymeric gels, and is therefore less likely to destroy the crystals 
within.278 
 
Figure 1.27: Recovery of a single crystal of thermodynamically stable Form III of carbamazepine by 
acetate anion-triggered gel dissolution of a bis-urea supramolecular gel. Reproduced from reference 
278 with permission. Copyright 2010, Springer Nature. 
The development of solid form-selective supramolecular gels has been the focus of 
significant work in recent years. Depending on the design of the system, this technique 
can have a number of outcomes, including the crystallisation of a specific polymorph, 
the discovery of new polymorphs and the modification of crystal habit. The 
mechanism of polymorph control in this technique is based on the degree of interaction 
between the drug and the gel. If there is little interaction between the two components, 
the self-assembly processes of gelation and crystallisation proceed as if they were 
separate. In this case, any change in solid form is likely due to physical confinement 
within the gel network. Larger degrees of interaction lead to the two processes having 
a greater influence on one another, which can cause differences in the nucleation and 
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growth of both the crystals and the gel fibres.267 In a typical gel-phase crystallisation, 
the drug and gelator are dissolved in the same solvent, sealed and then left to stand, 
allowing the gel and crystals to form over time. The ideal scenario is to have minimal 
interaction between the two components, such that the gel forms unhindered by the 
solute. The gel should form faster than the crystals to provide a high-energy surface 
capable of modifying crystal growth. To achieve solid-form modification, a small 
degree of interaction between the solute and the pre-formed gel network is required, 
and this interaction is easily tuned using supramolecular gels. 
An example in which the self-assembly processes of the gel and drug did not 
interact with each other concerned the growth of common APIs aspirin, caffeine, 
indomethacin and carbamazepine in an amide-based supramolecular gel (Figure 
1.28).279  
 
Figure 1.28: The achiral (R1) and chiral (R2) gelators published by Aparicio et al. with the drugs that 
were used for crystallisation experiments: aspirin, indomethacin, caffeine and carbamazepine. 
Reproduced from reference 279 with permission from The Royal Society of Chemistry. 
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The only solid-form modification observed in this study was the concomitant 
crystallisation of carbamazepine Forms II and III in the gel, whilst only Form III was 
formed in the corresponding solution. This modification was attributed to the viscous 
environment provided by the gel, given that the crystallisation of carbamazepine is 
strongly affected by rate of cooling and agitation.280 The gelator in this study displayed 
interesting chiral behaviour. With the end-group R1, the gelator is achiral and the 
molecules stack into helical columns, driven by π-stacking, hydrogen bonding 
between amide groups, and Van der Waals interactions between alkyl chains. If a small 
amount of the R2-containing, chiral gelator is added, this molecule intercalates into the 
columns, causing preferential formation of one helix and giving the system an overall 
chirality. In this case, the chirality was found to have no effect on the outcome of 
crystallisation, further reinforcing that the drug and gel display very little 
interaction.279 However, a similar technique has been used to achieve enantioselective 
crystallisation using polymeric gels.263 Chiral resolution using supramolecular gels 
remains a goal in this field.  
In contrast, a recent example shows greater interaction between the drug and gel, 
resulting in control of solid form. Four APIs were crystallised within a novel 
benzotriazole-based gel (Figure 1.29), yielding two examples of solid form 
modification. Niflumic acid displayed a change in crystal habit, from needles in 
solution to blocks in the gel, and sulfathiazole was crystallised as thermodynamically 
stable Form II in solution and metastable Form I in the gel. The production of a 
metastable polymorph in the gel suggests that the crystallisation process deviates from 
its typical solution-phase mechanism due to the presence of the gel fibres. This 
mechanism may include a reduction in the nucleation rate of Form II or an increase in 
the nucleation rate of Form I.281 
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Figure 1.29: Benzotriazole gelators used by Torres-Moya et al.281 
Similar results were obtained from the crystallisation of caffeine, carbamazepine 
and piroxicam from a tannic acid-Ti(IV) metallogel.282 Tannic acid is a natural  
polyphenol that has previously been shown to form metallogels by co-ordination to 
group four transition metals.283 Gelation was observed with a variety of solvents and 
over a range of conditions, concentrations, and metal-ligand stoichiometries. Unlike 
most supramolecular gelators, which require heating and cooling to trigger gelation, 
these materials can be formed by room temperature mixing of metal and acid solutions. 
For gel-phase crystallisation, the conditions were optimised to ensure that gelation 
preceded crystallisation, allowing the drug to interact with pre-formed gel fibres. All 
gel-grown crystals differed in size and habit, compared to those grown in solution, and 
the polymorphic drugs carbamazepine and piroxicam also differed in polymorphism 
(Figure 1.30). 
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Figure 1.30: The varied morphologies of carbamazepine crystals grown (a) in solution and (b,c) in 
tannic acid–TiIV metallogels. All crystals were a mixture of the dihydrate and Form III of 
carbamazepine, but Form III was the dominant phase in solution and the dihydrate was the dominant 
phase in the gel.  Adapted from reference 282 with permission. Copyright 2018, John Wiley and 
Sons. 
 Changing the gel composition and introducing additives to the system both led to 
changes in crystal size and morphology, which suggests that interaction with the gel 
network is responsible for the modification of solid form in this case. Interestingly, 
these systems have been proposed for potential use in sustained-release drug delivery 
formulations, as release of the API was found to be much slower from a gel containing 
crystalline, rather than molecular, caffeine. This observation reinforces the importance 
of the gel network in determining the properties of the crystallising API.282 
The first example of a supramolecularly assembled two-component organogel used 
for pharmaceutical crystallisation showed that the interaction between the drug and 
gel can either support or impair gelation. The gelators were composed of a lysine-
based dendron co-ordinated to an alkyl amine by the formation of an acid-base 
complex. This complex self-assembles into gel fibres via the formation of amide-
amide hydrogen bonds between dendrons. APIs including carbamazepine, caffeine, 
aspirin, and indomethacin were crystallised within these gels. Results showed a 
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difference in crystallisation behaviour depending on whether the drug contained a 
carboxylic acid (Figure 1.31).  
 
Figure 1.31: Lysine-based dendrons used by Buendia et al. to crystallise four APIs: carbamazepine, 
caffeine, aspirin and indomethacin. Reproduced from reference 284 with permission from The Royal 
Society of Chemistry. 
 Acid-containing molecules aspirin and indomethacin did not crystallise at all, 
whereas their non-acid-containing counterparts carbamazepine and caffeine, 
crystallised in every case. This result was attributed to the acid-amine hydrogen bonds 
between the API and the alkyl amine being stronger than those between the dendron 
and the alkyl amine. Thus, the two components could no longer self-assemble and 
form a gel. This theory was reinforced by the calculation of binding energies for the 
amine with both indomethacin and the dendron. The API-amine pair displayed a 
higher binding energy, showing that these interactions were in fact the strongest. The 
opposite effect was reported for the non-acid-containing APIs, which instead 
enhanced gelation. The enthalpy and entropy of gelation, calculated from 
variable-temperature 1H NMR studies, further confirmed this effect with both 
parameters increasing in the presence of carbamazepine, and suggesting increased 
ordering of the gel. For the drugs that did crystallise, a change in polymorphism was 
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only noted for carbamazepine when crystallised from the gel. Form III is obtained 
from solution whereas a mixture of Forms II and III was produced in certain gels. 
These results highlight the competitive interactions present in gel-phase crystallisation 
and show that it is possible to tune the structure of the gelator to promote the 
crystallisation of substrates containing specific functionalities.284 
A key development in this field has been the rational design of gelators, tailored to 
interact with a crystallising drug substrate. One method of ensuring an interaction 
between the two components is to incorporate known host-guest chemistry into the 
choice of drug and gelator. A characteristic example is the use of calixarene-based 
gelators for the crystallisation of hydrophobic drugs. Once self-assembled into a gel 
network, the calixarene cavities offer hydrophobic binding sites along the fibres. 
Binding of drug molecules to these sites promotes nucleation, facilitating the 
production of difficult to crystallise polymorphs. Two different gelators were used, 
with one- and two-component structures. The one-component approach uses 
directional hydrogen bonding units that are covalently attached to the calixarene to 
promote gelation behaviour (Figure 1.32).  
 
Figure 1.32: The one-component calixarene gelator published by Kaufmann et al., with a schematic 
representation of the molecule. Adapted from reference 285 with permission from The Royal Society 
of Chemistry. 
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The two-component approach uses the cation-binding ability of crown ethers to 
connect ammonium-terminated calixarene units and aromatic linking groups to 
produce a supramolecular polymer capable of forming gel fibres. (Figure 1.33).  
 
Figure 1.33: The two-component calixarene gelator published by Kaufmann et al., with schematic 
representations of the molecules. Adapted from reference 285 with permission from The Royal 
Society of Chemistry. 
This interaction can be overcome by the addition of KPF6, which causes breakdown 
of the gel, as the crown ether preferentially binds the potassium cations and the 
supramolecular polymer disassembles. (Figure 1.34). This behaviour is extremely 
useful for the recovery of crystals from the gel. 
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Figure 1.34: Schematic representation of the mechanism of gel breakdown, induced by addition of 
KPF6. Adapted from reference 285 with permission from The Royal Society of Chemistry. 
A range of model drug substances—paracetamol, fenbufen, monobenzone and 
chlorphenesin—were crystallised within the calixarene-based gels. Most experiments 
yielded the same polymorph as was formed in solution. The exception was 
chlorphenesin, for which a novel polymorph was discovered from the two-component 
gelator in 1,2,4-trichlorobenzene. An interesting feature of this polymorph is the 
presence of two molecules per asymmetric unit, which likely derives from a large 
hydrogen-bonded network within the structure. Although these specific gelators are 
not applicable to a wide range of chemical systems, they serve as proof of concept for 
the nucleation of hydrophobic drugs using classical host-guest chemistry.285  
A similar strategy for gel-phase crystallisation of pharmaceuticals is the design of 
gelators whose structures mimic that of the drug. This technique encourages a 
templating interaction between the drug and gel fibres, analogous to epitaxy. This 
strategy was first used to crystallise the highly insoluble anti-cancer drug cisplatin. 
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The gelators all contained a central platinum complex co-ordinated to functionalised 
pyridine ligands, and connected by spacers of varying length to a bis-urea (Figure 
1.35). Gel formation is driven by the self-assembly of these urea groups into one-
dimensional tapes. The ethylene-linked analogue was found to be the best gelator, 
evidenced by a high yield stress and well-defined fibres under SEM. This behaviour 
was thought to derive from the greater conformational freedom of the longer linker, 
which could allow the gel-forming and platinum-binding groups more freedom to 
adopt the most favourable orientation. 
 
Figure 1.35: The cisplatin-mimicking gelator published by Dawn et al., n = 0,1,2.286 
Unfortunately, the drug and gelator were not soluble in any of the same solvents, 
so the typical strategy of dissolving both components in the same solvent could not be 
employed in this case. The issue was overcome with the use of a biphasic sol-gel 
system in which a cisplatin solution was diffused into a pre-formed gel. These 
crystallisations led to habit modification of the known triclinic DMF solvate and 
discovery of a new DMA hemisolvate. The gel fibres were theorised to interact with 
cisplatin through amine-chloride hydrogen bonds and platinum-platinum interactions. 
Coupled with a geometric similarity between the drug and gelator, these factors both 
encourage nucleation of the new solid forms.286 
Similar results were observed for the crystallisation of isoniazid, a drug suspected 
to be monomorphic, within a structure-mimetic bis-urea gel (Figure 1.36). Isoniazid 
59 
 
has a very simple molecular structure terminated by a primary amine. This 
functionality serves as a convenient synthetic handle to attach the drug molecule to a 
linking group known to form strong gelators. Incorporating the entire drug structure 
should strengthen its interaction with the gel fibres and increase the templating effect. 
Gel tests yielded crystals in eight out of nineteen solvents, all of which were identified 
as the known form of isoniazid. Two crystals displayed a change in habit, with one 
growing much larger in the gel than in solution. This result is characteristic of the 
reduced convection and nucleation rate within the gel network. In this case, the gel, 
which was previously very stable, broke down upon formation of the crystals, which 
suggests the hydrogen bond network may be disrupted by a drug-gel interaction.163, 269 
These results were compared to a microemulsion crystallisation strategy, which has 
been reported to selectively generate the thermodynamic form. The same polymorph 
was obtained in all cases, which suggests isoniazid is truly monomorphic.163 
 
Figure 1.36: Isoniazid-mimetic gelators reported by Kennedy et al.163 
Instead of mimicking a functional group from the drug in the gelator, polymorph 
control can also be achieved my mimicking a conformational aspect of the molecule. 
A recent paper describes the polymorph-selective crystallisation of ROY using a 
conformationally mimetic gelator. ROY is a drug precursor that is famed for its high 
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degree of polymorphism. To date, there are thirteen known forms of ROY, ten of 
which are stable enough to be characterised experimentally,159, 287-290 although several 
more have been predicted computationally.291 Its polymorphs are easily 
distinguishable by their bright colours, deriving from different molecular 
conformations. Known gelator cores were functionalised with an ortho-nitroaniline 
group to mimic the same substituent in the structure of ROY (Figure 1.37).  
 
 
Figure 1.37: ROY-mimetic gelators published by Foster et al.292 
Gelator 2 could reproducibly crystallise the metastable red form of ROY, whilst the 
stable yellow form was produced from control experiments in solution, in 
non-drug-mimetic bis-urea gels, and even with the tailored gelator at a concentration 
below the gel point (Figure 1.38). This specificity suggests that polymorph selection 
in this system is caused by interaction with a structural feature of the gel network. 
Computational structure prediction showed that the nitroaniline group in the 
successful gelator adopts the same conformation as in the red form of ROY. Coupled 
with the local periodicity of the gel fibre, this structural matching led to epitaxial 
nucleation of the metastable form.292 
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Figure 1.38: (a) A summary of the results of ROY crystallisations in toluene gels of drug-mimetic 
gelator 2, non-drug-mimetic gelators 3, 4, 6 and 7, pure toluene solution, and a saturated toluene 
solution of gelator 2. (b) Crystallisation of the Y form of ROY in a gel of non-drug-mimetic gelator 7, 
and the R form of ROY in a gel of drug-mimetic gelator 2. Reproduced from reference 292 with 
permission from The Royal Society of Chemistry. 
In addition to use with pharmaceuticals, substrate-mimetic gels have also been 
applied to the crystallisation of inorganic compounds. For example, habit modification 
was observed when a copper(II) isonicotinate-N-oxide complex was crystallised using 
a substrate-mimetic gelator (Figure 1.39). These results were not reproduced in an 
agarose gel, which once again suggests that interaction with the gel network was the 
driving force for modification of solid form.293 
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Figure 1.39: The gelators used by Ghosh et al. for crystallisation of copper(II) isonicotinate–N-oxide 
complexes.293  
1.10  Project Aims and Overview 
This work aims to build on current gel-phase crystallisation strategies for 
polymorphic pharmaceuticals, and contribute to the development of a universal toolkit 
of tailored supramolecular gelators, which would be used to expand the scope of 
traditional solution-phase polymorph screens. In the first part of this work, mexiletine 
hydrochloride will be the target API. This small-molecule, anti-arrhythmic drug was 
chosen because its simple molecular structure will make the system easier to 
understand and to model. Similarly, the terminal amine provides an easy mechanism 
to synthesise drug-mimetic bis-urea gelators. Firstly, a polymorph screen of mexiletine 
will be undertaken to fill gaps in the literature data,294-298 and ensure that the 
polymorph landscape of the drug is well understood, in order to compare these results 
to gel-phase crystallisations. A variety of crystallisation techniques will be employed 
to access the full range of kinetic and thermodynamic solid forms, and each of the 
resulting polymorphs will be rigorously characterised using X-ray diffraction, 
spectroscopic and thermal techniques. The experimental polymorph screen will be 
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supported by computational crystal structure prediction to ensure that the polymorph 
landscape is complete. 
Building on previous work from the Steed group, drug-mimetic gelators will be 
synthesised to produce tailored crystallisation media capable of stabilising metastable 
or difficult to nucleate solid forms of mexiletine.163, 286, 292 In addition to the bis-urea 
gelators that have been reported previously,163, 202, 216, 269, 278, 292, 293, 299-304 this work 
will also incorporate a C3-symmetric tris-amide gelator. These molecules are reported 
to stack into helical fibres,234, 237 rather than the α-tape arrangement that is typical of 
bis-urea derivatives.235 It is possible that the different morphology of the tris-amide 
gel fibres may lead to differences in the interaction between the drug and the gel, 
which could alter the outcome of the crystallisation. The terminal amine allows the 
entire mexiletine molecule to be used as an end-group, connected to various 
gel-forming linkers via amide or urea bonds. Results of gel-phase crystallisations of 
mexiletine will be compared to the solution-phase results to identify any changes in 
polymorphism. 
Finally, experiments using a novel iodo-triphenyl imidazole (I-TPI) gelator aim to 
highlight a new class of gelators that can be applied to pharmaceutical crystallisation. 
In this case, the target drug is diatrizoic acid, an X-ray contrast agent that has limited 
structural similarity to the gelator, but a very diverse polymorph landscape.305 The 
varied solid-state behaviour of the I-TPI gelator306 may alter the thermodynamic 
landscape of the drug crystallisation within the gel. It is unusual to characterise the 
polymorphism of a gelator, so these experiments may highlight new mechanisms for 
solid-form modification of pharmaceuticals using gel-phase crystallisation. 
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2. The Polymorphism of Mexiletine Hydrochloride  
2.1  Introduction 
The polymorphs of an active pharmaceutical ingredient (API) can have very 
different physical and chemical properties, which impact pharmaceutically important 
parameters such as bioavailability, dissolution rate and tabletability. Therefore, the 
polymorphism of an API must be tightly controlled to ensure that the properties of the 
medicine are reliable.1, 2 The uncontrolled emergence of an unknown or undesirable 
solid form at any stage in the life-cycle of a pharmaceutical can drastically reduce the 
efficacy of the drug and incur severe knock on effects for patients and the 
manufacturer, as famously occurred with ritonavir.3 For these reasons, pharmaceutical 
companies face significant pressure to fully characterise and patent the solid-state 
landscape of new APIs, for example as part of a new drug application (NDA) filing.4, 
5 The most common method used to assess the solid-form landscape of a new API is 
a solution-phase polymorph screen, in which the drug is crystallised from a wide range 
of solvents, using a variety of solution-phase crystallisation techniques to access the 
full range of kinetic and thermodynamic solid forms.6, 7 These experiments can either 
be undertaken manually or more recently, using high-throughput robotics that are 
significantly more efficient.8 There has also been significant research into 
computational crystal structure prediction, which can be used to support experimental 
polymorph screens by identifying missed forms and predicting the conditions that may 
access new polymorphs.9  
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The API used in this polymorph screen is mexiletine hydrochloride, an anti-
arrhythmic drug used to treat patients with an irregular heatbeat10 (Figure 2.1). It is 
formulated as a racemate, but the two enantiomers have different pharmacokinetic 
profiles11 and there has been significant research into the stereoselective synthesis and 
crystallisation of the drug.12-18 Studies have shown that the enantiomeric excess of 
mexiletine can be determined by 1H NMR spectroscopy using a chiral solvating agent, 
and that this method is much simpler than traditional chromatographic tehcniques.19, 
20 The chloride counterion has also enabled characterisation using solid-state 35Cl 
NMR spectroscopy, which has emerged as a powerful method for distinguishing 
between the polymorphs of chloride-containing drugs.21, 22  
 
Figure 2.1: The structure of mexiletine hydrochloride. 
Mexiletine HCl is reported to have six polymorphs, of which two crystal structures 
are published in the CSD.21, 23-25 These forms have been characterised by IR 
spectroscopy, differential scanning calorimetry (DSC),24, 25 and in some cases, solid-
state NMR spectroscopy.21 DSC measurements show that mexiletine is an 
enantiotropic system in which two unsolvated polymorphs, termed Modifikation I and 
II by Kuhnert-Brandstätter et al.25 and Forms IV and VI by Kiss et al.,24 are 
thermodynamically stable at different temperatures. 24, 25 The structure of the room 
temperature stable form is known, but the high temperature stable form is yet to be 
characterised by X-ray diffraction. 
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The structure of the room temperature stable form of mexiletine was published in 
1991 by Sivy et al.23 Although mexiletine has a chiral centre, the structure is racemic 
and crystallises in a centrosymmetric space group. There are two molecules per 
asymmetric unit, which share the same gauche conformation of the aliphatic chain. 
The terminal ammonium cations hydrogen bond to the chloride counterions of 
neighbouring molecules, forming a hydrogen-bonded polymer along the 
crystallographic a-axis (Figure 2.2). There are two chloride environments, one that has 
two NH ··· Cl hydrogen bonds and one that has four. Previous studies have shown that 
these two environments can be distinguished by 35Cl solid-state NMR.22  
 
Figure 2.2: The room temperature stable form of mexiletine, viewed along the a-axis. 
The crystal structure of the first metastable form of mexiletine was published in 
2016 by Namespetra et al.21 This structure is once again a centrosymmetric racemate. 
There is only one molecule per asymmetric unit, which adopts a gauche conformation. 
The structure is a salt, with three NH···Cl hydrogen bonds per chloride anion. In 
contrast to the room temperature stable form, all chloride environments in this 
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structure are equivalent by NMR spectroscopy.21 Hydrogen-bonded mexiletine 
polymers run along the crystallographic c-axis, in which the molecules are arranged 
in a square (Figure 2.3).  The four molecules making up this motif are related by 
inversion, whilst the top and bottom layers are related by a c-glide plane.  
 
Figure 2.3: The anhydrous metastable form of mexiletine, viewed down the c-axis. The centre of 
inversion is shown by a black circle and the glide plane is shown by a black line. 
This work aims to fully characterise the solid-form landscape of mexiletine 
hydrochloride using X-ray diffraction, alongside spectroscopic and thermal 
techniques. A rigorous polymorph screen was undertaken using various solution-phase 
and high-temperature crystallisation methods, designed to access a range of kinetic, 
thermodynamic, solvated, and anhydrous solid forms. Each form was characterised by 
IR spectroscopy, PXRD, DSC, TGA and where possible, single-crystal X-ray 
diffraction. The experimental screen was supported by computational crystal structure 
prediction, which was used to ensure that the experimental solid-form landscape is 
complete. 
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2.2  Polymorph Screening 
According to this study, there are five solid forms of mexiletine. An enantiotropic 
pair of anhydrous polymorphs that are stable at different temperatures, one anhydrous 
metastable form, and two related families of metastable channel solvates. In the 
solvate structures, the drug molecules form a porous framework that can accommodate 
an extensive range of solvents. These solvates can be divided into two broad families, 
based on the packing arrangement in their mexiletine frameworks. Little change is 
observed in each of the host structures with a wide variety of guests26, 27 and in at least 
one case, the channel arrangement is retained in the absence of any solvent.28, 29 Eleven 
solvates of each type were observed in this study, and given this highly prolific solvate 
formation, it is likely that further solvates of similar structure are possible. Indeed, two 
further families of channel solvates were identified in Chapter 3. The large number of 
isomorphic solvates may account for the extra polymorph identified by IR 
spectroscopy in a previous study,24 as the incorporation of different solvents within 
the channels can significantly alter the IR spectrum of the material without inducing 
any significant structural change. 
All previous studies have used different names to refer to the polymorphs of 
mexiletine. In this work, the non-solvated forms will be named according to their 
thermodynamic stability. The room temperature stable form is termed Form 1, the 
enantiotropically related high temperature stable form is termed Form 2 and the non-
solvated metastable polymorph is termed Form 3. The previous nomenclature for these 
forms is summarised in Table 2.1. The two solvate families are termed Type A and B. 
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Table 2.1: Naming scheme for the polymorphs of mexiletine. 
 
This 
work 
Kuhnert-Brandstätter et al.25 Kiss et al.24 
Namespetra et 
al.21 
Form 
names 
Form 1 Modifikation II Form IV Mexi-I 
Form 2 Modifikation I Form VI Mexi-III 
Form 3 Not mentioned Not mentioned Mexi-II 
According to previous literature, Form 1 of mexiletine can be crystallised from 
ethanol and butanol.23, 24 In addition to these routes, our polymorph screen revealed 
that this form could also be accessed by slow and fast cooling (SC and FC), 
evaporation (EV) and anti-solvent precipitation (PPT) crystallisations, from a range of 
different solvents (Table 2.2). Single crystals of Form 2 were grown by sublimation at 
150 °C, over a period of seven hours. This procedure is similar to the one reported by 
Hildebrand et al., to access the high temperature form which they referred to as Mexi 
II.22 Although in this case, the use of sublimation allows the formation of single 
crystals rather than a powder. Namespetra et al.21 crystallised Form 3 by slow 
evaporation from acetone and in addition to this method, we have also crystallised this 
form by the evaporation of 1-propanol and fast cooling from nitromethane, acetonitrile 
and ethyl acetate solutions. In these experiments, Form 3 crystallises concomitantly 
with Form 1 which suggests that these structures are close in energy (Figure 2.4).  
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Figure 2.4: (a) PXRD pattern of the pure sample of Form 3, crystallised by evaporation of acetone, 
compared with the pattern calculated from the single crystal data, showing that they are the same. The 
experimental pattern exhibits some preferred orientation effects. (b) PXRD patterns of the mixtures of 
Form 3 and Form 1, crystallised by fast cooling from ethyl acetate, acetonitrile and nitromethane and 
evaporation of 1-propanol. PXRD patterns of pure Forms 1 and 3 are included for comparison.   
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The Type A and B solvates were crystallised by slow and fast cooling, evaporation 
and precipitation from a wide range of solvent systems (Table 2.2). The fast cooling 
and precipitation methods often involved very rapid crystallisation, which prevented 
the growth of diffraction-quality single crystals. However, for solvates that were 
crystallised by precipitation, single crystals could often be grown using vapour 
diffusion to reduce the rate of anti-solvent addition. In some vapour diffusion 
experiments, the anti-solvent was changed from hexane to octane as it has a lower 
vapour pressure and further reduced the rate of anti-solvent addition. Some conditions 
lead to the concomitant crystallisation of more than one form. Precipitation from 
chloroform/hexane yields a mixture of a Type B solvate and Form 1. Similarly, a 
mixture of Type A and Type B solvates crystallise concomitantly by precipitation from 
DCM/hexane. 
Table 2.2: Crystallisation conditions for all polymorphs of mexiletine. 
Name Crystallisation Technique 
Form 1 
As delivered 
Slow cooling from: chloroform (CHCl3), ethyl acetate (EtAc), acetonitrile 
(ACN), nitromethane (NM), amyl alcohol (AmOH), 1-butanol (1BuOH), 2-
butanol (2BuOH), 1-propanol (1PrOH), 2-propanol (2PrOH), ethanol (EtOH) 
Fast cooling from: CHCl3, AmOH, 1BuOH, 2BuOH, 1PrOH, 2PrOH, EtOH 
Precipitation from: 1BuOH/hexane, EtOH/hexane, MeOH/hexane 
Evaporation of: CHCl3, 1BuOH, 2BuOH, 2PrOH, EtOH, MeOH, ACN  
Form 2 Heat any other form above its transition temperature or, sublimation at 150 °C  
Form 3 
A pure sample can be obtained by evaporation of acetone. 
A mixture with Form 1 can be obtained by: 
Evaporation from: 1PrOH 
Fast cooling from: NM, EtAC, ACN 
Type A 
Solvates 
Slow cooling from: Tol, DCM, MeOH 
Fast cooling from: Tol 
Precipitation from: 1PrOH/hexane, AmOH/hexane, DMF/diethyl ether, 
2BuOH/hexane, 2PrOH/hexane  
Evaporation of: DCM 
Type B 
Solvates 
Slow cooling from: AcO, EMK, THF, Dio 
Fast cooling from: AcO, Dio, THF, DCM, EMK 
Precipitation from: CHCl3/hexane (mixture with Form 1) 
Both solvated polymorphs crystallise concomitantly by precipitation from DCM/hexane 
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The five solid forms of mexiletine were identified by PXRD, using the program 
PolySNAP30, 31  to group the patterns together by similarity. To ensure this analysis 
was accurate, only high-resolution PXRD patterns were used, and mixtures or low 
crystallinity samples were discounted. The discounted samples include Type A 
solvates crystallised by precipitation from CHCl3 or DCM/hexane and Type B solvates 
crystallised by fast cooling from DCM or THF and slow cooling from 1,4-dioxane. At 
a similarity coefficient of 0.65, the patterns were divided into five distinct clusters, 
except for the Type A methanol solvate. PolySNAP suggests that the methanol solvate 
is unrelated to any other form (Figure 2.5), although in fact it  is a member of the Type 
A solvates. At a similarity coefficient of 0.65, the PXRD patterns of Forms 1, 2 and 3 
are all unique. However, at similarity coefficient of 0.6, Form 2 falls into the same 
cluster as the Type B solvates, which shows that these two forms are structurally 
related. Within both solvate clusters, there are various sub-groups with higher 
similarity coefficients. The highest similarity sub-groups often contain the same 
solvate crystallised by different methods whereas more differences are observed 
between solvates containing different solvents.  
 
Figure 2.5: The PoySNAP packing similarity dendrogram. The red line at 0.65 shows the similarity 
coefficient that was used to cluster the patterns into the groups highlighted by different colours. 
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A similar clustering analysis was carried out on the single crystal structures of 
Forms 1, 2, 3 and seven of the Type A solvates, using the CSD-Materials module in 
Mercury.32 The packing similarity analysis generates a cluster of 20 molecules to 
represent each crystal structure.33 Pairs of clusters are overlaid and the resulting root 
mean square deviation (RMSD) can be used to quantify differences between the two 
forms (Table 2.3). If all of the molecules in both clusters overlap, an RMSD value of 
less than 0.6 Å shows that the two structures are the same,34 and based on these results, 
Mercury separates the crystal structures into groups representing each polymorph. 
The packing similarity analysis produced the same clusters as PolySNAP. 
Compared with all other crystal structures, Forms 1, 2 and 3 have unique packing 
arrangements and only one or two molecules overlap out of the group of 20. Similarly, 
all the Type A solvates have the same packing arrangement, except for the methanol 
solvate. The methanol solvate has the same packing arrangement as the Type A solvate 
crystallised from DMF/diethyl ether, with 20 out of 20 molecules overlapping and an 
RMSD value of 0.576 Å. However, differences are observed between the methanol 
solvate and the four solvates crystallised by precipitation with an alkane anti-solvent. 
In these comparisons, 19 or 20 out of 20 molecules overlapped, with RMSD values 
slightly above the cut-off: between 0.65 and 0.79 Å. These results highlight slight 
structural differences in the drug framework of the methanol solvate, which contribute 
to differences in the PXRD pattern of this form. 
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Table 2.3: The number of molecules, out of a group of 20, that overlapped in a packing similarity calculation using all crystal structures of mexiletine. The number in 
brackets is the resulting RMSD value in Å. The cells are colour coded to denote whether the two forms have the same packing arrangement. Pairs with fewer than 20 
molecules overlapping, or an RMSD of greater than 0.6 Å are not the same form and are coloured red. Pairs with 20 molecules overlapping and an RMSD of less than 0.6 Å 
are the same form and are coloured green. Pairs that show close similarity, but do not meet both criteria, are coloured orange.  
 Form 1 Form 2 Form 3 
Type A 
Solvent-free 
Type A  
MeOH 
Type A 
1PrOH/Oct 
Type A 
2BuOH/Oct 
Type A 
2PrOH/Hex 
Type A 
DCM/Hex 
Type A 
DMF/DEE 
Form 1 -          
Form 2 
1 
(0.629) -         
Form 3 
1 
(0.629) 
2 
(0.590) -        
Type A 
Solvent-free 
1 
(0.545) 
1 
(0.554) 
2 
(0.862) -       
Type A 
MeOH 
1 
(0.548) 
1 
(0.560) 
2 
(0.908) 
20 
(0.538) -      
Type A 
1PrOH/Oct 
1 
(0.548) 
1 
(0.548) 
2 
(0.682) 
20 
(0.474) 
19 
(0.793) -     
Type A 
2BuOH/Oct 
1 
(0.549) 
1 
(0.547) 
2 
(0.865) 
20 
(0.472) 
19 
(0.791) 
20 
(0.008) -    
Type A 
2PrOH/Hex 
1 
(0.544) 
1 
(0.549) 
3 
(1.170) 
20 
(0.452) 
19 
(0.759) 
20 
(0.056) 
20 
(0.054) -   
Type A 
DCM/Hex 
1 
(0.542) 
1 
(0.551) 
2 
(0.667) 
20 
(0.274) 
20 
(0.649) 
20 
(0.211) 
20 
(0.208) 
20 
(0.181) -  
Type A 
DMF/DEE 
1 
(0.542) 
1 
(0.555) 
2 
(0.864) 
20 
(0.135) 
20 
(0.576) 
20 
(0.348) 
20 
(0.345) 
20 
(0.321) 
20 
(0.144) - 
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2.3  Structures of the Non-Solvated Forms of Mexiletine 
Single crystals of Form 2 of mexiletine were grown by sublimation at 150 °C. 
Selected crystallographic information for this structure is given in Table 2.4, along 
with the other non-solvated forms for reference. Full crystallographic information for 
Form 2 can be found in Appendix 7.1. 
Table 2.4: Selected crystallographic information for the non-solvated forms of mexiletine. 
 
 
 
 
 
 
 
 
 
  
 Form 123 Form 2 Form 321 
Space Group P1ത Pccn Pbcn 
a/Å 8.796(15)  17.874(14)  35.116(2)  
b/Å 10.601(18)  18.678(15)  7.740(5)  
c/Å 14.229(24)  7.346(7)  9.154(5)  
α/° 78.74(13)  90  90 
β/° 79.89(14)  90  90 
γ/° 68.69(12)  90  90 
V/Å3 1204.3  2452.6(4)  2488.1(3)  
Z 4  8  8  
ρcalc g/cm3 1.19  1.17 1.15  
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As in all previously known structures of mexiletine, Form 2 is a racemic 
hydrochloride salt. The crystal structure is disordered and the model contains two 
different conformations of the mexiletine molecule (Figure 2.6).  
 
Figure 2.6: Asymmetric unit of Form 2 of mexiletine, showing how the disorder has been modelled. 
The anti-periplanar conformer, which has an O-C-C-N torsion angle of 174.5 °, has 
an occupancy of 0.63. Whereas the gauche conformer, which has an O-C-C-N torsion 
angle of 47.8 °, has an occupancy of 0.37. There are 56 entries in the CSD containing 
this R-O-CH2-CHR-NH3+ fragment, in which the O-C-C-N torsion angles range from 
44.1 ° to 75.4 ° (Figure 2.7). These angles all correspond to a gauche conformation, 
which suggests that the anti-periplanar conformer is less stable.  
 
 
 
 
 
 
 
 
 
Figure 2.7: O-C-C-N torsion angles in all structures containing the R-O-CH2-CHR-NH3+ fragment in 
the CSD. 
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In Form 2, there are three hydrogen bonds per chloride ion to the ammonium 
cations in adjacent molecules, forming a hydrogen-bonded polymer along the 
crystallographic c-axis. As in Form 3, the molecules within this polymer are arranged 
in a square, although the symmetry of this motif is different in Form 2. In this case, 
the molecules are related by two perpendicular c-glide planes, which intersect in the 
middle of the square (Figure 2.8). 
 
Figure 2.8: Form 2 of mexiletine, viewed down the c-axis. The c-glide planes are shown by black 
lines. For clarity, only the higher occupancy anti-periplanar conformer is displayed. 
Although Forms 2 and 3 have similar packing arrangements, Form 1 is very 
different (Figure 2.9). When viewed down the hydrogen-bonded polymers, which 
corresponds to the a-axis for Form 1 and the c-axis for Forms 2 and 3, the structures 
are all layered. In Form 1, the polymers align with each other in the b-direction but are 
offset in c due to the shape of the triclinic unit cell. Forms 2 and 3 are both 
orthorhombic and the molecules align in both the a- and b-directions. In both of these 
structures, the layers are shifted such that the chains line up in every other layer.  
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Figure 2.9: The packing arrangements of Forms 1, 2 and 3 of mexiletine, viewed down the hydrogen-
bonded chains, which corresponds to the crystallographic (a) a-axis and (b,c) c-axis. For clarity, only 
the higher occupancy anti-periplanar conformer in Form 2 is displayed. 
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IR spectroscopy was also used to characterise the non-solvated forms of mexiletine. 
The major differences between these spectra occur in the ammonium NH stretching 
region between 3300 and 2300 cm-1, which is unique for Forms 1, 2 and 3 (Figure 
2.10).  
 
 
Figure 2.10: IR spectra of Forms 1, 2 and 3 of mexiletine. Form 1 was used as delivered, Form 2 was 
crystallised by sublimation at 150 °C and Form 3 was crystallised by evaporation of acetone. 
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2.4  Thermodynamic Relationships Between the Non-
 Solvated Forms of Mexiletine 
The thermodynamic relationships between the three non-solvated forms of 
mexiletine was investigated by DSC (Figure 2.11, Table 2.5). These findings mirror 
previous reports24, 25 in which all polymorphs transform into Form 2 upon heating, 
which then melts at 202 °C. Hence, Form 2 is the only form that does not display a 
polymorphic transition or desolvation endotherm. The polymorphic transition in Form 
1 has an onset temperature of 148 °C and an enthalpy of 8.4 kJmol-1. Whereas Form 3 
transforms into Form 2 at an onset temperature of 167 °C and with an enthalpy of 
4.5 kJmol-1. Although Form 3 is metastable at room temperature, it has a higher 
polymorphic transition temperature than Form 1. Therefore, Form 3 is likely to be the 
most stable form between the polymorphic transition temperatures of Form 1 and 
Form 3: between 148 and 167 °C. The enthalpy of the polymorphic transition is lower 
for Form 3 than Form 1. The structure of Form 3 is more similar to Form 2 and 
therefore, less molecular reorganization is required to achieve the Form 3 to Form 2 
transformation, which is responsible for its lower enthalpy.  
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Figure 2.11: DSC thermograms of (a) Form 1, (b) Form 2 and (c) Form 3 of mexiletine.  
Table 2.5: The temperature and enthalpy of each transition in the DSC thermograms of Forms 1, 2 
and 3 of mexiletine.  
 
Polymorphic transition Melting point 
Onset / °C Peak / °C ΔH / kJmol
-1
 Onset / °C Peak / °C ΔH / kJmol
-1
 
Form 1 148 151 8.4 201 202 16.7 
Form 2 - - - 200 202 18.6 
Form 3 167 174 4.5 200 202 16.2 
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2.5  Structures of the Solvated Forms of Mexiletine 
Each family of channel solvates is characterised by a specific series of peaks in 
their PXRD patterns. These peaks are mostly observed at low angles and are consistent 
between all solvates of the same family. At higher angles there are some extra peaks 
or shifts between the patterns, which correspond to changes in the channel dimensions 
or the presence of different crystalline solvents within the pores. However, the 
similarities between all members of the same family are sufficient to qualify them as 
the same structure type.26, 27  
In the PXRD patterns of the Type A solvates, the characteristic peaks occur in the 
regions 6-7, 8-10, 13-14 and 15-16 ° and only shift slightly in position between each 
solvate (Figure 2.12). These patterns match closely at higher angles, except for the 
solvates crystallised from 1- and 2-propanol, which contain some extra peaks between 
17 and 27 °. It was not possible to obtain an experimental PXRD pattern of the Type 
A methanol solvate because the crystallisation requires such a high degree of 
supersaturation that when the crystals are removed from the mother liquor, Form 1 
immediately precipitates from solution, forming an inseparable mixture. As such, the 
PXRD pattern calculated from the single-crystal structure was used for comparison 
and it also matches closely with the rest of the group. 
 
 
  
100 
 
 
Figure 2.12: PXRD patterns of all Type A solvates. The crystallisation conditions are as follows, from 
the bottom up: slow cooling from DCM, slow cooling from toluene, fast cooling from toluene, 
evaporation from DCM, precipitation with diethyl ether from DMF, precipitation with hexane from 
amyl alcohol, precipitation with hexane from 1-propanol, precipitation with hexane from 2-propanol, 
precipitation with hexane from 2-butanol and slow cooling from methanol. The methanol pattern was 
calculated from the crystal structure. 
In the PXRD patterns of the Type B solvates, the characteristic peaks occur in the 
regions 6-7, 9-10, 13-14, 15-17, 19-20 and 23-25 ° (Figure 2.13). However, there is 
some subtle variation in the shape and position of the peaks at approximately 6 ° and 
between 15-18 °. The PXRD patterns of the Type B solvates are also strongly affected 
by preferred orientation, causing the intensity of several peaks to vary widely. This 
effect is most noticeable for the peaks at approximately 5, 6, 13 and 16 °. As in the 
Type A solvates, differences are observed between the Type B patterns at higher 
angles, particularly between 15 and 30 °. Some of the Type B solvates were 
crystallised by fast cooling, which leads to reduced crystallinity, broadened peaks, and 
a lower signal to noise ratio in their PXRD patterns. This effect is most noticeable for 
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the samples crystallised by fast cooling from DCM and EMK. However, the 
similarities in their key peaks between 13 and 27 °are sufficient to qualify them as 
Type B solvates. 
 
Figure 2.13: PXRD patterns of all Type B solvates. The crystallisation conditions are as follows, from 
the bottom up: slow cooling from THF, fast cooling from THF, slow cooling from 1,4-dioxane, fast 
cooling from acetone, slow cooling from acetone, slow cooling from EMK, fast cooling from 
1,4-dioxane, fast cooling from EMK, and fast cooling from DCM.   
Single-crystal structures of seven Type A solvates were determined. Although the 
dimensions of the channels and therefore the unit cells (Table 2.6), vary slightly with 
the incorporation of different guests, their overall packing arrangement varies very 
little.26, 27 Full crystallographic information for all of these forms can be found in 
Appendix 7.1.
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Table 2.6: Selected crystallographic information for the Type A solvates. 
 
 
Crystallisation 
Conditions 
DCM SC 
slow cooling 
MeOH SC 
slow cooling 
1PrOH/octane 
vapour diffusion 
2BuOH/octane 
vapour diffusion 
2PrOH/hexane 
vapour diffusion 
DCM/hexane 
vapour diffusion 
DMF/diethyl ether 
vapour diffusion 
Space group Pbcn Pbcn Pbcn Pbcn Pbcn Pbcn Pbcn 
a/Å 20.857(2) 20.243(7) 21.936(13) 21.924(14) 21.875(17) 21.456(3) 21.125(2) 
b/Å 17.378(18) 18.768(6) 17.106(10) 17.110(11) 17.211(13) 17.333(2) 17.358(16) 
c/Å 7.565(8) 7.550(2) 7.521(5) 7.520(5) 7.511(6) 7.5478(11) 7.563(7) 
α/° 90 90 90 90 90 90 90 
β/° 90 90 90 90 90 90 90 
γ/° 90 90 90 90 90 90 90 
V/Å3 2741.9(5) 2868.4(15) 2822.3(3) 2820.8(3) 2827.9(4) 2807.0(7) 2773.1(4) 
Z 8 8 8 8 8 8 8 
ρcalc g/cm3 1.045 1.147 1.015 1.016 1.013 1.021 1.033 
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The solvent-free form of the Type A solvates was crystallised by slow cooling a 
supersaturated solution in DCM. This form is isostructural with the rest of Type A 
solvates but in this case, the pores are empty, technically making this structure a fourth 
non-solvated polymorph of mexiletine.35 As in Forms 2 and 3, the solvent-free 
structure is a racemate and the asymmetric unit contains one mexiletine molecule. This 
molecule adopts a gauche conformation, with an O-C-C-N torsion angle of 60.8 º, 
which is in line with similar structures in the CSD. Each ammonium cation hydrogen 
bonds to three chloride counterions, forming a hydrogen-bonded polymer along the 
crystallographic c-axis, in which the molecules are arranged in a square formation with 
the same symmetry as Form 3. Down the a- and b-axes, the packing arrangement in 
the solvent-free Type A structure is also very similar to Form 3, although the 
molecules are oriented differently (Figure 2.14). 
 
Figure 2.14: The structure of the solvent-free Type A structure of mexiletine, compared to Form 3. 
Structures are viewed down the (a) a-axis, (b) b-axis and (c) c-axis. The centres of inversion are 
shown as black circles and the c-glide planes are shown as black lines.  
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The defining features of the solvent-free Type A structure are the large, continuous 
voids running along the crystallographic c-axis (Figure 2.15). Calculated using the 
inward-facing surface of a spherical 1.4 Å3 probe,36 the voids occupy 255 Å3 per unit 
cell or, 9.3 % of the crystal volume. This volume reduces to 40 Å3 or 1.5 % when only 
the solvent-accessible voids, mapped using the centre of the spherical probe, are 
considered. This estimate of the solvent-accessible volume within this crystal structure 
is likely to be conservative because Mercury uses hard spheres to model both the host 
framework and the included solvent. In reality, both the solvent molecules and the host 
framework have a more nuanced shape and some degree of flexibility, which allow a 
larger volume of solvent to be included within the channels.37  
  
Figure 2.15: The void structure in the solvent-free Type A form of mexiletine, viewed down the (a) 
a-axis and (b) c-axis. The voids are highlighted in yellow and were calculated in Mercury using a 1.4 
Å3 spherical probe.36   
Both types of void are continuous, but the solvent-accessible voids are small and 
narrow, which means only small or linear solvents can be included as guests. The 
surface of the channels is lined by mexiletine’s aromatic rings, creating a hydrophobic 
environment that favours the crystallisation of hydrophobic solvents. It is most likely 
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the steric bulk of these aromatic groups that promotes a low-density packing 
arrangement in this form, stabilised by the strong charge-assisted hydrogen bonds 
from the ammonium groups. No solvent masking procedure was employed during the 
refinement of the solvent-free structure, and SQUEEZE38 indicates a residual electron 
density in the channels of only 6 electrons per unit cell. Hence, the voids really are 
devoid of crystalline solvent. The experimental PXRD pattern of the solvent-free form 
matches exactly with the calculated pattern from the crystal structure and is repeatable 
over several experiments, which further demonstrates the reliability of the 
single-crystal data (Figure 2.16).  
 
Figure 2.16: Experimental and calculated PXRD patterns of the solvent-free Type A structure, 
crystallised by slow cooling from DCM. The crystal structure was recorded at 100 K whereas, the 
experimental PXRD pattern was recorded at room temperature.  
The Type A methanol solvate is the only crystal structure of this family that contains 
well resolved crystalline solvent within the channel, and the only disorder in this 
structure can be modelled by two positions of the alcohol proton. The methanol 
molecules do not interact with the host framework and instead hydrogen bond with 
each other, forming separate chains along the crystallographic c-axis (Figure 2.17). 
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Due to the hydrophobic channel surface, the methanol molecules pack with their 
alcohol groups facing inwards towards each other and their methyl groups facing 
outwards towards the channel. Full crystallographic information for this structure can 
be found in Appendix 7.1. 
 
Figure 2.17: The Type A methanol solvate of mexiletine, viewed down the c-axis. The centre of 
inversion is shown as a black circle and the c-glide plane is shown as a black line.  
The host frameworks in the Type A methanol solvate and the solvent-free form are 
isostructural. Both structures consist of offset layers, which alternate every half unit 
cell in both the a- and b-directions, so that the channels line up every other layer 
(Figure 2.18).  However, there are slight differences in the unit cell dimensions of 
these two forms. In the methanol solvate, the a-axis is shorter and the b-axis is longer, 
showing that the channel dimensions have changed to accommodate the solvent 
molecules (Table 2.6).   
 
Figure 2.18: The packing arrangement of (a) the solvent-free Type A form and (b) the Type A 
methanol solvate, viewed down the c-axis. 
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The crystal structures of five more isostructural Type A solvates were determined 
using crystals grown by vapour diffusion of hexane, octane, or diethyl ether into a 
supersaturated solution of mexiletine in 1-propanol, 2-propanol, 2-butanol, or DMF. 
Full crystallographic information for these materials can be found in Appendix 7.1. 
As with the methanol solvate, slight variations in the cell dimensions of these 
compounds occur perpendicular to the channels, signifying a change in the channel 
dimensions to accommodate various solvents (Table 2.6). In all these structures, the 
solvent molecules are highly disordered and were modelled using a solvent masking 
procedure. The Mercury packing similarity analysis (Table 2.3) shows that the 
structure of the host framework in the solvates grown by vapour diffusion is slightly 
different to the methanol solvate. This difference was likely caused by the crystalline 
solvent within the pores of the methanol solvate interacting with the channel walls, in 
contrast to the disordered guests present in the other forms. 
One single-crystal structure of a Type B solvate was recorded using a crystal grown 
by slow cooling from a supersaturated solution in ethyl methyl ketone, EMK. It is 
extremely disordered (Figure 2.19) and although several attempts were made to grow 
a better-quality crystal, these solvates crystallised exclusively as tiny needles that were 
very weakly diffracting. As a result, the precision of this structure is poor, but the 
approximate model does give insight into the gross structural features. The unit cell 
dimensions of this structure are given in Table 2.7 and full crystallographic 
information can be found in Appendix 7.1.  
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Figure 2.19: Asymmetric unit of the Type B EMK solvate of mexiletine, showing how the disorder 
has been modelled. 
Table 2.7: Unit cell dimensions of the Type B EMK solvate of mexiletine. 
 
 
 
 
 
 
 
 
 
The Type B EMK solvate is a 2:1 hemisolvate, with two mexiletine molecules per 
asymmetric unit. As in all other metastable polymorphs, the ammonium cations 
hydrogen bond to chloride anions, forming a hydrogen-bonded polymer along the 
crystallographic c-axis (Figure 2.20). However, in contrast to the other metastable 
forms, there are two different hydrogen bonding motifs in this structure. One consists 
of four molecules, related by a 4-fold rotation axis, and connected by three hydrogen 
Crystallisation 
Conditions 
EMK SC 
slow cooling 
a/Å 27.91(2) 
b/Å 27.91(2) 
c/Å 7.515(8) 
α/° 90 
β/° 90 
γ/° 90 
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bonds per chloride anion. The other contains two pairs of molecules, related by two 
perpendicular c-glide planes, and connected by two hydrogen bonds per chloride 
anion. The latter motif has the same symmetry as the hydrogen-bonded polymers in 
Form 2, and although Form 2 has one more hydrogen bond per chloride ion, the 
arrangement of molecules within the two motifs are the same. The structural similarity 
between Form 2 and the Type B solvates was also observed in their PXRD patterns, 
highlighted by the PolySNAP similarity dendrogram (Figure 2.5).  
 
Figure 2.20: The Type B EMK solvate of mexiletine, viewed down the c-axis. For clarity, only one 
disordered component has been displayed. The c-glide planes are labelled as black lines and the 4-fold 
rotation axis is labelled as a black cross.  
As in the Type A solvates, the solvent molecules in the Type B EMK solvate are 
accommodated in channels within the host framework and do not interact significantly 
with the mexiletine molecules. The surface of these channels is lined with aromatic 
rings, making them hydrophobic and encouraging the solvent molecules to pack with 
their hydrophobic functionality facing the channels (Figure 2.21). This structure is 
layered, with every other layer containing solvent molecules. The layers alternate 
every quarter unit cell along both the a- and b-axes, so that the same structural features 
line up every fifth layer.  
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Figure 2.21: Packing arrangement of the Type B EMK solvate of mexiletine, viewed down the c-axis. 
For clarity, only one disordered component has been displayed. 
13C solid-state NMR spectroscopy was used to further characterise the channel 
solvates. Two different methods were used for each sample: cross-polarisation and 
direct-excitation, which differ in the relaxation times of the nuclei that they detect. 
Cross-polarisation was used to assess the crystalline, slowly relaxing parts of the 
structure, whilst direct-excitation was used to probe the more mobile, “liquid-like”, 
and rapidly relaxing components. As the solvates are metastable, the NMR samples 
were also characterised by IR spectroscopy and PXRD both before and after 
measurement of the NMR spectra, to ensure they had not transformed during the 
experiment. The expected mexiletine signals were observed in every cross-
polarisation spectrum and for all samples apart from the solvent-free forms, solvent 
signals were also visible in one or both spectra. These solvent resonances were used 
to determine the contents of every channel solvate, as shown in Table 2.8 and Table 
2.9. A mexiletine signal is observed at approximately 14 ppm in all the 
direct-excitation spectra, corresponding to the aliphatic methyl group, which has a 
faster relaxation time than the other carbon atoms due its high rotational freedom. 
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Table 2.8: Chemical shift values of solvent signals in solid-state NMR spectra of all Type A solvates. 
SC = slow cool, PPT = precipitation, EV = evaporation, FC = fast cool, * = all solvent signals are 
significantly stronger in this spectrum, †= solvent peak overlaps a mexiletine peak, ‡= two solvent 
peaks overlap each other. 
Crystallisation 
conditions 
Solvent signals 
cross-polarisation 
Solvent signals 
direct-excitation 
Channel 
contents 
Tol SC  125.8, 128.3, 128.9, 138.0 *125.8, 128.9, 129.2, 138.0 Toluene 
DCM SC 
- 
Signal would have been 53-55 
- 
Signal would have been 53-55 
Empty 
MeOH SC N/A N/A Methanol 
1PrOH/Hex PPT 13.9†, 23.6, 32.9 *13.9†, 23.6, 32.9 Hexane 
AmOH/Hex PPT 14.0†, 23.6, 32.9 *14.0†, 23.6, 32.9 Hexane 
DMF/DEE PPT 15.7, 66.0 *15.8, 66.0 
Diethyl 
ether 
2BuOH/Hex PPT 13.9†, 23.5, 32.9 *13.9†, 23.5, 32.9 Hexane 
2PrOH/Hex PPT 13.9†, 23.6, 32.9 *13.9†, 23.6, 32.9 Hexane 
DCM EV 
- 
Signal would have been 53-55 
- 
Signal would have been 53-55 
Empty 
Tol FC  125.7, 128.6, 129.2, 138.0 *125.7, 129.0‡, 138.0 Toluene 
 
Table 2.9: Chemical shift values of solvent signals in solid-state NMR spectra of all Type B solvates. 
SC = slow cool, FC = fast cool, * = all solvent signals are significantly stronger in this spectrum. 
 
 
Crystallisation 
conditions 
Solvent signals 
cross-polarisation 
Solvent signals 
direct-excitation 
Channel  
contents 
AcO SC *30.5, 204.5 30.5, 204.6 Acetone 
EMK SC *8.9, 29.3, 36.9, 207.2 9.0, 29.3, 36.9, 207.2 EMK 
THF SC *26.3, 67.9 26.3, 67.9 THF 
Dio SC *67.4 67.4 Dioxane 
AcO FC *30.6, 204.7 30.6 Acetone 
Dio FC *67.4 67.4 Dioxane 
THF FC *26.4, 68.0 26.3, 68.2 THF 
DCM FC 
- 
Signal would have been 53-55 
- 
Signal would have been 53-55 
Empty 
EMK FC *9.1, 29.5, 36.8, 207.5 9.1, 29.5, 36.8, 207.3 EMK 
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For most of the Type A solvates, solvent resonances were visible in both types of 
SS NMR spectra. However, they were much stronger by direct-excitation, which 
suggests that the solvent is highly mobile but not entirely liquid-like. All precipitation 
experiments that yielded a Type A solvate involved a polar, hydrogen-bonding solvent 
and a non-polar, aprotic anti-solvent. In every case, NMR data shows that the anti-
solvent is contained within the channels, which is likely caused by the hydrophobic 
nature of the channel surface. In contrast, no solvent signals were observed in either 
SS NMR spectrum of the samples crystallised by slow cooling and evaporation of 
DCM, which highlights that both of these methods result in solvent-free Type A 
structures and confirms that the pores in this form are truly empty. The Type A 
solvates crystallised by fast and slow cooling from toluene are a particularly 
interesting case. The PXRD patterns of both samples match the pattern of the solvent-
free form exactly, which suggests that the pores may be empty. However, toluene 
peaks are observed weakly in the cross-polarisation spectra and strongly in the direct-
excitation spectra of these forms, which shows that the channels actually contain 
highly mobile toluene molecules that are too disordered to diffract X-rays (Figure 
2.22).  
113 
 
 
Figure 2.22: Solid-state NMR spectra of the Type A solvates of mexiletine, crystallised by slow 
cooling from (a) toluene and (b) DCM. In both cases, the top spectra were recorded using direct-
excitation and the bottom spectra using cross polarization. 
Solvent signals were also observed in the cross-polarisation and direct-excitation 
spectra of the Type B solvates. The signals were stronger in the cross-polarisation 
spectra, suggesting that the solvent in these structures is quite crystalline. This trend 
is reflected in the PXRD patterns of this form, which are much more varied than Type 
A, suggesting a larger variation in the crystalline components of the Type B solvates. 
A solvent-free Type B form was also identified by SS NMR, crystallised by fast 
cooling from DCM. No solvent signals were observed in either NMR spectrum of this 
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sample, showing that the pores are empty. Since the solvent-free Type A form was 
also produced by crystallisation from DCM, it is likely that while this solvent 
facilitates the crystallisation of channel solvates, it is too volatile and interacts with 
the hydrophobic channels too weakly to be retained.  
Solid-state 13C NMR spectroscopy could also be used to distinguish between the 
Type A and B solvates, and to distinguish them both from Form 1. This technique has 
previously been applied to distinguish between Forms 1, 2 and 3.21 All spectra differ 
in the four fingerprint regions identified by Namespetra et al.: between 154-156, 
70-72, 47-49, and 10-20 ppm (Figure 2.23).21 The spectra of the Type A solvates, 
which have one molecule per asymmetric unit, are always much simpler than those of 
Type B and Form 1, which have two molecules per asymmetric unit. For certain nuclei, 
signals from these two symmetry-independent molecules can be resolved by NMR, as 
seen at approximately 48 and 72 ppm. At 48 ppm, the two signals overlap and so the 
peak appears broad, with a small shoulder. There are also significant differences in the 
aromatic region between 120-135 ppm that are more characteristic of the solvates 
(Figure 2.23). Once again, the aromatic region is much simpler for the Type A 
solvates, including only the expected four signals. Whereas, the spectra of the Type B 
solvates and Form 1 contain more peaks, due to their higher values of Zʹ. All three 
forms can be distinguished by differences in the chemical shift, which were used to 
confirm the polymorphism of the poorly crystalline samples that produced low-
resolution PXRD patterns: the Type B solvates crystallised by fast cooling from 
acetone, DCM and EMK. 
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Figure 2.23: Cross-polarisation SS NMR spectra of (a) the Type B solvate crystallised by slow 
cooling from THF, (b) the Type A solvate crystallised by precipitation from amyl alcohol / hexane, 
and (c) Form 1 used as supplied. Solvent peaks are highlighted with arrows, corresponding to (b) 
hexane and (a) and THF. The hexane signal at 14 ppm in spectrum (b), highlighted with an asterisk, 
overlaps with a mexiletine signal, hence the higher intensity of this peak. 
 
The structure of the mexiletine solvates was also characterised by IR spectroscopy. 
As with the non-solvated polymorphs, the IR spectra of the Type A and B solvates are 
very similar, and it was not possible to distinguish the two families by this method. 
Similarly, there is little variation between different solvates of the same family, 
showing that any slight changes in crystal packing cannot be resolved by IR 
spectroscopy. Representative IR spectra of the Type A and B solvates are shown in 
Figure 2.24 and this data was predominantly used as a convenient method to confirm 
the polymorphism of a sample before characterising it in more detail using another 
technique. 
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Figure 2.24: Representative IR spectra of the Type A and 2 solvates, crystallised by: slow cooling 
from DCM (Type A solvent free), precipitation from 1-propanol using hexane (Type A hexane), fast 
cooling from DCM (Type B solvent free) and slow cooling from THF (Type B THF).  
In the Type A solvates, there are no solvent peaks in any of the IR spectra. However, 
solvent peaks were observed in the spectra of five Type B solvates (Figure 2.25). In 
the EMK and acetone solvates, the carbonyl stretch of the solvents are observed at 
1715 and 1710 cm-1 respectively, and in the dioxane solvates, the CH2 twisting 
vibration of the solvent is observed at 1289 cm-1.39 
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Figure 2.25: IR spectra of the Type B EMK, acetone and dioxane solvates, in which there are extra 
peaks due to solvent, compared to a representative Type B pattern that contains no solvent signals. 
The crystallisation conditions are, from the top down: slow cooling from THF, slow cooling from 
EMK, fast cooling from EMK, fast cooling from acetone, slow cooling from dioxane, and fast cooling 
from dioxane. 
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2.6  Thermodynamic Relationships Between the Solvated 
 Forms of Mexiletine 
Both solvate families are metastable with respect to Form 1. If removed from the 
mother liquor and stored under ambient conditions, the solvates transform into Form 
1 in a time ranging from one hour to one day, depending on how the sample was 
crystallised and which solvent is included in the pores. If either of the channel solvates 
are subject to desolvation at increased temperatures, they transform into the high 
temperature stable Form 2, which was confirmed using PXRD (Figure 2.26). 
 
Figure 2.26: PXRD pattern of Form 2 calculated from the crystal structure, compared to experimental 
PXRD patterns of various Type A and B solvates, heated above their transition temperatures on a hot 
stage microscope. From the bottom up, samples were crystallised by: sublimation at 150 °C for 7 
hours, slow cooling from toluene, slow cooling from DCM, precipitation using hexane from 2-
propanol, slow cooling from EMK, and slow cooling from 1,4-dioxane.  
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DSC measurements showed that the polymorphic transition to Form 2 occurs at a 
different temperature for each solvate. Representative DSC thermograms of each 
solvate family are shown in Figure 2.27. In some cases, the polymorphic transition is 
well defined, whereas in others it is very broad and often, the data is not reproducible. 
Despite this variation, the melting transition in all solvates occurs at approximately 
202 °C, which corresponds to that of Form 2, and confirms that the transition has taken 
place. The broad peaks and inconsistent desolvation behaviour signify that the solvent 
is non-stoichiometric and loosely bound within the channels. As a result, the solvent 
content will vary between different samples and may change over time if the sample 
was stored prior to measurement, leading to differences in the desolvation endotherm. 
This effect is compounded in the Type B solvates due to their structural similarity with 
Form 2, which means that very little molecular rearrangement is required to change 
between the two forms, and the transition has a low enthalpy. Therefore, the 
desolvation endotherms are much broader in the Type B solvates than Type A.  
Similar inconsistencies were also observed when the solvates were characterised 
using TGA. The measurement was repeated multiple times for each solvate, and 
almost never led to consistent results, which is further confirmation that the solvent is 
non-stoichiometric and loosely bound within the channels. For these reasons, TGA 
was not a suitable technique to characterise the channel solvates. 
120 
 
 
Figure 2.27: DSC thermograms of (a) three Type A solvates, crystallised by slow cooling from 
toluene, precipitation from 2-propanol/hexane and evaporation from DCM (b) three Type B solvates, 
crystallised by slow cooling from dioxane, EMK and acetone. 
 Table 2.10: The enthalpy and onset temperature of each transition in the above DSC thermograms. 
  
 
Desolvation Melting point 
Onset / 
°C 
Peak / 
°C 
ΔH / 
kJmol
-1
 
Onset / 
°C 
Peak / 
°C 
ΔH / 
kJmol
-1
 
A Tol SC 104 120 7.7 201 
 
201 14.2 
 
A 2PrOH/Hex 142 
 
150 6.3 
 
201 
 
202 13.8 
 
A DCM EV 133 
 
141 3.1 
 
196 
 
202 17.2 
 
B Dio SC 85 115 11.4 201 201 14.2 
B EMK SC - - - 201 201 15.6 
B AcO SC - - - 201 202 14.0 
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2.7  Characterisation of Mixtures 
Concomitant crystallisation of multiple forms was observed in precipitation 
experiments from CHCl3/hexane and DCM/hexane. PXRD data shows that the sample 
crystallised from CHCl3/hexane is a mixture of Form 1 and a Type B solvate (Figure 
2.28a). The Type B solvate rapidly transforms into Form 1 and as a result, it was not 
possible to characterise this form by SS NMR. 
 
Figure 2.28: (a) PXRD patterns of the Type B solvate crystallised by precipitation from CHCl-
3/hexane, compared with the Type B solvate crystallised by slow cooling from THF, and Form 1. (b) 
PXRD patterns of the Type B solvate crystallised by precipitation from DCM/hexane, compared with 
the Type B solvate crystallised by slow cooling from acetone. 
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The mixture crystallised from DCM/hexane contained large and small crystals. 
Single-crystal X-ray diffraction revealed the larger crystals to be a Type A solvate 
containing highly disordered electron density within the pores (Table 2.6). There were 
no residual peaks large enough to correspond to a chlorine atom and so the solvent 
was assumed to be hexane, which mirrors the behaviour of other Type A solvates 
crystallised by precipitation. The smaller crystals did not allow the determination of a 
full structure, but their unit cell (Table 2.11) and PXRD pattern (Figure 2.28b) showed 
them to be a Type B solvate.  
Table 2.11: Unit cell dimensions of the Type B solvate crystallised by vapour diffusion of hexane into 
DCM, compared to the Type B EMK solvate crystallised by slow cooling. 
 
 
 
 
 
 
  
Crystallisation 
Conditions 
EMK SC 
slow cooling 
DCM/hexane  
vapour diffusion 
a/Å 27.91(2) 7.473(12) 
b/Å 27.91(2) 27.72(2) 
c/Å 7.515(8) 27.74(2) 
α/° 90 90 
β/° 90 90 
γ/° 90 90 
123 
 
The cross-polarisation SS NMR spectrum of this mixture contained signals from 
both DCM and hexane, but only hexane was observed by direct-excitation (Figure 
2.29). As the hexane molecules were attributed to the Type A solvate, this data 
suggests that the Type B solvate contains crystalline DCM within the pores. Given 
that solvent-free forms of both the Type A and B solvates were crystallised from DCM, 
it is surprising that crystalline DCM was found within this Type B solvate. Perhaps 
the addition of hexane to the solvent mixture provides a means to stabilise this unusual 
structure. 
 
Figure 2.29: (a) Cross-polarisation and (b) direct-excitation 13C SS NMR spectra of mexiletine, 
crystallised by precipitation from DCM/hexane. The arrows highlight the solvent peaks, 
corresponding to DCM at 52.8 ppm and hexane at 33.2 and 23.7 ppm. The hexane signal at 14 ppm, 
highlighted with an asterisk, overlaps with a drug signal and is therefore higher intensity. The inset 
spectrum highlights the aromatic region of the cross-polarisation spectrum that confirms the sample 
was a mixture of a Type A and Type B solvate. 
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2.8  Conformational Polymorphism 
The molecular conformation in all polymorphs of mexiletine, except for the highly 
disordered Type B EMK solvate, are shown in Figure 2.30. 
 
Figure 2.30: The molecular conformation in (a) molecule 1 of Form 1, (b) molecule 2 of Form 1, (c) 
the gauche conformer of Form 2, (d) the anti-periplanar conformer of Form 2, (e) Form 3 and (f) the 
solvent-free Type A form. 
The differences between these conformations were quantified using Mercury.32  
Two equivalent atoms in a pair of molecules from different crystal structures were 
overlaid, producing a root mean square deviation (RMSD) for their atomic positions. 
A review of nearly 3000 crystal structures from the CSD concluded that for two 
conformations to be considered unique, they require an RMSD greater than 0.375 Å.40 
The results of these comparisons can be found in Table 2.12. 
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Table 2.12: RMSD values (Å) deriving from a comparison of the molecular conformation in all the crystal structures of mexiletine. The cells are colour coded to denote 
whether the conformations are the same (green) or different (red), based on whether their RMSD value. 
 
 Form 1  
Molecule 1 
Form 1  
Molecule 2 
Form 2  
Gauche 
Form 2  
Anti 
Form 3 
Type A  
Solvent-free 
Type A  
MeOH 
Type A  
1PrOH/Oct 
Type A  
2BuOH/Oct 
Type A  
2PrOH/Hex 
Type A 
DCM/Hex 
Type A  
DMF/DEE 
Form 1  
Molecule 1 
-            
Form 1  
Molecule 2 
0.041 -           
Form 2  
Gauche 
0.138 0.131 -          
Form 2  
Anti 
0.635 0.629 0.615 -         
Form 3 0.636 0.629 0.596 0.492 -        
Type A  
Solvent-free 
0.548 0.545 0.517 0.554 0.203 -       
Type A  
MeOH 
0.549 0.548 0.522 0.560 0.222 0.026 -      
Type A  
1PrOH/Oct 
0.551 0.548 0.521 0.548 0.194 0.028 0.036 -     
Type A  
2BuOH/Oct 
0.550 0.548 0.522 0.547 0.194 0.028 0.036 0.006 -    
Type A  
2PrOH/Hex 
0.547 0.544 0.518 0.549 0.199 0.026 0.033 0.010 0.009 -   
Type A  
DCM/Hex 
0.545 0.542 0.514 0.551 0.196 0.023 0.039 0.023 0.023 0.021 -  
Type A  
DMF/DEE 
0.545 0.542 0.515 0.555 0.202 0.014 0.027 0.019 0.019 0.017 0.018 - 
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These results show that the non-solvated polymorphs of mexiletine, Forms 1, 2 and 
3, are conformational polymorphs, producing RMSD values above the threshold  
(0.375 Å).40 The lower occupancy, gauche conformer of Form 2 is an exception, and 
shares its conformation with Form 1. However, as the higher occupancy, anti-
periplanar conformer is significantly different to all the other forms, Form 2 can also 
be considered a conformational polymorph of the other non-solvated forms. The major 
difference between Forms 1, 2 and 3 is the position of the terminal ammonium group, 
which is evident from the O-C-C-N torsion angles that range from 47.8 to 67.8 ° (Table 
2.13). A slight difference in torsion angle is also observed between the two symmetry 
independent molecules of Form 1, even though their conformations are the same, 
producing an RMSD value of only 0.041 Å. The Type A solvates all share the same 
conformation, with RMSD values less than 0.04 Å, and only a slight variation in 
O-C-C-N torsion angle of 5–7 ° (Table 2.13). The Type A solvates also have the same 
conformation as Form 3, with RMSD values around 0.2 Å. Given that these forms 
share similar structural motifs (Figure 2.14), this conformational similarity suggests 
that the Type A solvates may be modifications of Form 3, adapted to allow for the 
incorporation of solvent within the lattice.  
Table 2.13: O-C-C-N torsion angles in all crystal structures of mexiletine. The number in brackets is 
the error on the final digit. 
 
 
 
 
 
 
Solid Form Conformation O-C-C-N Torsion Angle / ° 
Form 1 molecule 1 Gauche 57.9(8) 
Form 1 molecule 2 Gauche 60.6(8) 
Form 2 gauche Gauche 47.8(15) 
Form 2 anti Anti-periplanar 174.5(6) 
Form 3 Gauche 67.8(3) 
Type A solvent-free Gauche 60.8(3) 
Type A MeOH Gauche 61.4(1) 
Type A 1PrOH/Oct Gauche 61.6(2) 
Type A 2BuOH/Oct Gauche 61.7(2) 
Type A 2PrOH/Hex Gauche 62.1(2) 
Type A DCM/Hex Gauche 60.9(4) 
Type A DMF/DEE Gauche 60.8(2) 
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2.9  Crystal Structure Prediction 
Alongside experimental techniques, the polymorph landscape of mexiletine 
hydrochloride was also investigated by crystal structure prediction, using a force-field 
approach designed by AstraZeneca, AZ-FF.34 A detailed description of the calculation 
procedure can be found in the experimental section, Chapter 5. Of the 1000 predicted 
structures, 77 were found to be within 10 kJmol-1 of the minimum energy form, which 
corresponds to structures that may be accessible using standard experimental 
techniques. The relative energies of these forms at 0 K are shown in Figure 2.31, as a 
function of density. This calculation predicted structures with only one mexiletine 
molecule per asymmetric unit and did not consider solvated forms. As a result, neither 
Form 1 nor the Type B solvates could not be found in this CSP search, as they both 
have two molecules per asymmetric unit. Despite having one molecule per asymmetric 
unit, neither Form 2 nor the Type A solvates were predicted by the calculation, likely 
due to their very high relative energy and large voids, respectively. However, Form 2 
is closely related to predicted Form 314. Form 3 was successfully predicted by the 
calculation and is isostructural with predicted Form 973. In Figure 2.31, predicted 
structures that are isostructural with known forms are highlighted in red. For 
comparison, the relative energies of the known Forms 1, 2, 3 and the Type A solvent-
free form were calculated from their crystal structures and are also plotted in red. The 
Type A form has a much lower density and so for clarity, its relative energy is shown 
in a separate plot. 
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Figure 2.31:  The relative energies of the predicted crystal structures of mexiletine, compared to the 
known forms. The known forms are labelled F1-F3 and the predicted structures are numbered. Known 
forms, and the predicted forms that are isostructural with known forms, are highlighted in red. 
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The calculated energies of the known forms reflect the experimental DSC data. 
Form 1 has the lowest relative energy of the four experimental polymorphs, at 
0.2 kJmol-1 and Form 3 is close in energy to Form 1 at 0.4 kJmol-1. Likely due to the 
presence of large voids, the Type A solvent-free form is much higher in energy at 
3.6 kJmol-1 although, it is still lower energy than most of the predicted structures. 
Finally, as excepted, Form 2 has the highest relative energy at 8.8 kJmol-1. The very 
small energy difference between Forms 1 and 3 may explain why they often crystallise 
concomitantly and DSC data suggest that Form 3 may be more stable than Form 1, 
above the Form 1 to 2 transition temperature.  
There is a very small difference in energy between Form 3 and its isostructural 
predicted Form 973, which derives from small differences in unit cell dimensions, and 
is within the accuracy of this technique. However, there is a very large difference in 
energy between Form 2 and the closely related predicted Form 314. The only structural 
difference between these two structures is that the molecules in Form 314 are spaced 
slightly wider apart in the b-direction, leading to a lower density. The Mercury packing 
similarity analysis of Forms 2 and 314 shows that all 20 molecules in the group 
overlap, with an RMSD of 0.185l Å, indicating that the packing arrangements are 
essentially the same. Similarly, the molecular conformation in Form 314 is identical 
to that of the anti-periplanar molecule in Form 2, with an RMSD of only 0.0984 Å. 
The lower energy of Form 314 may therefore derive from the lack of disorder. 
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Predicted Form 937 stands out because it is very low energy, at 0.4 kJmol-1. This 
form was not observed experimentally but is in fact a high symmetry version of Form 
3, in which the a-axis has been halved (Figure 2.32). The density of Form 937 is 
slightly higher than Form 3 because the molecules pack more closely together but 
other than that, the packing arrangements of the two forms are very similar. The 
molecular conformation in Form 314 is also identical to Form 3, with an RMSD of 
only 0.0322 Å. It seems that the predicted Form 937 is a more idealized version of 
Form 3, which is prohibited from crystallising experimentally due to defects during 
the nucleation or growth step. 
 
 
 
 
 
 
 
 
Figure 2.32: Packing arrangement in one unit cell of (a) Form 3 and (b) predicted Form 937 of 
mexiletine, viewed down the c-axis. 
Although the Type A solvent-free form was not found in this CSP search, predicted 
Form 662 has the same space group and similar hydrogen bonding motifs. As in the 
Type A structures, there are three hydrogen bonds per chloride ion that produce a 
hydrogen-bonded mexiletine polymer down the crystallographic c-axis, in which the 
molecules are arranged in a square formation (Figure 2.33).  However, only 1 out of a 
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group of 20 molecules overlapped when two structures were overlaid, with an RMSD 
value of 0.545 Å showing that their packing arrangements are very different.  
 
Figure 2.33: Predicted Form 662 of mexiletine, viewed down the c-axis.  
The main difference between Form 662 and the solvent-free Type A form is the 
density. Due to a lack of voids, Form 662 is significantly more dense, at 1.22 gcm-3, 
compared to 1.045 gcm-3 for the solvent-free Type A form. Even the Type A methanol 
solvate, which does not have empty voids, is less dense than Form 662 at 1.15gcm-3. 
The molecules pack much more closely together in Form 662, which leads to its higher 
density.  
In Form 662, the mexiletine molecule adopts an anti-periplanar conformation that 
is only observed in the highest energy experimental polymorph, Form 2. This 
anti-periplanar conformation is observed in all the predicted structures, apart from 
Form 924, and the two forms that are isostructural with Form 3: Forms 973 and 937. 
Form 924 is markedly different to all the known forms in terms of both molecular 
conformation and packing arrangement. The gauche molecule in Form 2 has the most 
similar conformation to Form 924, although an RMSD value of 0.485 Å shows the 
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two conformations are statistically different. Similarly, the Mercury packing similarity 
analysis showed that only 2 or 3 molecules of Form 924 overlap with Forms 1, 2 and 
3, out of a group of 20. Although the hydrogen bonding motifs in Form 924 are very 
similar to Form 3, it is clear that the change in molecular conformation causes the 
molecules to pack together very differently (Figure 2.34).  
 
Figure 2.34: The packing arrangement in predicted Form 924 of mexiletine, compared to Form 3, 
viewed down the (a) a-axis, (b) b-axis and (c) c-axis. In image (c), the centres of inversion are shown 
as black circles and the c-glide planes are shown as black lines. There are more glide planes in 
Form 924, which have been omitted for clarity.  
A gauche conformation is observed in both the lowest energy predicted Forms 973 
and 937. All the other predicted structures are significantly higher in energy, and apart 
from one exception, have an anti-periplanar conformation. These results suggest that 
the anti-periplanar conformation is higher energy than the gauche one, and mirror 
experimental observations in which an anti-periplanar conformation is only observed 
133 
 
in the highest energy Form 2. This high energy, anti-periplanar conformation is 
probably difficult to nucleate under ambient conditions and therefore, it is unlikely 
that any of the predicted forms would be accessible using standard experimental 
techniques. The only possible exception is Form 436, which is extremely dense and 
has a low relative energy of 3.5 kJmol-1. Although this form includes an anti-periplanar 
conformation, the barrier to nucleating the less stable conformation may be overcome 
by crystallising mexiletine under high pressure.41 Taken as a whole, the CSP results 
come close to correctly identifying Form 3 as the most stable Z' = 1 polymorph under 
ambient conditions. The room temperature stable Z' = 2 Form 1 is denser and lower in 
energy, confirming it as the thermodynamic form at room temperature. The high 
temperature Form 2 is entropically stabilised and appears high on the CSP landscape. 
The absence of other low energy polymorphs in the CSP solid-form landscape gives 
confidence that the experimental screening has identified all the accessible non-
solvated forms of mexiletine hydrochloride. 
2.10  High-Pressure Crystallisation  
Aiming to find predicted Form 436 of mexiletine, which has a high density but low 
relative energy, a single crystal of Form 2 was compressed to 3.56 GPa in a diamond 
anvil cell. Form 2 was chosen for this experiment because it has the same anti-
periplanar conformation as Form 436, which minimises the molecular rearrangement 
required to carry out the transformation. Although the crystal remained intact under 
high pressure, the quality reduced dramatically, and it was no longer birefringent 
(Figure 2.35). 
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Figure 2.35: A single crystal of mexiletine Form 2, compressed to 3.56 GPa in a diamond anvil cell, 
photographed under crossed polars.  
A slight expansion of the unit cell was observed when the crystal was compressed 
(Table 2.14). Due to the reduced crystal quality, the diffraction at high pressure was 
very weak and the resolution was poor, which may have led to the discrepancy in unit 
cell dimensions. Similarly, the high-pressure data were recorded at room temperature 
whereas the ambient-pressure structure of Form 2 was recorded at 120 K, which may 
also have contributed to the expansion of the unit cell. Although predicted Form 436 
was not observed in this experiment, these changes in unit cell dimensions suggest that 
there is significant potential for further study of mexiletine at high pressure. 
Table 2.14: Unit cell dimensions obtained by compressing a crystal of Form 2 of mexiletine to 3.56 
GPa. Data were recorded at room temperature in a diamond anvil cell. 
 
  
 Crystal compressed to 3.56 GPa 
a/Å 18.680(3) 
b/Å 18.125(9) 
c/Å 7.398(4) 
α/° 90 
β/° 90.04(10) 
γ/° 90 
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2.11  Gas Sorption Studies 
To further investigate the porosity of the solvent-free Type A and B forms, gas 
sorption experiments were carried out using I2 vapour.36 Iodine is a common choice 
for these experiments due to its characteristic colour, which provides a visual 
indication of whether the gas has been absorbed. Tests were carried out by placing a 
crystalline sample of the solvent-free form of both polymorphs into a sealed vial close 
to, but not touching a similar mass of solid iodine (Figure 2.36). The experiments were 
carried out at room temperature, allowing the iodine to sublime gradually and diffuse 
into the porous crystals. The crystals were monitored for colour changes that would 
signify iodine absorption, and each sample was also characterised by PXRD to 
investigate any structural change. A typical vapour diffusion set-up involving two 
vials placed one inside the other was not effective for this experiment because iodine 
does not sublime rapidly at room temperature so very little iodine vapour diffused into 
the inner vial before the crystals transformed to Form 1. The mexiletine and iodine 
powders were therefore placed on opposite sides of the same vial to maximise iodine 
exposure. This meant that the front of the drug powder was exposed more directly to 
the iodine vapour than the back, which led to uneven iodine adsorption in the early 
stages of the experiment. However, the solvates both became uniformly coloured 
within one hour of iodine exposure and in each case, the mexiletine-containing powder 
was thoroughly mixed before PXRD analysis. These tests were also carried out using 
Form 1, to act as a control, and given the metastability of the solvates, the whole 
process was undertaken within 24 hours to minimise the transformation to Form 1. 
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When exposed to iodine vapour, crystals of the solvent-free Type A form began to 
change colour immediately and darkened significantly over time from light pink, to 
purple, to brown. When viewed under a microscope, the Type A crystals appeared 
uniformly coloured, implying that iodine permeates the channels in the structure, 
rather than simply absorbing onto the crystal surface. Similar results were observed 
for the solvent-free Type B form, which rapidly darkened in colour when exposed to 
the vapour (Figure 2.36). Although individual Type B crystals became uniformly 
brown after 24 hours, the bulk sample remained patchy in colour and did not absorb 
iodine as efficiently as Type A, which is likely due to a polymorphic transition to Form 
1. These observations confirm that both solvent-free structures are porous and suggest 
that the iodine molecules are accommodated within the channels in the drug 
framework.  
 
Figure 2.36: Gas sorption experiments showing the colour change of the Type A and B solvent-free 
forms after 1, 3.5 and 25 hours of exposure to iodine vapour.  
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In contrast, Form 1 showed a much slower colour change from white to light brown. 
The colour was more intense on the edge of the powder than in the middle, which 
suggests this form is not permeable to iodine and the sample undergoes some limited 
surface sorption (Figure 2.37).   If removed from the iodine vapour and stored in air, 
the purple colour was lost rapidly from all samples, which suggests that the iodine 
molecules are only loosely bound to the drug structure, mirroring the behaviour of 
other guests bound within the channel solvates.   
 
Figure 2.37: Gas sorption experiment showing the colour change of Form 1 after 3.5 hours of 
exposure to iodine vapour. The inset image is viewed from the back, showing that the colour change 
is localised to the surface of the powder. 
The PXRD patterns of all forms developed a significant amorphous background 
with increased exposure to iodine vapour, signifying a decrease in crystallinity of the 
samples as the mexiletine molecules reorganise to maximise favourable interactions 
with the iodine (Figure 2.38). The solvent-free Type B structure could not be 
characterised using this method because its PXRD pattern already contains a 
significant amorphous background, as it is crystallised by fast cooling. The PXRD 
pattern of Form 1 remained unchanged with exposure to iodine, except for the reduced 
crystallinity. However, some differences were observed for the solvent-free Type A 
form. With a short exposure time, some small shifts and extra peaks were observed in 
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the PXRD pattern, but the key peaks characteristic of the Type A structures remained 
the same. However, with a longer exposure time, a new PXRD pattern was produced 
that does not match either the Type A solvates or Form 1, nor is it a mixture of the 
two. 
 
Figure 2.38: PXRD patterns of the solvent-free Type A structure and Form 1, following exposure to 
iodine vapour for different lengths of time. 
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To further investigate the co-crystallisation of mexiletine and iodine, a 
solution-phase crystallisation was carried out by vapour diffusion of hexane into an 
equimolar solution of mexiletine and iodine in DCM. The resulting structure is a 2:1:1 
co-crystal solvate containing mexiletine, I2 and DCM, respectively (Figure 2.39). 
Selected crystallographic information for this form can be found in Table 2.15 and the 
full crystallographic information is given in Appendix 7.1.  
Table 2.15: Selected crystallographic information for the co-crystal solvate containing mexiletine, 
iodine and DCM. 
Crystallisation 
Conditions 
Vapour diffusion of hexane into a DCM 
solution of mexiletine and I2 
Space Group P1ത 
a/Å 8.722(9) 
b/Å 13.657(14) 
c/Å 14.685(14) 
α/° 70.816(4) 
β/° 76.280(4) 
γ/° 78.824(4) 
V/Å3 1592.1(3) 
Z 4 
ρcalc g/cm3 1.607 
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In the co-crystal solvate, both the DCM and iodine molecules are disordered over 
two positions. Each DCM molecule has an occupancy of 0.5, whereas the iodine 
molecules have occupancies 0.97 and 0.03.  The two mexiletine molecules in the 
asymmetric unit have identical conformations (Figure 2.39), with an RMSD of only 
0.044 Å. This conformation is the same as in Form 1, producing an RMSD of 0.040 Å 
when the two were compared.  
 
Figure 2.39: The asymmetric unit of the 2:1:1 co-crystal solvate containing mexiletine, I2 and DCM. 
Both DCM molecules have an occupancy of 0.5, iodine molecule 1 has an occupancy of 0.97 and 
iodine molecule 2 has an occupancy of 0.03. 
Both the unit cell dimensions and the packing arrangement of mexiletine molecules 
in the iodine co-crystal solvate are very similar to Form 1 (Figure 2.40). The overlap 
between the two forms was 12 out of a group of 20 molecules, with an RMSD of 
0.357 Å, which signifies a moderate degree of similarity between them. In the co-
crystal solvate, there are two chloride environments: one with two NH contacts and 
one with four, and these NH···Cl hydrogen bonds connect hydrogen-bonded 
mexiletine polymers along the crystallographic a-axis. Although the hydrogen 
bonding motifs in co-crystal solvate are very similar to Form 1, the packing 
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arrangements down the b- and c-axes are reversed, so that the b-axis of one form 
mirrors the c-axis of the other. The molecules are also spaced more widely apart in the 
co-crystal, to accommodate the iodine and DCM. As is observed in the solvated forms, 
neither the iodine nor the DCM molecules interact with the drug framework and they 
are located in between the hydrogen-bonded mexiletine polymers (Figure 2.40).  
 
Figure 2.40: Packing arrangement in the 2:1:1 co-crystal solvate containing mexiletine, I2 and DCM, 
viewed down the a-axis. As they have equal occupancy, both DCM molecules are displayed in full 
but for clarity, only the higher occupancy iodine molecule is displayed.  
The calculated PXRD pattern of the iodine co-crystal solvate is a partial match for 
that of the solvent-free Type A structure following exposure to iodine vapour for 24 
hours. The PXRD pattern of the iodine-exposed sample contains some peaks 
corresponding to the solvent-free Type A structure and others corresponding to the co-
crystal solvate, suggesting that the sample is a mixture of the two forms (Figure 2.41). 
It is likely that the iodine is first absorbed into the channel solvate, and over a longer 
exposure time, the structure transforms to the co-crystal. The structure of the co-crystal 
is very different to both solvates and the high degree of molecular reorganization 
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required to change between these two forms is likely responsible for the amorphisation 
of these samples. 
 
Figure 2.41: PXRD pattern of the solvent-free Type A form, exposed to iodine vapour for 24 hours, 
compared to the calculated PXRD pattern of the mexiletine-iodine co-crystal solvate.  
2.12  Conclusions 
In conclusion, this polymorph screen has revealed that the solid-state landscape of 
mexiletine hydrochloride includes three non-solvated polymorphs, termed Forms 1, 2 
and 3 and two families of isomorphic channel solvates, termed Types A and B. In both 
solvate families, the drug framework acts as a host and remains mostly unchanged 
with the inclusion of different guests. The solvates differ in their value of Zʹ, with Type 
A having one molecule per asymmetric unit and Type B having two. The two families 
are related by similar packing arrangements and hydrogen bonding motifs, but the 
Type B structure is significantly more complex. We have found eleven modifications 
of each solvate, including a wide range of different solvents with aliphatic, aromatic, 
polar and non-polar functionalities. Mexiletine was previously known to be an 
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enantiotropic system, in which Form 1 is stable at low temperatures and Form 2 is 
stable at high temperatures. This study reports for the first time, the single-crystal 
structure of Form 2, which was accessed by sublimation and is structurally related to 
the Type B solvates. The structure of each polymorph was characterised by PXRD and 
IR spectroscopy, and the composition of the solvates was also investigated using 13C 
solid-state NMR spectroscopy, because the solvent was often too disordered to diffract 
X-rays. The experimental results were supported using computational tools including 
Mercury and PolySNAP, which compared the structures and quantified their 
similarity. Finally, a crystal structure prediction study replicated many of the structural 
and hydrogen bonding motifs seen in the experimental forms, including the prediction 
of precise structural analogues of Forms 2 and 3. This calculation showed that Forms 
1 and 3 are close together in energy whilst Form 2 is significantly less stable at 0 K. 
This result mirrors experimental trends in which Form 3 crystallised concomitantly 
with Form 1, and Form 2 was only accessible at high temperatures. Most of the 
predicted forms include an anti-periplanar conformation of mexiletine’s aromatic 
chain, which was only observed experimentally in the high temperature stable Form 
2. The inclusion of this high energy conformation likely explains why very few of the 
predicted forms crystallised experimentally. The porous Type A and B structures are 
capable of reversibly including iodine vapour and in the case of Type A, the iodine 
inclusion complex undergoes a rearrangement to an iodine co-crystal.  
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3. Tailored Supramolecular Gelators for the 
Crystallisation of Mexiletine Hydrochloride 
3.1  Introduction 
Controlling the solid form of an API is paramount in creating a safe and effective 
medicine1-5 and there is increasing pressure on pharmaceutical companies to 
characterise and patent the solid-form landscape of new APIs.6, 7 As a result, many 
novel crystallisation techniques have emerged, to increase the scope of traditional 
solution-phase polymorph screens and ensure the solid-form landscape of an API is 
fully understood before marketing the product. These include soluble crystallisation 
additives, heterogeneous nucleation, epitaxy, macro- and nano-scale confinement, 
microemulsions, self-assembled monolayers and gel-phase crystallisation.8-10 
Gel-phase crystallisation originated from the field of protein crystallography, in which 
polymeric hydrogels such as silica or agarose were used to increase crystal quality by 
slowing diffusion and limiting nucleation.11-13 Small molecule supramolecular gels, 
held together by non-covalent interactions, are tuneable, reversible and more varied in 
structure than their polymeric counterparts.14-17 Several studies report alterations to the 
size, habit, quality and solid form of crystals grown within supramolecular gels. In 
some cases, the self-assembly processes of the gel and crystals are orthogonal and 
changes in solid form derive from reduced nucleation within the gel environment.10, 
18, 19 Whereas in others, the gelators were designed to interact with the target drug. In 
these systems, the gel fibres can act as a heterogeneous nucleation surface and provide 
a template to encourage epitaxial overgrowth of highly metastable or difficult to 
nucleate solid forms.20-25 If the correct functionality is included, the gelation can even 
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be switched off by the addition of anions so that the crystals can be retrieved by 
filtration.26 
Gelator molecules can interact with a crystallising drug by several different 
mechanisms. Acid-amine hydrogen bonds between a carboxylic acid containing drug 
and an amine containing dendron gelator supported the crystallisation of an unusual 
polymorph of carbamazapeine.22 Similarly, a novel polymorph of chlorphenesin was 
crystallised from a calixarene-based gel, in which the drug molecules bound to the 
hydrophobic cavities along the gel fibres, acting as nucleation sites for the new form.23 
Cis-platin mimicking gelators have shown that incorporating some chemical 
functionality from the drug structure into the gelator provides a template for the 
crystallisation of unusual drug polymorphs. In this case, a previously unknown solvate 
of cis-platin.24 Similarly, ROY-mimetic gelators containing the same torsion angle as 
ROY’s metastable R polymorph led to the reliable crystallisation of this form, from 
solvents that would typically crystallise the thermodynamically stable Y form.20 A 
recent study suggests that, in systems where there is a significant interaction between 
the drug and gelator, nucleation of the gel fibres and drug crystals can become 
competitive rather than orthogonal processes, preventing the formation of a gel 
network.27  
This work reports the design of drug-mimetic supramolecular gelators for the 
crystallisation of the antiarrhythmic drug mexiletine hydrochloride (Figure 3.1). As 
described in Chapter 2, mexiletine has five known solid forms. Forms 128 and 2 are an 
enantiotropic pair of anhydrous polymorphs that are stable at different temperatures, 
Form 329 is an anhydrous metastable polymorph and there are two related families of 
metastable channel solvates termed Type A and B.  
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Figure 3.1: The structure of mexiletine hydrochloride. 
Mexiletine is a prolific solvate former, with eleven members of each family 
discovered to date. It is therefore likely that more solvated forms with a similar 
structure are possible. Several forms of mexiletine also crystallise as mixtures, because 
two polymorphs are close together in energy. The potential for undiscovered solid 
forms and the opportunity to separate concomitantly crystallising polymorphs makes 
mexiletine HCl an ideal candidate for gel-phase crystallisation. Indeed, gel-phase 
crystallisation of mexiletine has already been attempted by our group, using a 
nanocellulose gelator that was designed to form hydrogen bonds with the target drugs. 
However, due to the high solubility of mexiletine in the solvent used to form these 
gels, the drug did not crystallise.25 The gelators described in this work gel a much 
wider range of solvents and therefore present a greater opportunity for drug 
crystallisation. 
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3.2  Gelator Design 
Two of the gelators used in this study are bis-urea dimers, composed of a central 
linking group that provides the gelling properties of the molecule, and mexiletine 
mimetic end-groups that act as a template for the crystallising drug molecules. The 
linking groups were chosen due to their strong gelling ability, which has been 
discussed widely in previous work from our group.20, 26, 27, 30-39 The third gelator is a 
tris-amide trimer, with a central benzene 1,3,5-tricarboxamide group, derivatives of 
which have previously demonstrated reliable hydro-40-43 and organo-gelation44-48 
behaviour. The terminal amine in mexiletine HCl means that the entire drug structure 
could easily be connected to the linker molecule. Using the whole molecule as an end-
group, instead of mimicking one structural feature,20, 24, 31 is likely to strengthen the 
templating effect by increasing the structural similarity between the drug and gelator.31 
The three gelators used in this study are shown in Figure 3.2. 
 
Figure 3.2: Structure of the three gelators, compounds 1, 2 and 3. 
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All three gelators were synthesised using simple, one-step reactions between the 
linking group and mexiletine HCl, in the presence of triethylamine (Figure 3.3). In the 
bis-urea syntheses, the isocyanate form of the linking group was used whereas, 
1,3,5-benzenetricarbonyl trichloride was used to make the tris-amide gelator.  
 
Figure 3.3: Synthetic routes to compounds 1, 2 and 3.  
The isocyanate form of linker 1 was synthesised according to the literature method; 
from the corresponding amine and di-tert-butyl dicarbonate49 (Figure 3.4), whereas 
the other starting materials could be purchased from standard commercial sources. 
Full experimental details and characterisation data for all three gelators can be found 
in the experimental section, Chapter 5. 
 
Figure 3.4: Synthesis of bis(3,5-diethyl-4-isocyanatophenyl)methane. 
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3.3  Gel Characterisation 
The gelation behaviour of compounds 1, 2 and 3 was tested in 46 solvents, spanning 
a wide range of chemical functionality. A 2 % w/v solution of the gelator was heated 
to its boiling point in a sealed vial, using a heat gun. The solution was placed in an 
insulating wooden block at room temperature and monitored for 24 hours. Gelation 
was identified by the inversion test. If the material supported its own weight and did 
not flow when the vial was inverted, the material was classed as a gel. The results of 
gel screening are shown in Table 3.1. Compound 1 was the best gelator, gelling 35 out 
of the 46 solvents tested, whereas compound 2 gelled 13 solvents and compound 3 
gelled 8. This pattern reflects previous studies, in which compounds based on linker 1 
were the strongest gelators.20, 30, 33 Of the 46 solvents used for gel testing, 20 were 
included in the solution-phase polymorph screen of mexiletine that is described in 
Chapter 2. Including partial gels, compound 1 gelled 15 of these solvents, compound 
2 gelled 3 and compound 3 did not gel any. These solvents were used for most of the 
gel-phase crystallisation experiments because the solution-phase polymorphism data 
could be used as a control. 
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Table 3.1: Gel screening results for Compounds 1, 2 and 3. G = gel, PG = partial gel (part of the 
sample has gelled, but part remains in solution), S = solution, I = insoluble, PPT = precipitate, C = 
crystals. * = These solvents were included in the solution-phase polymorph screen in Chapter 2. 
Solvent Compound 1 Compound 2 Compound 3 
1,2,4-trichlorobenzene G G G 
1,2-dibromoethane G G G 
Ethyl methyl ketone, EMK* G S I 
1,2-dichlorobenzene G G G 
1,3-dichlorobenzene G G G 
1,4-dioxane* G S PPT 
1-butanol* G S PPT 
1-pentanol* G S PPT 
1-propanol* G S I 
2-butanol* G S I 
2-Ethyl pyridine G S G 
2-Picoline G S PG + C 
2-propanol* G S I 
3-chloro-1-propanol S S PPT 
3-Picoline G S S 
4-Ethyl pyridine G S S 
4-Picoline G S S 
Acetone* I S I 
Acetonitrile* G PPT I 
Benzene PPT G I 
Benzyl alcohol G S S 
Chlorobenzene G G G 
Chloroform* S S PPT 
Cyclohexane PPT PPT I 
Cyclohexanone G S PPT 
Cyclopentanone G S S 
Dichloromethane* G S PPT 
Diethyl ether* I I I 
Diethylene glycol G S I 
Diisopropyl ether I I I 
Dimethylacetamide G S S 
DMF* G S S 
DMSO* G S S 
Ethanol* G S I 
Ethyl acetate* PPT G I 
Ethylene glycol PPT G I 
Ethylene glycol butyl ether G S PPT 
Mesitylene PG G I 
Methanol* G S I 
Nitrobenzene G PG G 
Nitromethane* PG G PPT 
p-xylene G G S 
Pyridine G S PPT 
THF* PG S PPT 
Toluene* S G I 
Water I I PPT 
Solvents gelled 35/46 13/46 8/46 
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 At a concentration of 2 % w/v, gels of compound 1 were either opaque or contained 
visible particles of undissolved gelator. Transparent gels of compound 1 could be 
achieved by reducing the concentration to 1 % w/v although, solid gelator particles 
were unavoidable in gels of apolar or low boiling point solvents. Compounds 2 and 3 
were more soluble and these gels were therefore transparent. SEM images of the dried 
xerogels prepared from compounds 1, 2 and 3 in nitrobenzene all showed a fibrillar 
network characteristic of a supramolecular gel (Figure 3.5).50  
 
Figure 3.5: SEM micrographs of dried xerogels prepared from: (a) a 1 % (w/v) gel of compound 1 in 
nitrobenzene (b) a 2 % (w/v) gel of compound 2 in nitrobenzene (c) a 2 % (w/v) gel of compound 3 in 
nitrobenzene. Samples were coated in 7 nm gold-palladium.  
Oscillatory rheology was used to probe the mechanical properties of the gels. A 
1 % w/v gel of compound 1, and 2 % w/v gels of compounds 2 and 3 in 
1,2,4-trichlorobenzene were characterised using this technique. This solvent was 
chosen because its high boiling point and low vapour pressure produced uniform gels 
that did not dry out during the measurement (Figure 3.6). A lower concentration was 
used for compound 1 because this gelator has a lower solubility, and gels at 2 % w/v 
concentration contained undissolved solid that may alter their rheological properties. 
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Figure 3.6: (a) 1 % w/v gel of compound 1 in 1,2,4-trichlorobenzene, (b) 2 % w/v gel of compound 2 
in 1,2,4-trichlorobenzene and (c) 2 % w/v gel of compound 3 in 1,2,4-trichlorobenzene. 
The gel phase can be identified by a storage modulus approximately one order of 
magnitude greater than the loss modulus, that does not vary with frequency.51 This 
linear region was observed in the frequency sweep data for all gels, between 0.6 and 
210 rad/s (Figure 3.7a), and confirms that these materials all display the elastic 
behaviour characteristic of a gel. The yield stress of a gel, which is used to quantify 
its strength, can be identified from stress sweep data as the oscillation stress at which 
the storage and loss moduli are equal (Figure 3.7b). The bis-urea gels of compound 1 
and 2 were significantly stronger than the tris-amide gel of compound 3, due to the 
addition of an extra hydrogen bonding group. Despite the lower concentration, 
compound 1 produced the strongest gel, with a yield stress of ca. 320 Pa. The gel of 
compound 2 had a comparable yield stress of ca. 200 Pa whereas, compound 3 
produced a much weaker gel, with a yield stress of ca. 70 Pa. This trend mirrors 
previous reports in which bis-urea gelators containing the linking group in compound 
1 are stronger than those based on the linking group in compound 2.20, 30, 33  A weak 
strain overshoot was observed in gels of compound 1; where the loss modulus, G′′, 
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increases just before the yield stress. This behaviour is indicative of a second mode of 
aggregation, in which components of the gel fibre align in the direction of the applied 
shear, forming a weak structure that is capable of resisting deformation for a short 
time, before it yields and the gel begins to flow.52 Weak strain overshoot is common 
in systems containing hard particles.53, 54 The low solubility of compound 1 may have 
led to precipitation within the gel, which could have contributed to this behaviour.  
 
Figure 3.7: Oscillatory (a) frequency and (b) stress sweeps for a 1 % w/v gel of compound 1 in 
1,2,4-trichlorobenzene, and 2 % w/v gels of compounds 2 and 3 in 1,2,4-trichlorobenzene. Error bars 
indicate the standard deviation from repeated measurements. For clarity, only the positive error bars 
are displayed. 
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3.4  Solution-Phase Polymorph Screening 
Compound 3 did not gel any of the solvents that were included in the polymorph 
screen described in Chapter 2. Therefore, preliminary solution-phase crystallisations 
of mexiletine hydrochloride were carried out in the 6 solvents that were gelled by all 
three gelators, so that these results could be compared to the gel-phase crystallisations. 
Solution-phase crystallisations were carried out by slow cooling a supersaturated 
solution of mexiletine, formed by dissolving 20 mg of mexiletine powder in the 
minimum possible solvent and heating it to boiling in a sealed glass vial. The mixture 
was allowed to cool to room temperature in an insulating wooden block and monitored 
for crystallisation over time. PXRD was used to assess the polymorphism of the 
resulting crystals, as summarised in Table 3.2. 
Table 3.2: Polymorphism of the samples crystallised from by slow cooling from a supersaturated 
solution in 1,2-dibromoethane, chlorobenzene, 1,2-dichlorobezene, 1,3-dichlorobenzne, 
1,2,4-trichlorobenzene and nitrobenzene.  
Solvent Solid-Form Outcome 
Chlorobenzene (CB) Type A Solvate 
1,2-Dichlorobenzene (12DCB) Type A Solvate 
1,3-Dichlorobenzene (13DCB) Type A solvate 
1,2-Dibromoethane (DBE) Type B Solvate 
1,2,4-Trichlorobenzene (TCB) Type C TCB Solvate 
Nitrobenzene (NB) Type D NB Solvate 
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Four of the solution-phase crystallisations led to known forms characterised in 
Chapter 2. Crystallisation from the chlorinated solvents chlorobenzene, 
1,2-dichlorobenzene and 1,3-dichlorobenzene yielded Type A solvates with PXRD 
patterns that match the Type A diethyl ether solvate crystallised by vapour diffusion 
of diethyl ether into a saturated solution of mexiletine in DMF (Figure 3.8). 
 
Figure 3.8: PXRD patterns of the Type A solvates of mexiletine crystallised by slow cooling from 
chlorobenzene (CB), 1,2-dichlorobenzene (12DCB) and 1,3-dichlorobenzene (13DCB), compared to 
the Type A diethyl ether solvate crystallised by vapour diffusion of diethyl ether into a mexiletine 
solution in DMF (DMF/DEE). 
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Crystallisation from 1,2-dibromoethane produced a Type B solvate, with a PXRD 
pattern that matches the Type B solvate crystallised by slow cooling from EMK 
(Figure 3.9). 
 
Figure 3.9: PXRD patterns of the Type B dibromoethane (DBE) and ethyl methyl ketone (EMK) 
solvates of mexiletine, crystallised by slow cooling. 
Two new solvated polymorphs of mexiletine were crystallised from 
1,2,4-trichlorobenzene and nitrobenzene. Their PXRD patterns are not related and 
therefore, they will be referred to as the Type C 1,2,4-trichlorobenzene solvate and the 
Type D nitrobenzene solvate. In addition to the five forms characterised in Chapter 2, 
the discovery of these new solvates means that mexiletine has seven known solid 
forms. The PXRD pattern of the Type C polymorph contains unique peaks at  12.9, 
15.4 and 16.4 °, that are not observed in any of the forms identified in Chapter 2 
(Figure 3.10).  
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Figure 3.10: PXRD patterns of the form crystallised by slow cooling from 1,2,4-trichlorobenzene 
(TCB), compared to the Type D nitrobenzene solvate, and the five known forms from Chapter 2. For 
clarity, one representative example of the Type A and B solvates is shown. 
A single-crystal structure of the Type C solvate was recorded using a crystal grown 
by slow cooling a supersaturated solution of mexiletine in 1,2,4-trichlorobenzene. Full 
crystallographic information for this structure is given in Appendix 7.1.  The Type C 
structure is a 4:1 tetartosolvate in which the solvent molecules are situated inside 
channels that run along the a-axis of the mexiletine host framework. The structure is 
a racemate, with the asymmetric unit containing two identical pairs of mexiletine 
molecules and one 1,2,4-trichlorobenzene molecule. The two symmetry-independent 
mexiletine molecules both adopt a gauche conformation, with O-C-C-N torsion angles 
of 62.2 and 58.1 º, which are in line with other structures containing the 
R-O-CH2-CHR-NH3+ fragment in the CSD. Each ammonium cation hydrogen bonds 
to three chloride counterions, forming a hydrogen-bonded polymer along the 
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crystallographic a-axis. When viewed along this axis, the molecules are arranged in a 
square formation, versions of which are observed in all forms of mexiletine other than 
Form 1. In this case, the four molecules making up the square motif are related by 
inversion, as shown in Figure 3.11a. Although the solvent molecules in this structure 
are disordered, it was possible to model them without using a mask and they are clearly 
visible within the channels (Figure 3.11b). A precise solvent model was only obtained 
for one of the seven Type A solvate structures and this unusual behaviour is most 
likely caused by the limited number of positions that the large trichlorobenzene 
molecule can occupy within the small channel.  
 
Figure 3.11: The Type C 1,24-trichlorobenzene solvate, viewed down the a-axis, showing (a) the 
square motif with the inversion centre labelled as a black circle and (b) the disordered solvent situated 
inside one unit cell of the porous mexiletine framework.  
Although the Type C solvate has a different symmetry, the packing arrangement, 
hydrogen bonding motifs and unit cell dimensions are closely related to the Type A 
solvates. When compared to the Type A methanol solvate, which is the only member 
of that family in which the solvent molecules are clearly resolved in the crystal 
structure, several similarities are visible. Viewed down the channels, the packing 
arrangement of molecules within the mexiletine framework of the two solvates are 
nearly identical. Both structures consist of offset layers that alternate every half unit 
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cell, so the channels line up every other layer (Figure 3.12). The molecules are 
arranged very differently down the other two axes, although the hydrogen bonding 
motifs between molecules are closely related. There are slight differences in the unit 
cell dimensions of these two forms, which reflect changes in the channel dimensions 
to accommodate different solvents (Table 3.3).  
 
Figure 3.12: Packing arrangements in the Type C 1,2,4-trichlorobenzene solvate of mexiletine, 
compared to the Type A methanol solvate. 
Table 3.3: Selected crystallographic information for the Type C 1,2,4-trichlorobenzene solvate of 
mexiletine, compared to the Type A methanol solvate. 
 Type C TCB Type A MeOH 
Space group P21/c Pbcn 
a/Å 7.538(3) 20.243(7) 
b/Å 20.972(9) 18.768(6) 
c/Å 18.043(8) 7.550(2) 
α/° 90 90 
β/° 93.725(7) 90 
γ/° 90 90 
Volume/Å3 2846.0(2) 2868.4(15) 
Z 2 8 
ρcalc g/cm3 1.219 1.147 
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When stored for 24 hours under ambient conditions, the Type C trichlorobenzene 
solvate transformed into a Type A solvate, producing a PXRD pattern that closely 
matched the Type A diethyl ether solvate crystallised by vapour diffusion (Figure 
3.13). The Type A solvates are metastable with respect to Form 1 and so this unusual 
result suggests that the trichlorobenzene solvate may be very close in energy to the 
Type A solvates. As the two forms are structurally similar, only a small degree of 
molecular rearrangement is required during the transformation, which is reflected in 
the high crystallinity of the sample after storage.  
 
Figure 3.13: PXRD pattern of the Type C 1,2,4-trichlorobenzene solvate of mexiletine, compared 
with the same sample after being stored for 24 h, and the Type A diethyl ether solvate crystallised by 
vapour diffusion of diethyl ether into a saturated solution of mexiletine in DMF. 
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The polymorphic outcome of the crystallisations from nitrobenzene depended on 
the concentration of mexiletine. Low concentrations produced Form 1 whereas higher 
concentrations led to the Type D nitrobenzene solvate. The PXRD pattern of this form 
lacks several key peaks from each of the known forms and contains a unique peak at 
12.3 ° (Figure 3.14).  
 
Figure 3.14: PXRD patterns of the two forms of mexiletine crystallised by slow cooling from 
nitrobenzene, at a high and low concentration, compared with the five known forms from Chapter 2. 
For clarity, one representative example from the Type A and B solvates is shown.  
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Form 1 has a very characteristic IR spectrum and so IR spectroscopy was used to 
identify the concentration that favours the Type D polymorph over Form 1. Seven 
solutions were prepared, at varying concentrations according to Table 3.4. When 
20 mg of mexiletine was dissolved in 0.15 mL of nitrobenzene or less (>13.3 % w/v), 
the new form was produced. Whereas, solvent volumes of 0.2 mL and above (<10 % 
w/v) led to Form 1.  
Table 3.4: Polymorphic outcome of seven slow cooling crystallisations containing various 
concentrations of mexiletine in nitrobenzene.  
Mass of 
mexiletine / mg 
Volume of 
nitrobenzene / mL 
Concentration of  
mexiletine / % w/v 
Solid-Form 
Outcome 
20 0.05 40 Type D NB Solvate 
20 0.1 20 Type D NB Solvate 
20 0.15 13.3̇ Type D NB Solvate 
20 0.2 10 Form 1 
20 0.3 6.6̇ Form 1 
20 0.4 5 Form 1 
20 0.5 4 Form1 
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The Type D form can only be crystallised at high degrees of supersaturation, which 
suggests that it is metastable, and accordingly, it transformed into a mixture with Form 
1 when stored for 24 hours under ambient conditions (Figure 3.15). 
 
Figure 3.15: PXRD patterns of the Type D nitrobenzene solvate of mexiletine, crystallised at high 
concentrations from nitrobenzene, compared to the same sample after being stored for 24 h, and Form 1. 
The Type C and D solvates were further characterised by IR spectroscopy. Both 
forms have unique spectra, different to each other and the known forms (Figure 3.16). 
Both spectra also contained solvent peaks, which confirms that they are solvates. In 
the Type C 1,2,4-trichlorobenzene solvate, the solvent peaks occur at 1457, 866, 815, 
and 678 cm-1. Whereas, in the Type D nitrobenzene solvate, these peaks occur at 1527, 
1350, 1317, 852, 843, and 682 cm-1. From this data, it is not possible to know how the 
solvent molecules are incorporated into the Type D crystal structure. However, given 
that all previous solvated forms are channel solvates, it is likely that this form has a 
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similar structure. Similarly, there are likely to be more possible Type C solvates, 
incorporating different solvents into the channels. 
 
 
Figure 3.16: IR spectra of the Type C 1,24-trichlorobenzene solvate and Type D nitrobenzene  
solvate, both crystallised by slow cooling, compared to the five known forms from Chapter 2. For 
clarity, one representative example from the Type A and B solvates is shown. 
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It was not possible to characterise the Type C and D solvates by DSC and TGA 
because the extremely low vapour pressure of the solvents they were crystallised from 
caused significant amounts of solvent to adsorb onto the surface of the powders, 
meaning that the thermograms contained mostly solvent peaks. The powders could be 
dried in a desiccator or a low temperature oven, but by the time the solvent had 
evaporated, the samples had changed form.  
3.5  Gel-phase Crystallisation 
Gel-phase crystallisations of mexiletine were carried out using all three gelators, in 
solvents that were included in the solution-phase polymorph screens. The 
concentrations of the drug and gelator were optimised to ensure that where possible, 
gelation occurred before crystallisation, so that the gel network could interact with the 
crystallising drug molecules. Compound 1 was sparingly soluble in most solvents so 
a low concentration of gelator was used in these experiments, to avoid large gelator 
peaks in the PXRD patterns. The drug and gelator were dissolved in 0.5 mL of the 
required solvent by heating the mixture to the boiling point of the solvent in a sealed 
glass vial. The vials were placed in an insulating wooden block and monitored for 
gelation and crystallisation (Figure 3.17). After 24 hours, the vials were emptied onto 
filter paper, left to dry in air, and the resulting powder was characterised by PXRD. 
PXRD patterns of the gel-grown samples were compared to the solution-phase 
polymorph crystallised from the same solvent, to establish whether any change in 
polymorphism had occurred due to the presence of the gel network.  
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Figure 3.17: Gel-phase crystallisations of mexiletine in (a) a nitrobenzene gel of compound 2, at 
concentrations of 2 % w/v gelator 5 % w/v drug, and (b)a 1,2-dichlorobenzene gel of compound 1, at 
concentrations of 1 % gelator 5 % w/v drug. In results Tables 3.5, 3.6 and 3.7, samples like image (a) 
were described as gel + crystals whereas samples like image (b) were described as gel + precipitate. 
All gel-phase crystallisations using compound 3 resulted in the same solid forms as 
in solution (Table 3.5). Crystallisation within gels of 1,2-dichlorobenzene, 
1,3-dichlorobenzene and chlorobenzene led to Type A solvates, gels of 
1,2-dibromoethane crystallised a Type B solvate and gels of 1,2,4-trichlorobenzene 
and nitrobenzene produced Type C and D solvates, respectively. Gels of compound 3 
were an order of magnitude weaker than both the bis-urea gels, which suggests that 
they contained fewer gel fibres. The gel network may therefore have been insufficient 
to encourage the growth of new polymorphs, leading to the same crystallisation 
behaviour as in solution. 
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Table 3.5: Results of gel-phase crystallisations of mexiletine using compound 3. G = gel, C = crystals. 
Solvent 
Gelator 
Concentration 
/ % w/v 
Drug 
Concentration 
/ % w/v 
Gelation 
Behaviour 
Solid-Form 
Outcome 
1,2-Dichlorobenzene 2 5 G+C Type A 
1,3-Dichlorobenzene 2 5 G+C Type A 
Chlorobenzene 2 5 G+C Type A 
1,2-Dibromoethane 2 5 G+C Type B 
1,2,4-Trichlorobenzene 2 5 G+C Type C TCB 
Nitrobenzene 2 5 G+C Type D NB 
Mexiletine crystallised within 13 of the 15 gel-phase crystallisation experiments 
using compound 1 (Table 3.6). Due to its high solubility in polar solvents, mexiletine 
did not crystallise in any gel containing ethanol or methanol and the resulting PXRD 
patterns matched the gelator. These experiments are therefore omitted from Table 3.6.  
Table 3.6: Results of gel-phase crystallisations of mexiletine using compound 1.  
G = gel, C = crystals, P = precipitate, * = gel and solution-phase crystallisations yield different forms. 
Solvent 
Gelator 
Concentration 
/ % w/v 
Drug 
Concentration 
/ % w/v 
Gelation 
Behaviour 
Solid-Form 
Outcome 
Nitromethane 2 5 G+PPT Form 1 
Nitromethane 1 2 G+C Form 1 
1-Propanol 1 10 G+C Form 1 
2-Propanol 1 10 G+C Form 1 
1-Butanol 1 10 G+C Form 1 
2-Butanol 1 10 G+C Form 1 
Amyl Alcohol 1 10 G+C Form 1 
Acetonitrile 1 2 C Form 1 
Acetonitrile 2 5 C Form 3 
DCM 1 2 G+PPT Type A 
DCM 2 5 G+C Type A 
THF 1 2 G+C Type B 
THF 0.5 1 G+C Type B 
1,4-Dioxane 1 10 G+C Type B 
1,4-Dioxane 0.5 10 G+C Type B 
EMK 1 2 G+C Type B 
EMK 0.5 1 G+C Form 3* 
DMF 2 5 G+PPT Type A* 
DMF 1 10 PPT Type A* 
DMSO 2 5 G+PPT Type A* 
1,2-Dichlorobenzene 1 5 G+C Type A 
1,3-Dichlorobenzene 1 5 G+C Type A 
Chlorobenzene 1 5 G+PPT Type A 
1,2-Dibromoethane 1 5 G+C Type B 
1,2,4-Trichlorobenzene 1 5 G+C Type C TCB 
Nitrobenzene 1 5 G+C Type D NB 
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 Most gel-phase crystallisations using compound 1 yielded the same solid form as 
in solution. Form 1 was crystallised form gels of nitromethane, 1-propanol, 
2-propanol, 1-butanol, 2-butanol, and amyl alcohol. Type A solvates crystallised from 
gels in all chlorinated solvents: DCM, 1,2-dichlorobenzene, 1,3-dichlorobenzene and 
chlorobenzene, and Type B solvates crystallised from gels in THF and dioxane. 
Similarly, gels of 1,2,4-trichlorobenzene and nitrobenzene produced Type C and D 
solvates, respectively. Incorporation of mexiletine inhibited the gel formation of 
compound 1 in acetonitrile and accordingly, the result of these crystallisations was 
also the same as in solution. At concentrations of 1 % w/v gelator and 2 % w/v drug, 
mexiletine crystallised as Form 1, as observed in slow cooling crystallisations from 
pure acetonitrile. At a higher supersaturation, using 2 % w/v of gelator and 5 % w/v 
of drug, mexiletine crystallised as the metastable Form 3. This result mirrors 
solution-phase behaviour in which a mixture of Forms 1 and 3 can be crystallised by 
fast cooling from pure acetonitrile. 
In contrast, gel-phase crystallisations using compound 1 in EMK, DMF and DMSO 
produced different solid forms than in solution. A Type B solvate crystallises from 
EMK solution and the same form is observed from a gel containing 1 % w/v gelator 
and 2 % w/v drug. However, when the concentrations are reduced to 0.5 % w/v gelator 
and 1 % w/v drug, Form 3 is produced (Figure 3.18). Form 3 is a metastable 
polymorph, very close in energy to Form 1, and pure samples have only been 
crystallised previously from solution in acetone. The crystallisation of pure Form 3 
within this drug-mimetic gel highlights its ability to stabilise and selectively nucleate 
a metastable solid form. 
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Figure 3.18: PXRD patterns of the two solid forms of mexiletine crystallised within two EMK gels of 
compound 1, compared to Form 3, the Type B EMK solvate and compound 1. 
Finally, a crystalline solid form is produced from gels of compound 1 in DMF and 
DMSO, whereas mexiletine does not crystallise from solution in either of these 
solvents. The PXRD patterns of the gel-crystallised samples all contain gelator peaks, 
showing that only a small amount of the drug has crystallised. The crystallinity of the 
samples increases with drug concentration and at 1 % w/v gelator and 10 % w/v drug, 
some clear mexiletine peaks are observed at 4.9, 6.4, 19.5, 19.9, 24.4, 25.0, 29.3 and 
30.0 ° (Figure 3.19). These peaks match most closely with the Type A diethyl ether 
solvate, which is crystallised by vapour diffusion of diethyl ether into DMF. Although 
the low crystallinity of their PXRD patterns means that it is not possible to assign the 
polymorphism of these gel-grown crystals unequivocally, they are likely to be Type 
A solvates because that form can also be crystallised from DMF by vapour diffusion. 
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Similar behaviour was observed when sulfapyridine was crystallised from a 
nanocellulose organogel in DMSO. Crystallisation was not observed from a solution 
under the same conditions, even though the solution was highly supersaturated, and 
the gel network was thought to be acting as a kinetic nucleation promoter.25 It is 
therefore likely that in this case, the gel fibres are acting as nucleation sites to enable 
the crystallisation of a Type A solvate from an unusual solvent.  
 
Figure 3.19: PXRD patterns of the mexiletine solid forms crystallised from three DMF and DMSO 
gels of compound 1, compared to the gelator, and the Type A diethyl ether solvate crystallised by 
vapour diffusion of diethyl ether into DMF. 
The greatest changes in polymorphism were observed when mexiletine was 
crystallised using compound 2. The polymorphic outcome of these crystallisations was 
dependent on the concentration of mexiletine and in many cases, gelation was 
switched off in experiments that led to a change in solid form. This behaviour suggests 
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that there were significant interactions between the drug and gelator molecules that 
hindered the self-assembly of gel fibres.27 It is likely that the strong interactions 
between the drug and gelator molecules played a key role in the nucleation of unusual 
solid forms. Due to the inconsistent gelation behaviour of this system, several 
experiments were repeated multiple times, so that a reliable trend could be established 
(Table 3.7).  
Table 3.7: Results of gel-phase crystallisations of mexiletine using compound 2. G = gel, C = crystals, 
P = precipitate, * = gel and solution-phase crystallisations yield different forms, Type A′ = the 
contents of the channels differs between the Type A solvates crystallised from solutions and gels.  
Solvent 
Gelator 
Concentration 
/ % w/v 
Drug 
Concentration 
/ % w/v 
Gelation 
Behaviour 
Solid-Form 
Outcome 
Nitromethane 2 5 C Form 1 
Nitromethane 2 2 G+C Form 1 
Nitromethane 2 2 C Form 1 
Nitromethane 2 1 Weak G+C Form 1 
Nitromethane 2 1 C Form 1 
Toluene 2 5 C Type A Tol 
Toluene 2 2 C Type A Tol 
Toluene 2 2 G+C Type A Tol 
Toluene 2 1 C Type A Tol 
Toluene 2 1 PG+C Type A′* 
Ethyl Acetate 2 5 C Type A* 
Ethyl Acetate 2 2 C Type A* 
Ethyl Acetate 2 2 C Form 1 
Ethyl Acetate 2 2 G+C Form 1 
Ethyl Acetate 2 1 C Form 1 
Ethyl Acetate 2 1 C Type A′* 
1,2-Dichlorobenzene 2 5 G+C Type A 
1,3-Dichlorobenzene 2 5 G+C Type A 
Chlorobenzene 2 5 G+C Type A 
1,2-Dibromoethane 2 5 G+C Form 2* 
1,2,4-Trichlorobenzene 2 5 G+C Type C TCB 
Nitrobenzene 2 5 G+C Type D NB 
 
In several cases, the same solid form crystallised from gels as from solution. Form 
1 crystallised from gels of compound 2 in nitromethane, and Type A solvates 
crystallised from gels in 1,2-dichlorobenzene, 1,3-dichlorobenzene and 
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chlorobenzene. Similarly, Type C and D solvates crystallised from gels of 
1,2,4-trichlorobenzene and nitrobenzene, respectively. The majority of crystallisations 
from toluene also produced the same form as in solution: a Type A solvate. However, 
in one crystallisation with a low drug concentration of 1 % w/v, a new solid form was 
produced. The PXRD pattern of this form contains the key peaks characteristic of a 
Type A solvate and many extra peaks between 12–27 ° that are not present in the 
pattern of the toluene solvate crystallised from solution (Figure 3.20). The extra peaks 
in the PXRD pattern of the gel form suggest that the contents of the channels differ 
from the solution form. This new Type A solvate also crystallised from ethyl acetate 
at concentrations of 2 % w/v gelator and 1 % w/v mexiletine (Figure 3.20). This result 
is particularly unusual because mexiletine crystallises as Form 1 from ethyl acetate 
solution. In both of these cases, gelation was switched off by interactions between 
mexiletine and the gelator.27 
 
Figure 3.20: PXRD patterns of mexiletine crystallised from toluene and ethyl acetate solutions, at 
concentrations of 2 % w/v gelator and 1 % w/v drug, compared to Form 1, the Type A toluene 
solvate, and the gelator. 
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Two other ethyl acetate crystallisations, with concentrations of 2 % w/v gelator and 
2 or 5 % w/v drug, also led to a Type A form, although in these cases the PXRD pattern 
matched the Type A solvent-free structure (Figure 3.21). In this form, the channels 
may be empty or, could be filled with highly disordered solvent that does not diffract 
X-rays. It is clear that compound 2 has a profound effect on the nucleation of the Type 
A solvates, and the crystallisation of solvent within the channels. 
 
Figure 3.21: PXRD patterns of mexiletine crystallised from solutions in ethyl acetate, at 
concentrations of 2 % w/v gelator and 2 or 5 % w/v drug, compared to the Type A solvent-free form, 
and the gelator. 
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Finally, Form 2 crystallised from a gel of compound 2 in 1,2-dibromoethane 
(Figure 3.22). Form 2 is extremely high in energy and previously, has only been 
crystallised by sublimation or by heating another form above its transition 
temperature. Crystallisation within this gel is therefore the only known method to 
access Form 2 at room temperature. The sample did gel in this experiment, which 
suggests that the nucleation processes of the drug and gelator occurred on different 
timescales, likely driven by the high solubility of mexiletine in 1,2-dibromoethane. As 
a result, the gel network formed before the crystals began to grow, facilitating epitaxial 
overgrowth of crystals upon the gel fibres, and stabilising this extremely high energy 
solid form.  
 
Figure 3.22: PXRD pattern of the mexiletine solid form crystallised from a gel of compound 2 in 
1,2-dibromoethane, compared to Form 2, the Type B form crystallised from 1,2-dibromoethane 
solution, and the gelator.  
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3.6  Conclusions 
In conclusion, this work demonstrates the versatile gelation behaviour of three 
mexiletine-mimetic supramolecular gelators. Significant changes in polymorphism 
were observed when the API mexiletine HCl was crystallised within the two bis-urea 
gels. Gels of compound 1 in DMF and DMSO facilitated the crystallisation of a Type 
A solvate, in solvents from which mexiletine does not crystallise in solution. Similarly, 
in an EMK gel of compound 1, mexiletine crystallised as Form 3, which is metastable 
and often crystallises concomitantly with Form 1. This gel is only the second known 
route to access a pure sample of Form 3, which shows that the gel network can 
selectively nucleate a metastable solid form. Similarly, Form 2 was crystallised from 
a 1,2-dibromoethane gel of compound 2. Form 2 is the high temperature stable 
polymorph of mexiletine and is significantly higher in energy than all the other forms. 
Crystallisation within this gel is the only known route to access this form at room 
temperature, which demonstrates the powerful stabilising effect of this gel network. 
Compound 2 also enabled the crystallisation of unusual Type A solvates. 
Crystallisation from ethyl acetate solutions of compound 2 at drug concentrations of 
2 and 5 % w/v presented new route to a known Type A structure. Whereas, a new 
Type A solvate was crystallised from the same mixture, at a lower drug concentration 
of 1 % w/v. This novel Type A solvate can also be accessed from solutions of 
compound 2 in toluene, at a 1 % w/v concentration of mexiletine. In these experiments, 
the mixture did not form a gel, which suggests that interactions between the drug and 
gelator inhibited the self-assembly of gel fibres. It is likely that these interactions are 
responsible for the changes in polymorphism observed in these experiments. These 
results demonstrate the versatile ability of drug-mimetic supramolecular gels to 
achieve solid-from modification of an API. Finally, two additional solvated 
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polymorphs of mexiletine were crystallised from solutions in 1,2,4-trichlorobenzene 
and nitrobenzene, which further highlights the prolific solvate-forming behaviour of 
this compound. A crystal structure of the Type C trichlorobenzene solvate showed that 
it is another channel solvate, which suggests that there may be more modifications of 
this polymorph to be found. 
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4. Supramolecular Gelation as the First Stage in 
Ostwald’s Rule 
4.1  Introduction 
Throughout many decades of research into the mechanism and applications of 
crystallisation, a range of empirical rules have emerged, acting as general guidelines 
to predict and characterise the result of a crystallisation process.1 A notable example 
is Ostwald’s rule of stages, which refers to the observation that a kinetically favoured, 
metastable polymorph will often crystallise from solution before the form that is most 
thermodynamically stable under the same conditions.2 The classic example is 
benzamide, in which the least stable form, orthorhombic Form II, is initially produced 
by crash cooling, followed by the monoclinic Form III, and finally, the most stable 
form, monoclinic Form I.3 Because nucleation is the critical step in a crystallisation 
process, and is kinetically controlled, the crystallisation progresses towards 
equilibrium via a series of kinetically favoured, metastable polymorphs. Traditionally, 
this rule has been applied to purely crystalline systems, but recent work suggests that 
the formation of supramolecular materials can also follow Ostwald’s rule.4 It is 
therefore plausible that the rule holds true for the breakdown of other supramolecular 
systems, such as low molecular weight gels.  
Formation of a small-molecule supramolecular gel requires the organisation of 
molecules into a low-dimensional aggregate, such as a fibril5 or scrolled sheet.6 This 
behaviour is most commonly displayed by molecules whose non-covalent interactions 
are strongest in one direction,5 such as ureas or amides, which provide strong 
directional NH···O=C hydrogen bonds.7, 8 It is well known that gelation and 
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crystallisation are two closely related self-assembly processes.9 Although this 
relationship is not sufficiently well understood to allow the rational design of a 
molecule that will preferentially gel or crystallise, work is underway in this area. 
Theoretical and computational studies have probed the stability relationships between 
gels and crystals,10, 11 and empirical studies on gels that gradually form microcrystals 
have probed systems sitting right on the boundary between gelation and 
crystallisation.12-14 In some cases, crystals have been observed to grow directly from 
the gel. Despite originally being thought of as extremely rare, this phenomenon has 
recently been observed with increasing frequency, and within a chemically diverse 
range of both hydro- and organogels.15-22 Understanding this phenomenon, and the 
balance between gelation and crystallisation in general, is important because the 
ability to precisely control both of these processes would be extremely useful in 
chemical industry. For example, the antibiotic drug cefpiramide has been observed to 
form an organogel that is stable for several days before it breaks down and 
crystallises.23 This behaviour is by no means unique to this drug,24 and is highly 
undesirable for large-scale manufacturing because it reduces the time and cost 
efficiency of the process.   
Sterically hindered 2,4,5-triphenylimidazole (TPI) or, lophine, derivatives have 
classically been exploited for their luminescence properties, allowing them to be used 
as versatile analytical probes.25, 26 Similarly, lophine radicals have been shown to 
exhibit photo-, thermo-, and piezo-chromism through the formation of reversible 
dimers.27 These materials therefore lend themselves to application in display 
technologies and chemical or molecular switches.28-30 A previous study of a series of 
mono-halogenated 2,4,5-triphenylimidazole derivatives (Figure 4.1) showed that 
changing the halogen substituent in a single position has a significant effect on the 
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solid-state structure and properties of these materials.31 A key finding was the much 
more significant change in properties between the chloro- and bromo- derivatives, than 
between any other adjacent pair in the series. 
 
 
Figure 4.1: Structure of the mono-iodinated 2,4,5-triphenyl imidazole derivative (I-TPI). 
The crystal structures of all halogenated TPIs were based on hydrogen-bonded 
imidazole chains, which is the dominant motif observed in other imidazole 
derivatives.31-34 All TPIs formed methanol solvates, in which the solvent intercalates 
into the imidazole chains.31 Previous work characterised the methanol solvates of all 
halogenated TPI derivatives by powder X-ray diffraction (PXRD), and reported 
single-crystal structures for the fluoro- and bromo-TPI solvates. The layered structures 
of the two solvates were closely related, but there was a shift in the layers with the 
larger bromine substituent. Two anhydrous polymorphs of each TPI derivative were 
also characterised by PXRD, and for the methanol solvates, the desolvated form 
showed no structural similarity to the solvate.  
This work reports the supramolecular gelation behaviour of the I-TPI analogue in 
methanol. Whilst imidazole functionalities have been incorporated into gelators 
before,35-38 they are rarely the functional group solely responsible for gelation. 
Imidazole derivatives typically prefer to crystallise, often forming NH···N hydrogen 
bonds between molecules.34 In the case of I-TPI, gelation is most likely driven by the 
unidirectional hydrogen bonds between imidazole groups, coupled with weaker 
interactions perpendicular to the hydrogen-bonded chains, caused by the peripheral 
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aromatic rings and the large size of the halogen substituent. The I-TPI gel 
spontaneously crystallised, forming a series of distinct polymorphs, one after the other. 
This study presents a detailed investigation of the solid-form landscape of I-TPI, 
probing the delicate balance between gelation and crystallisation. It appears that this 
system behaves as an unusual example of Ostwald’s rule of stages. 
4.2  Characteristics of the I-TPI Gel 
The gelation behaviour of I-TPI was first noted in methanol, in which a stable and 
optically transparent gel is formed from a supersaturated solution, when heated to 
65 °C and left cool under ambient conditions for ten minutes (Figure 4.2a). The gel is 
thermoreversible, meaning it will dissolve when heated and reform when cooled a 
second time. However, it is not thixotropic and will not reform after being broken 
down by mechanical stress. SEM images of the dried xerogel demonstrate an unusual 
morphology, composed of short aggregates with dimensions ca. 0.5 x 0.05 μm, which 
explains why the gel is transparent in visible light (Figure 4.2b).  
 
Figure 4.2: (a) Photograph of a 2% w/v I-TPI gel, showing its optical transparency. (b) SEM 
micrograph of a xerogel prepared from a 2% w/v gel of I-TPI in methanol. Sample was coated in 
2 nm platinum. 
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The blocky morphology in the I-TPI gel differs considerably from the long 
intertwined fibres typical of a supramolecular gel,39, 40 but it is possible this may be 
artefact from drying the native gel.41, 42 Because this gel was known to crystallise, a 
series of SEM images were recorded at different magnifications to confirm that the 
gel morphology was consistent throughout the sample (Figure 4.3a,b,c), and that it 
differed from that of a crystal (Figure 4.3d,e). Whilst the gel morphology does differ 
significantly from that of a macroscopic crystal, its blocky appearance suggests some 
degree of crystallinity. It is possible that the very early stages of the gel to crystal 
transition occurred during the drying process, leading to this unusual morphology. 
(a) (b) (c) 
 
 
 
 
 
 
 
Figure 4.3: SEM images of a xerogel prepared from a 2% w/v gel of I-TPI in methanol. Images a-c 
show the sample at different magnifications, to confirm that the morphology was consistent. Images d 
and e compare the morphologies of a gel and a crystal, to confirm they are noticeably different 
(crystals are highlighted in white). Samples were coated in 2nm platinum. 
(d) (e) 
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The gelation behaviour of I-TPI was tested in a wide range of solvents. A 2% w/v 
solution of I-TPI in the test solvent was heated to the boiling point of the solvent in a 
sealed glass vial, left to cool to room temperature, and monitored for gelation or crystal 
growth. Of the 47 solvents tested, gelation was only observed in methanol, over a 
small range of concentrations. By cooling under ambient conditions, the critical 
gelling concentration (CGC) in methanol, determined by the inversion test, is 1.9% 
w/v, but this can be reduced to 1.25% w/v by sonication or crash cooling in ice, in 
which cases the gel forms in a reduced time of five minutes (Table 4.1). This finding 
fits well with the hypothesis that the gel is favoured by Ostwald’s rule.  
Table 4.1: Gel screening results of I-TPI in methanol. G = gel, PG = partial gel (part of the sample has 
gelled, but part remains in solution), S= solution. Critical gelation concentrations are shaded. 
 
Oscillatory rheology probes the mechanical properties of the gel. Frequency sweep 
data from a 2% w/v gel show the storage modulus to be approximately one order of 
magnitude greater than the loss modulus, demonstrating the elastic behaviour 
characteristic of a gel (Figure 4.4).43 The yield stress of the gel, used to quantify its 
strength, can be estimated from stress sweep rheology as the oscillation stress at which 
the storage and loss moduli are equal. In the case of a 2% w/v I-TPI gel, a yield stress 
Concentration / 
mg mL-1 
Concentration 
/ mol dm-3 
Concentration 
/% (w/v) 
Result from 
Cooling 
Result from 
Sonication 
20 0.047 2 G G 
19 0.045 1.9 G G 
18 0.043 1.8 S G 
17 0.040 1.7 S G 
16 0.038 1.6 S G 
15 0.036 1.5 S G 
12.5 0.030 1.25 S PG 
10 0.024 1 S S 
7.5 0.017 0.75 S S 
5 0.012 0.5 S S 
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of ca. 300 Pa proves the material to be quite robust44 and as expected, the 1.9 % w/v 
gel is slightly weaker, with a yield stress of ca. 200 Pa (Figure 4.4) 
 
Figure 4.4: Oscillatory frequency (top) and stress (bottom) sweeps for 2 and 1.9 % w/v gels of I-TPI 
in methanol. Gels were formed and measurements taken at 10 °C. Error bars indicate the standard 
deviation from repeated measurements. 
Gelation was observed over a much wider range of concentrations by cooling the 
solution to 0 °C, and all of these materials also displayed the elastic behaviour 
characteristic of a supramolecular gel (Figure 4.5). Gels formed at 0 °C were stronger 
than gels of the same concentration that were formed at 10 °C. The yield stress of a 2 
% w/v I-TPI gel increased from ca. 300 Pa when formed at 10 °C to ca. 1000 Pa when 
formed at 0 °C, most likely caused by the precipitation of more gel fibres due to the 
increased supersaturation at a lower temperature. 
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Figure 4.5: Oscillatory frequency (top) and stress (bottom) sweep data for gels of 2-1.6% w/v I-TPI in 
methanol. Gels were formed and measurements taken at 0°C. Error bars indicate the standard 
deviation from repeated measurements.  
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If stored, the I-TPI gel breaks down yielding large, block-shaped single crystals 
(Figure 4.6). The length of time taken for this crystallisation to occur varies due to the 
inconsistent nature of the nucleation process, however general trends can be 
established depending on the storage conditions of the gel. If left undisturbed and at a 
constant temperature, some gels were stable for several months, whilst crystallisation 
occurred more commonly between one day and two weeks. The effect could be 
accelerated to occur between five minutes and three hours through any kind of 
mechanical agitation of the gel, including shaking, cutting, stirring or an oscillatory 
rheology experiment. The more the gel was disrupted, the more quickly it crystallised. 
The crystals forming reproducibly were identified by single-crystal X-ray diffraction 
as a 1:1 methanol solvate termed Form SI, in which the “S” denotes that the structure 
is a solvate. 
 
Figure 4.6: Crystals of Form SI of I-TPI. 
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4.3  Incorporating Crystallisation Additives 
Based on a large body of previous work into additive-mediated crystallisation,45-47 
the crystallisation behaviour of the I-TPI gel was investigated further, by incorporating 
a chemically diverse range of additives. Previous studies have shown that 
crystallisation additives can have a variety of different effects, notably including 
suppression of the kinetically stable forms favoured by Ostwald’s rule, to promote the 
production of a desired thermodynamic polymorph.48-51 The additives used in this 
study were 1,4-diiodobenzene, pyrene, 1-aminopyrene and tetrabutylammonium 
(TBA) chloride (Table 4.2), as they have a variety of potential modes of interaction 
with the gelator, that could lead to the suppression of the kinetically favoured gel 
phase.52 For solid additives, gels were prepared by dissolving the required additive at 
concentrations ranging from 0.4–8 % w/v in a 2 % w/v solution of I-TPI in methanol, 
before cooling to room temperature. Gelation of solvent mixtures was also 
investigated, with methanol mixtures containing between 1-14 % v/v of hexane, water 
or DMSO (Table 4.3). 
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Table 4.2: Results of gel testing incorporating solid additives. G = gel, PG = partial gel, S = solution, I = insoluble, C = crystals, - = experiment not performed 
 
 
 
 
 
 
 
Table 4.3: Results of gel testing using solvent mixtures. G = gel, PG = partial gel, S = solution, I = insoluble, C = crystals, - = experiment not performed 
 
 
 
Additive 1,4-diiodobenzene Pyrene 1-aminopyrene TBA Chloride 
 Mass / mg mmol Result mmol Result mmol Result mmol Result 
2 0.006 G 0.010 G 0.009 G - - 
5 0.015 G 0.025 G 0.023 G - - 
10 0.030 PG 0.049 C then G 0.046 G 0.007 G 
15 0.061 I - - - - - - 
20 0.006 G 0.099 C then G 0.092 G 0.018 G 
25 - - 0.124 - 0.115 G 0.036 G 
30 - - 0.148 - 0.138 PG 0.072 G 
40 - - 0.198 - 0.184 S 0.090 G 
Additive Hexane Water DMSO 
Volume / μL mmol Result mmol Result mmol Result 
5 0.038 G 0.277 G 0.070 G 
10 0.076 G 0.555 G 0.141 G 
20 0.153 G 1.110 G 0.282 G 
30 0.229 - 1.665 G 0.422 - 
40 0.306 - 2.220 G 0.563 - 
50 0.382 G 2.775 I 0.704 G 
60 0.459 I 3.330 - 0.845 PG 
70 0.535 I 3.885 - 0.986 S 
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In all additive-containing gels, except those including TBA chloride, crystallisation 
was observed within the intact gel over the course of one hour to one week, depending 
on the nature of the additive. These crystals were large plates; a noticeably different 
morphology to the block-shaped crystals of Form SI (Figure 4.7a).  
 
Figure 4.7: (a) crystals of Form SII grown within a gel containing 5 μL of DMSO, (b) the concomitant 
crystallisation of Forms SI, SII and SIV from a gel containing 10 mg of 1,4-diiodobenzene. 
Single-crystal X-ray diffraction was used to characterise a crystal from eighteen 
different gels and in every case except one, the crystals were identified as a second 1:1 
methanol solvate, Form SII. The exceptional case occurred when 1,4-diiodobenzene 
was incorporated into the gel, which caused concomitant crystallisation of Forms SI, 
SII and a further unidentified form termed Form SIV (Figure 4.7b). In addition to the 
incorporation of additives, the growth of Form SII crystals within the gel could be also 
triggered by forming the gel very quickly in ice, which increases the supersaturation 
of the solution. Or, by repeatedly heating and reforming the material, which ensures 
all seeds and nucleation sites for Form SI are removed and allows Form SII to grow. 
This behaviour points towards the metastable character of Form SII, as per Ostwald’s 
rule. 
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All gels in which Form SII crystallised broke down over a time period ranging from 
one hour to three days after crystal formation, which was much quicker than the pure 
2% w/v material. The dissolution of these gels was likely caused by the incorporation 
of gelator molecules into the crystals, causing the solution concentration to drop below 
the critical point required for gelation. Following the breakdown of the gel, crystals of 
Form SII consistently transformed into Form SI, either within the mother liquor or 
when removed and stored under ambient conditions. These observations imply that 
Form SI is more stable than Form SII.  
Rheological characterisation of gels containing DMSO, hexane and TBA chloride 
allowed the effect of these additives or mixed media to be quantified. DMSO and 
hexane were selected for more detailed analysis because they have opposite effects on 
the solubility of the gelator and should therefore represent two extremes of 
behaviour.53 Increasing the concentration of DMSO in the solvent mixture from 2 to 
6 % v/v caused a decrease in elastic and viscous moduli, Gʹ and Gʹʹ respectively, and 
a decrease in yield stress (Figure 4.8). This behaviour is consistent with the increasing 
solubility of the gelator in the DMSO-containing solvent mixture, which inhibits the 
formation of solid-like gel fibres.  
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Figure 4.8: Oscillatory frequency (top) and stress (bottom) sweeps for 2% w/v I-TPI gels in methanol 
containing 2%, 4% and 6% v/v DMSO. Gels were formed and measurements taken at 10 °C. Error 
bars indicate the standard deviation from repeated measurements. 
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Increasing the concentration of hexane in the solvent mixture from 2 to 6 % v/v 
produced little variation in shear moduli, but an increase in yield stress (Figure 4.9). 
Due to the low solubility of I-TPI in hexane, this gel crystallised on the timescale of a 
rheology experiment (ca. two hours). One possible explanation of this rheological 
behaviour may be the formation of solid particles within the gel, as small crystallites 
begin to grow.54  
 
Figure 4.9: Oscillatory frequency (top) and stress (bottom) sweeps for 2% w/v I-TPI gels in methanol 
containing 2%, 4% and 6% v/v hexane. Gels were formed and measurements taken at 10 °C. Error 
bars indicate the standard deviation from repeated measurements. 
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TBA chloride-containing gels were selected for rheological characterisation 
because the addition of anions has typically been shown to disrupt gelation,55-58 but 
the opposite seemed to be true in this case. The chloride-containing I-TPI gels 
remained stable for much longer than any other gel tested and at sufficient chloride 
concentration, were not observed to crystallise at all. A decreasing yield stress was 
observed as the concentration of TBA chloride was increased from 2 to 6 % w/v. This 
behaviour is consistent with a high concentration of anions disrupting the hydrogen-
bonded network as previously reported.55-58 However, in this case, there was no 
significant effect on the shear moduli with increasing concentration of chloride (Figure 
4.10). 
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Figure 4.10: Oscillatory frequency (top) and stress (bottom) sweeps for 2% w/v I-TPI gels in 
methanol containing 2%, 4% and 6% w/v TBA chloride. Gels were formed and measurements taken 
at 10 °C. Error bars indicate the standard deviation from repeated measurements. 
Regardless of the concentration of additive, the inclusion of DMSO, hexane or TBA 
chloride all produced a small but reproducible trend towards higher shear moduli and 
yield stress than the pure gelator in methanol. A representative example is shown in 
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Figure 4.11, comparing the 2% w/v pure I-TPI gel in methanol, to gels containing 2% 
w/v I-TPI and either 2% w/v TBA chloride or, 2% v/v hexane or DMSO.  
 
Figure 4.11: Oscillatory frequency (top) and stress (bottom) sweeps for 2% w/v I-TPI gels in 
methanol containing either 2% w/v TBA chloride or 2% v/v DMSO or hexane, compared to the pure 
2% w/v gel in methanol. Gels were formed and measurements taken at 10 °C. Error bars indicate the 
standard deviation from repeated measurements. 
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I-TPI is insoluble in hexane, and therefore, the increase in strength of this gel is 
likely due to the formation of more gel fibres, because the solution is more 
supersaturated. DMSO can accept multiple hydrogen bonds and may form lateral links 
between gel fibres, causing greater entanglement of the gel network and increasing its 
strength relative to the pure material; a phenomenon commonly observed when 
polymers or surfactants are incorporated into supramolecular gels.59-62 Finally, the 
incorporation of anions into supramolecular gels has been reported to have both 
strengthening63-65 and weakening effects,55-58 depending on the gelator in question. 
This anion-tuning behaviour has commonly been observed in urea-based gelators and 
has been attributed to the anions either promoting63, 64 or disrupting55-58 formation of 
the urea-tape motif that is responsible for gelation in these materials. One notably 
different example concerns the anion-triggered gelation of a calix[4]arene derivative, 
rationalised using the Hofmeister series.65 In the I-TPI gel, the chloride ions may cause 
a salting out effect,66, 67 prompting the formation of more gel fibres and strengthening 
the gel.  
A qualitative assessment, carried out by observing all the additive-containing gels 
over time, showed that the rate of formation of Form SII crystals within the gels is 
affected by the chemical nature of the additive. Gels of solvent mixtures containing 
DMSO crystallised much more slowly, over a minimum of two days, than those 
containing hexane and water, in which Form SII grew within three hours. This trend 
is to be expected given the high solubility of I-TPI in polar organic solvents. 
Hydrogen-bonding additives noticeably slowed the rate of crystallisation, as did the 
incorporation of TBA chloride. The chloride-containing gels were particularly stable 
and did not crystallise throughout the entire duration of this work, or about a year. 
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4.4  Crystal Structures of I-TPI 
Further investigation into the crystallisation behaviour of I-TPI led to the discovery 
of three more solid forms, in addition to the three solvates SI, SII and SIV obtained 
from the gel phase. Despite several attempts, a full structure of Form SIV could not be 
obtained due to poor crystal quality. However, the unit cell volume is consistent with 
a methanol monosolvate,68 and the cell dimensions also match closely with the other 
three solvates, which adds weight to this hypothesis. When paper fibres were 
serendipitously included into a 2% w/v solution of I-TPI in methanol, gelation was 
inhibited, and large single crystals grew on the fibres. These were identified by single-
crystal X-ray diffraction as a third methanol solvate polymorph, Form SIII. Attempts 
to reproduce this form have been repeatedly unsuccessful, despite the incorporation of 
a wide range of solid particles to the gel, including paper fibres, microcrystalline 
cellulose, silica gel, and PVA beads. These difficulties suggest that Form SIII has an 
extremely high energy barrier to nucleation or is highly metastable, immediately 
converting to or outgrown by a more stable polymorph.69  
High-temperature crystallisations aimed to produce the anhydrous forms identified 
by PXRD in previous work.31 Two non-solvated forms, Forms V and VI, were 
successfully identified and fully characterised by single-crystal X-ray diffraction. 
Form V was crystallised from pure methanol at 50 °C, a condition under which the gel 
did not form, even at sufficient concentration. Whereas, Form VI was produced by 
sublimation, a technique that was used to investigate the crystallisation behaviour of 
I-TPI in the absence of methanol. Selected crystallographic data for the six crystal 
forms of I-TPI identified in this work are given in Table 4.4 and the full information 
can be found in Appendix 7.2.  
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Table 4.4: Selected crystallographic data for the novel polymorphs of I-TPI  
Crystal Form Form SI Form SII Form SIII Form SIV Form V Form VI 
Space group P21/c P21/c P21 Unit cell only P21 P1 
a/Å 12.662(9) 6.086(4) 14.668(12) 6.209(5) 8.922(7) 8.901(8) 
b/Å 12.608(11) 11.591(8) 12.091(10) 13.991(8) 32.728(2) 11.904(11) 
c/Å 12.750(10) 27.260(16) 17.388(14) 22.072(25) 11.912(9) 33.334(3) 
α/° 90 90 90 103.790(3) 90 81.404(3) 
β/° 109.050(19) 92.094(19) 110.237(3) 92.300(5) 94.579(3) 82.994(3) 
γ/° 90 90 90 91.350(4) 90 85.467(3) 
V/Å3 1923.9(3) 1921.5(2) 2893.5(4) 1910.0(3) 3467.0(5) 3459.5(5) 
Z 4 4 6  8 8 
ρcalc /g cm-3 1.568 1.570 1.564  1.618 1.621 
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The crystal structures of imidazole derivatives are typically characterised by chains 
of imidazole units, connected by NH···N hydrogen bonds.31, 34 This arrangement is 
observed in both anhydrous polymorphs of I-TPI, Forms V and VI (Figure 4.12). 
 
Figure 4.12: Hydrogen-bonded chains in Forms V and VI of I-TPI. 
For both structures V and VI, there are four independent molecules per asymmetric 
unit and there are four different NH···N hydrogen bonds in each structure. The average 
N···N distance in both forms is 2.9 Å, which is typical for a substituted imidazole.70 
In I-TPI, steric interactions between the bulky phenyl substituents cause the imidazole 
rings to twist out of plane with each other, as was observed in other sterically hindered 
lophine derivatives.34 Both structures have a high Zʹ of 4, which suggests some degree 
of awkwardness in their packing. A significant correlation has been found between 
Zʹ> 1 “parent” phases and solvate or co-crystal formation, which may explain the 
prevalence of solvates in this system.71, 72 
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Although the basic packing motif of both anhydrous polymorphs are essentially the 
same, the stacking of these motifs shows a subtle difference (Figure 4.13).  
 
Figure 4.13: Packing arrangement of Form V crystal structure, and schematic representations of Form 
V and VI,  all viewed along the crystallographic a axis. The red dotted overlay in the schematic of 
Form VI represents the deviation in packing observed in Form V. 
Both crystal forms display layered packing when viewed along the crystallographic 
a-axis. The layers contain the typical hydrogen-bonded chains, in which two are 
packed together to form strands stabilised by π-stacking of the iodo-phenyl moieties. 
In Figure 4.13, each double strand is represented by a rhomboid to simplify the 
stacking of the crystal structure. This schematic representation shows that a shift in 
the layers occurs in Form VI compared to Form V, due to the different symmetry of 
the two crystal forms. In Form V the layers are related through the 21-screw axis 
resulting in the monoclinic cell of the crystal structure, whereas Form VI shows only 
the inversion centre of the triclinic space group P1ത. The latter results in a larger shift 
of every third layer against the first when compared to Form V. These small 
differences in the packing arrangement of polymorphs has been shown for other 
pharmaceutical compounds such as aspirin73, or larger supramolecular assemblies 
such as calix[4]arene.74 
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Forms SI–SIII are discrete-site solvates containing 1:1 I-TPI and methanol. In these 
materials, methanol molecules are incorporated into the imidazole chains, linked by 
O-H···N and N-H···O hydrogen bonds (Figure 4.14). The same arrangement has 
previously been reported for other halogenated TPI derivatives.31 
 
Figure 4.14: Hydrogen-bonded chains in forms SI, SII and SIII of I-TPI. 
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The formation of solvates from alcohols and water is known in sterically hindered 
imidazole derivatives, as the incorporation of solvent allows a greater distance 
between molecules.34 The large aromatic substituents in I-TPI cause the imidazole 
rings to deviate from co-planarity with one another, as observed in the anhydrous form. 
In this case, however, the deviation is much greater. Similarly, the I-TPI molecules in 
the solvated forms adopt an alternating arrangement, in which equivalent substituents 
are positioned on opposite sides of the chain, further decreasing steric interactions. 
The stability relationship between these polymorphs can be deduced from the 
conditions under which they form. Following formation of the gel, under the correct 
conditions, crystals of Form SII appear first, without disturbing the gel phase. When 
the gel breaks down, these crystals transform spontaneously into Form SI, which 
according to Ostwald’s rule, implies that Form SI is more stable than Form SII. Form 
SI can also crystallise directly from the gel phase, concomitant with the gel’s break-
down, bypassing the formation of Form SII. Crystals of Form SIII also transform into 
Form SI over time, but despite several attempts, could not be re-grown for thermal 
analysis. The difficulty encountered in re-growing this form, and the fact that it 
requires heterogeneous nucleation, both imply that it is highly metastable.75 Given that 
the packing motif of Form SIII is similar to the other methanol solvates (Figure 4.14), 
it may represent another step in the sequential crystallisation of the I-TPI gel. The high 
Zʹ of 3 and the metastability of this structure suggest it may appear early on in the 
sequence and rapidly transform into a more stable polymorph, which is consistent with 
the difficulty encountered in reproducing this form.   
  
208 
 
To further probe this stability order, the total packing energy of each form was 
calculated from its crystal structure, using the UNI intermolecular interactions tool in 
Mercury, an empirical force field calculation.76, 77 The calculated energies are given in 
Table 4.5, and correlate with the stability of each crystal form, assuming entropic 
effects are approximately equal. 
Table 4.5: Calculated total packing energies of Forms I-V of I-TPI 
 
These results show that Form SI has the lowest packing energy of the three solvates, 
which is to be expected given that it is the most thermodynamically stable under 
ambient conditions. Form SII has a higher energy than Form SIII, which is the opposite 
trend to what would be expected based on the crystallisation observations. However, 
since both crystal structures have higher R-values, these results will have to be taken 
with care. Form SII has the highest density of the three solvates, which is unusual 
given its observed metastability, and following the rule of density, suggests that this 
crystal form is the most stable of all three methanol solvates at absolute zero.78 It is 
possible that forms SI and SII undergo an enantiotropic transition at lower 
temperatures. The two anhydrous polymorphs, Forms V and VI, have very similar 
packing energies, which is to be expected, given their extremely close structural 
similarity.  
  
 Form SI Form SII Form SIII Form V Form VI 
Total Packing  
Energy / kJ mol-1 
-229.1 -222.8 -225.0 -189.5 -190.0 
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Relationships between the solvated and anhydrous forms were characterised by 
DSC (Figure 4.15).  
 
Figure 4.15: DSC thermograms of Forms SI, SII, V and VI. Peak onset temperatures are as follows: 
Form SI desolvation 93.95 °C, melt 268.82 °C; Form SII desolvation 78.25 °C, melt 269.04 °C; Form 
V melt 269.17 °C; Form VI melt 268.79 °C. 
The DSC thermograms of Forms SI and SII, the two solvates that were stable 
enough to analyse, show desolvation peaks at 91 °C and 77 °C, respectively. These 
desolvation temperatures are much greater than the boiling point of methanol (64 °C), 
which shows that the solvent is strongly bound into the crystal structure. The structure 
of the desolvated form was characterised using PXRD, by heating a sample of Forms 
SI and SII above their transition temperatures. Both experiments showed the presence 
of Form V after desolvation (Figure 4.16). DSC thermograms of Forms SI, SII, and 
Form V all contain a melting endotherm at 269 °C. The DSC thermograms of Form 
VI and Form V show no reproducible thermal event before the melting point at 269 ˚C. 
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Figure 4.16: Experimental PXRD patterns of Forms I and II after their phase transitions, compared to 
the calculated patterns of Forms IV and V (top), showing that both forms transform into Form IV 
after desolvation (bottom). The legends show the temperature each sample was heated to. 
The ability of the gel to nucleate the metastable Form SII suggests a small energetic 
difference, and a potential structural similarity, between the crystal structure of Form 
SII and the gel fibre.79 Given the importance of one-dimensional intermolecular 
interactions in supramolecular gelation,5 it is likely that the alternating methanol/I-TPI 
chains comprise the building blocks of gel fibres. Kinetic restrictions on packing 
molecules orthogonal to these chains promote one-dimensional fibre formation over 
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three-dimensional crystallisation on a short timescale, leading to the formation of a 
supramolecular gel. The powder X-ray diffraction pattern of the dried xerogel is most 
similar to the calculated pattern of Form SI (Figure 4.17).  
 
 
Figure 4.17: Experimental PXRD patterns of the dried I-TPI xerogel, compared with calculated 
patterns of metastable methanol solvates, Forms SI–SIII. 
This is to be expected, as the gel was left to dry overnight, which allowed time for 
the metastable gel fibres to begin the transformation into Form SI. However, there are 
several additional peaks that do not correspond to any known form and suggest that 
the xerogel does not share its structure with any of the known methanol solvates. The 
unique structure of the gel is consistent with its role as the first step in the 
crystallisation regime of I-TPI. 
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4.5  Pharmaceutical Crystallisation 
The ability of the I-TPI gel to selectively crystallise a metastable polymorph of a 
methanol solvate suggests that this property may also be applied to other substrates, 
and hence that the material may be applicable as a medium for the controlled 
crystallisation of pharmaceuticals. To investigate this suggestion, diatrizoic acid, 
DTA, was crystallised within the I-TPI gel (Figure 4.18).  
 
 
 
Figure 4.18: Structure of diatrizoic acid (DTA).  
Recent work shows that polymorph control can be achieved by matching the 
structure of a supramolecular gelator to that of the target drug.79 Whilst there are some 
structural similarities between DTA and I-TPI, including the iodo- substituent and 
anti-parallel arrangement of hydrogen bond donor and acceptor groups, I-TPI could 
not be classed as a “drug-mimicking” gelator.  
Previous studies of DTA have resulted in the discovery of two hydrates, nine 
solvates and three anhydrous polymorphs.41 The strongest intermolecular interaction 
in all the crystal structures involves the carboxylic acid.80 Most commonly, a hydrogen 
bond is donated to the solvent in an interaction found to be stronger than the halogen 
bonds in this system. These interactions mirror that of I-TPI, in which hydrogen 
bonding is dominant. Matching the principal supramolecular motifs of the gelator and 
drug substrate should further reinforce interactions between the two, in order to 
facilitate control of solid form.  
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Various concentrations of DTA, ranging from 1–5 % w/v, were incorporated into a 
2 % w/v I-TPI gel in methanol, according to Table 4.6. 
Table 4.6: Results of gelation screening of mixtures containing 2 % w/v I-TPI in methanol, and 
varying concentrations of diatrizoic acid (DTA). G = gel, C = crystals. 
Mass of DTA / mg Amount of DTA / mmol Result 
10 0.016 G then C 
15 0.024 G then C 
20 0.033 G then C 
25 0.041 G then C 
30 0.049 G then C 
35 0.057 C 
40 0.065 C 
45 0.073 C 
50 0.081 C 
 
The DTA-containing samples were all found to crystallise in a stepwise manner, 
forming two distinct crystal habits, over a similar timescale to the crystallisation of the 
pure I-TPI gel. First, all samples grew clusters of small, white needles over the course 
of one hour to one day. Samples with a higher drug concentration crystallised faster, 
and those above 3% w/v no longer exhibited gelation but crystallised immediately 
from solution. If left for a time ranging from four days to two weeks, the gel broke 
down and these needles were replaced by transparent, block-shaped single crystals 
(Figure 4.19). This transformation occurred for every concentration of DTA but once 
again, the rate of the change was faster for gels with a higher drug loading.  
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Figure 4.19: (a) Small needle-like crystals initially grown within a 2 % w/v I-TPI gel containing 2% 
w/v DTA. (b) Block-like single crystals formed after break-down of the same gel. 
Attempts to determine the single-crystal structure or PXRD pattern of the needle-
like crystals resulted in amorphous background, and it is possible that these crystals 
are either too small to show diffraction or that they amorphise when removed from the 
gel. Solution-state 1H NMR spectroscopy showed that these crystals contain a 2:1 ratio 
of I-TPI and DTA. However, due to the fast exchange of the carboxylate proton, it is 
not possible to determine by this method whether the structure is a salt or a co-crystal. 
Solid-state 13C NMR confirmed the presence of both DTA and I-TPI, and also proved 
that the structure contains methanol, and is therefore another solvate. To confirm that 
the sample was not simply a mixture of pure crystals of DTA and I-TPI, the IR 
spectrum was measured and compared to those of the two components. The spectrum 
of the needles was different to both pure compounds, and was not a sum of the two, 
which proves that they are a distinct crystalline form containing DTA, I-TPI, and 
methanol (Figure 4.20). 
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Figure 4.20: IR spectra of pure I-TPI, pure DTA and the needle shaped co-crystals 
Formation of the needle-shaped crystals occurred over a few hours to one day, and 
was accompanied by breakdown of the gel, due to the incorporation of gelator 
molecules into the crystals. Rheological characterisation of the DTA-containing gels 
was not possible, due to the fast formation of crystallites under the experimental 
conditions, which subsequently caused the gel to break down. The larger, block-
shaped crystals were more stable and were identified by single-crystal X-ray 
diffraction as a salt solvate, in which the asymmetric unit contains one molecule of a 
deprotonated DTA anion, one molecule of a protonated I-TPI cation, and two 
methanol molecules. Whilst this structure contains the same molecules as the needles, 
the stoichiometry is different. Selected crystallographic information for this structure 
can be found in Table 4.7 and the full information can be found in Appendix 7.2. 
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Table 4.7: Selected crystallographic data for the salt solvate containing I-TPI and DTA. 
Crystal Form TPI-DTA Salt Solvate 
Space group P1ത 
a/Å 9.700(5) 
b/Å 12.806(6) 
c/Å 15.467(8) 
α/° 73.556(2) 
β/° 80.454(2) 
γ/° 82.492(2) 
V/Å3 1810.0(16) 
Z 4 
ρcalc /g cm-3 2.019 
 
The drug and gelator form hydrogen-bonded chains with an alternating sequence: 
I-TPI, methanol, DTA (Figure 4.21a). Unlike the I-TPI solvates, these chains are 
connected via hydrogen bonds from the methanol in one chain to the carboxylate group 
of the DTA anion in an adjacent chain (Figure 4.21b). The multiple hydrogen-bonding 
groups in DTA facilitate the formation of stacks of DTA molecules orthogonal to the 
alternating chains. (Figure 4.22a). This stacking prompts the organisation of I-TPI and 
DTA into discrete layers (Figure 4.22b). This crystal structure demonstrates the 
formation of a hydrogen bonded network between I-TPI, DTA and methanol, 
reinforcing the assumption that structural similarity between drug and gelator 
encourages them to interact.  
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Figure 4.21: (a) Hydrogen-bonded chains in the I-TPI/DTA/MeOH salt solvate. (b) The hydrogen 
bonding motif between chains in the I-TPI/DTA/MeOH salt solvate. The black circles in both 
diagrams show points at which the carbonyl oxygen from DTA forms hydrogen bonds between 
adjacent chains, linking them together. In diagram (b) the red dashed lines show hydrogen bonds 
within a chain and the blue dashed lines show hydrogen bonds between chains.  
 
Figure 4.22: (a) Hydrogen-bonded stacks of DTA molecules (b) Layered packing pattern of the salt 
solvate structure. 
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There have been numerous recent examples of pharmaceutical polymorph-control 
techniques in which a gelator selectively nucleates a known solid form, or facilitates 
the crystallisation of a new one.55, 79, 81-84 In this case, however, a series of solid forms 
are produced, in order of increasing thermodynamic stability, obeying Ostwald’s rule 
of stages and mirroring the crystallisation regime of the gelator itself. Gels that can 
stabilise a metastable polymorph of their gelator may therefore represent a new avenue 
in the field of pharmaceutical crystallisation, in line with recent suggestions that the 
function of a supramolecular system is defined more by its energy landscape than by 
the chemical structure of its components.85 
4.6  Conclusions 
In conclusion, the supramolecular gelation behaviour of a mono-iodinated 2,4,5-
triphenyl imidazole derivative was observed at high concentrations in methanol, 
driven by the formation of hydrogen-bonded chains of imidazole and methanol. Steric 
interactions between peripheral groups mean that whilst the gel is thermodynamically 
metastable, it is the most kinetically accessible state in the system. Gelation therefore 
occurs first, followed by a stepwise crystallisation forming three increasingly stable 
methanol solvates. Thus, the supramolecular gel can be considered the first stage in 
the crystallisation regime of the gelator, as described by Ostwald’s rule of stages. The 
incorporation of a pharmaceutical drug within the gel produces a similar stepwise 
crystallisation, yielding two increasingly stable solid forms of a drug-gelator salt. This 
behaviour highlights the possibility of using other gelators that crystallise as a 
metastable crystal form within the gel network, as a crystallisation medium to access 
metastable pharmaceutical polymorphs. 
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5. Experimental 
5.1  Materials  
All solvents and reagents were purchased from standard commercial sources and 
used without further purification. 
5.2  Instrumentation for the Characterisation of Pharmaceutical 
 Solid Forms 
Powder X-Ray Diffraction, PXRD 
Powder X-ray diffraction, PXRD, was performed using either a Bruker D8 or 
PANalytical Empyrean powder X-ray diffractometer in Bragg-Brentano geometry. 
Samples were mounted on a silicon single-crystal wafer and analysed using Cu-Kα 
radiation at a wavelength of 1.5406 Å. X-rays were produced using an operating 
voltage of 40 kV and current of 40 mA. Samples were scanned over an angle range of 
2-40° 2θ, with a step size of 0.02 ° and a scan rate between 0.5-1.5 s/step.  
Single-Crystal X-Ray Diffraction 
Ambient pressure X-ray single-crystal data were collected using one of two 
methods: 
1. At a temperature of 120 K, using Mo Kα radiation (λ =0.71073Å), on a Bruker 
D8 Venture diffractometer (Photon100 CMOS detector, IμS-microsource, 
focusing mirrors) equipped with a Cryostream 700+ (Oxford Cryosystems) 
open-flow nitrogen cryostat. Single crystals were coated in perfluoro polyether 
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oil, mounted on a MiTeGen sample holder and placed directly into the 
precooled cryostream.  
2. At a temperature of 100 K, on a Rigaku Saturn 724+ diffractometer at station 
I19 of the Diamond Light Source synchrotron (undulator, λ = 0.6889 Å, ω-
scan, 1.0°/frame).  
High-pressure X-ray single-crystal data were obtained by in situ compression of 
crystals grown at ambient pressure, in a Merrill–Bassett diamond anvil cell (DAC), 
using Fluorinert™ FC-70 as an inert pressure transmitting fluid. A 0.25 mm thickness 
steel gasket, pre-indented to 0.15 mm, with a precision drilled 300 µm hole created 
the sample chamber between the two diamond anvils, of culet size 0.8 mm. A ruby 
chip was included in the sample chamber for pressure determination, using the R1 ruby 
fluorescence method.1 The DAC was directly attached to a goniometer head and 
mounted onto a XIPHOS II2, 3 diffractometer, a custom-built four circle Huber 
diffractometer with an Ag-Kα IμS4 generator and APEXII CCD detector, located at 
Newcastle University. 
The data were  processed using Bruker APEXII software, the structure was solved 
by direct methods and refined by full-matrix least squares on F2 against all data using 
Olex25 and SHELXTL6 software. All non-hydrogen atoms were refined 
anisotropically, hydrogen atoms in structures were placed in the calculated positions 
and refined in riding mode.  
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Infra-red Spectroscopy 
Fourier transform infra-red spectroscopy (FTIR) was carried out using either a 
Perkin Elmer Spectrum 2 or a Perkin Elmer Spectrum 100 spectrometer, fitted with a 
diamond universal Attenuated Total Reflectance (ATR) accessory. Four scans were 
collected for each sample at a resolution of 2 cm-1 over a wavenumber region of 4000 
cm-1 to 600 cm-1. 
Thermogravimetric Analysis, TGA 
Thermogravimetric analysis, TGA, was carried out using a TA Instruments Q 500 
TGA analyser. Between 1 and 5 mg of sample was weighed into platinum pans and 
dry nitrogen was used as the purge gas (flow rate: 60 mL min-1). 
Differential Scanning Calorimetry, DSC 
Differential scanning calorimetry, DSC, was performed using either a TA 
Instruments Q2000 calorimeter or a Perkin Elmer 8500 calorimeter, both calibrated 
using an indium standard (melting point onset = 156.6 °C, heat of fusion = 28.57 J 
g−1). Between 1 and 3 mg of sample was weighed accurately (±0.01 mg) using a 
Sartorius microbalance into sealed aluminium pans and dry nitrogen was used as the 
purge gas (flow rate: 50 mL min−1).  
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Solid-State Nuclear Magnetic Resonance Spectroscopy, SS NMR 
Solid-state 13C NMR spectra were obtained at 100.63 MHz using a Bruker Avance 
III HD spectrometer and a 4 mm (rotor outside diameter) magic-angle spinning probe. 
They were recorded using one of two methods: 
1. Cross polarisation with TOSS spinning sideband suppression with a 1-7 s 
recycle delay, 1-7 ms contact time, at a spin rate of 8 kHz and a temperature of 
10 or 20 °C, depending on the stability of the sample. 
2. Direct excitation with proton decoupling with a 1-7 recycle delay, at a spin rate 
of 8 kHz and a temperature of 10 or 20 °C, depending on the stability of the 
sample. 
Spectral referencing was with respect to external, neat tetramethylsilane, carried 
out by setting the high-frequency signal from adamantane to 38.5 ppm. 
5.3  Instrumentation for the Structural Characterisation of Gels 
 and Gelators 
Nuclear Magnetic Resonance Spectroscopy, NMR 
Solution-state NMR spectra were recorded in DMSO-D6 or CDCl3, without an 
internal reference, using either a Bruker Avance III-HD-400 spectrometer with 
operating frequencies of 399.95 MHz for 1H and 100.57 MHz for 13C, a Bruker Neo-
400 spectrometer with operating frequencies of 400.20 MHz for 1H, and 100.63 MHz 
for 13C, or a Varian VNMRS-600 spectrometer with operating frequencies 
of 599.42 MHz for 1H and 150.72 MHz for 13C. 
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Mass Spectrometry 
Liquid chromatography mass spectrometry was carried out using a Waters SQD 
mass spectrometer and Acquity UPLC, equipped with an Acquity UPLC BEH C18 1.7 
µm (2.1 mm x 50 mm) column. Samples were prepared as dilute solutions 
(<1 mg mL-1) in either methanol or acetonitrile and the mobile phase was either water 
containing formic acid (0.1 %v /v):methanol or water containing formic acid 
(0.1 % v/v):acetonitrile, eluted at a flow rate at 0.6 mL min-1. A solvent gradient was 
used, changing from 95 % water and 5 % organic solvent to 5 % water and 95 % 
organic solvent over 4.5 minutes.  
 Elemental Analysis 
Elemental analysis was performed using an Exeter CE-440 Elemental Analyser. 
Oscillatory Rheometry 
Oscillatory rheometry measurements were performed using a TA Instruments AR 
2000, on a rough Peltier plate, with a 25 mm rough plate geometry and 2.5 mm gap. 
Samples were prepared by heating gelator solutions to the boiling point of the solvent 
in sealed 7 cm3 vials. The hot solutions were then poured into a 25 mm cylindrical 
glass mould on the Peltier plate, which was set to maintain a temperature of either 10 
or 0 °C throughout formation and analysis of the gels, in order to minimise evaporation 
of the solvent. The gels were allowed to form over 30 minutes prior to analysis, after 
which time the mould was removed. Frequency sweep experiments were performed 
with a constant applied stress of 1 Pa, and stress sweep experiments with a constant 
frequency of 1 Hz. 
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Scanning Electron Microscopy, SEM 
SEM samples were prepared on silicon wafers, dried in air for 2 days, and coated 
with either 2 nm of platinum using a Cressington 328 Ultra High Resolution EM 
Coating System, or 7 nm of gold-palladium using a Cressington 108 Auto Sputter 
Coater. The images were obtained using either an FEI Helios NanoLab DualBeam 
microscope or a Zeiss Sigma 300 VP microscope. 
5.4  Chapter 2: The Polymorphism of Mexiletine Hydrochloride 
Detailed Crystallisation Procedures 
Solvent crystallisations were carried out using one of five methods: 
1. Slow cooling: Approximately 20 mg of mexiletine hydrochloride was 
weighed into a small glass vial. Sufficient solvent was added to dissolve the 
material when heated to boiling using a heat gun. The sealed vial was left 
to cool in an insulating wooden block under ambient conditions and 
monitored for crystallisation. 
2. Fast cooling: Approximately 20 mg of mexiletine hydrochloride was 
weighed into a small glass vial. Sufficient solvent was added to dissolve the 
material when heated to boiling using a heat gun. The sealed vial was cooled 
quickly in an ice bath and monitored for crystallisation. 
3. Evaporation: Approximately 20 mg of mexiletine hydrochloride was 
weighed into a small glass vial. Sufficient solvent was added to dissolve the 
material without heating. The vial was left open on the bench to evaporate 
under ambient conditions and monitored for crystallisation. 
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4. Precipitation: Approximately 20 mg of mexiletine hydrochloride was 
weighed into a large glass vial. Sufficient solvent was added to dissolve the 
material without heating. A miscible anti-solvent (either hexane or diethyl 
ether) was gradually added to the vial until small crystallites were visible. 
The vial was then sealed, left to stand under ambient conditions, and 
monitored for crystallisation. 
5. Vapour Diffusion: Approximately 20 mg of mexiletine hydrochloride was 
weighed into a small glass vial. Sufficient solvent was added to dissolve the 
material without heating. The small vial was left unsealed and placed into a 
larger vial containing a miscible anti-solvent (a range of alkanes and ethers 
were used). The large vial was then sealed, and the system was left to stand 
under ambient conditions and monitored for crystallisation. 
Sublimation crystallisation was carried out using a microscope hot-stage. A small 
amount of mexiletine hydrochloride powder was placed on a microscope slide, 
surrounded by a small O-ring and covered with a glass cover slip. The system was 
heated using the hot-stage to 150 °C, at which point small crystallites began to appear 
on the cover slip. The temperature was held constant for 7 hours before being allowed 
to cool to room temperature and the long, needle-shaped crystals could be collected 
from the cover slip (Figure 5.1). 
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Figure 5.1: (a) Experimental set up for sublimation crystallisation, (b) single crystals of Form 2 of 
mexiletine hydrochloride grown by sublimation. 
PolySNAP Clustering Procedure 
Before the PXRD patterns were compared by the software, the backgrounds were 
removed, and the intensities normalised. The area between 30 and 40 ° was masked in 
all patterns because it contained only low intensity data that decreased the accuracy of 
the clustering calculation. A horizontal shift was permitted in each pattern, to allow 
for the variation in unit cell dimensions between different modifications of same 
solvate.  
CSD-Materials Packing Similarity Calculation 
This method is based on the programme COMPACK,7 which generates a small 
cluster of molecules, as a representation of the whole crystal structure. The cluster is 
based on a central molecule and a specified number of its nearest neighbours. Clusters 
representing the two target crystal structures are then compared, first by searching for 
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a match for the central molecule, and then by expanding the search to include its 
nearest neighbours. The two clusters are superimposed to maximise the number of 
overlapping molecules, within a defined set of tolerances. This calculation yields a 
root mean square deviation for the atomic positions in the two structures, which can 
be used to determine whether the two crystal structures represent the same polymorph. 
Based on previous literature, a group of 20 molecules were compared, using the 
standard tolerances of 20% on all distances, and 20 ° on the angles.8 This comparison 
excluded the smallest components of the crystal structures, which removed any solvent 
molecules from the solvates, and ensured that only the drug structures were bring 
compared.   
Crystal Structure Prediction 
First, one mexiletine cation conformer was extracted from the single-crystal 
structure of Form 1 of the hydrochloride salt, its geometry was optimised at the 
B3LYP-D3/6-31G** level of theory, and atomic CHELPG charges were calculated 
using GAUSSIAN09.9 The AZ-FF force-field10 was then generated and applied to 
produce a number of potential racemic crystal structures of the chloride salt, in the 20 
most common space groups, using the GRACE machinery.11, 12 The 1000 most stable 
crystal structures were then fully re-optimized and ranked in terms of their relative 
energies, using dispersion-corrected density functional theory, specifically the PBE 
functional13 with Neumann-Perrin dispersion.10, 11 
  
233 
 
5.5  Chapter 3: Tailored Supramolecular Gelators for the 
 Crystallisation of Mexiletine Hydrochloride 
Synthesis and characterisation of bis(3,5-diethyl-4-isocyanatophenyl)methane 
 
Bis(3,5-diethyl-4-isocyanatophenyl)methane was synthesised according to the 
literature method.14 A solution of di-tert-butyl dicarbonate (6.00 g, 34.4 mmol) in dry 
acetonitrile (20 mL) was slowly added to a solution of 4-DMAP (0.33 g, 2.70 mmol) 
in dry acetonitrile under a flow of nitrogen. A solution of 4,4'-methylenebis(2,6-
diethylaniline) (4.00 g, 12.9 mmol) in dry acetonitrile (20 mL) was slowly added to 
the previous solution and the resulting mixture was stirred for 2 hours at room 
temperature under nitrogen. Concentrated H2SO4 (2 mL) was slowly added to 
acetonitrile (3 mL), this solution was added to the reaction mixture and stirred for 5 
minutes. The reaction was quenched with water (65 mL) and the solution was 
extracted with hexane (4 × 100 mL). The combined hexane extracts were dried over 
MgSO4, filtered and the solvent was removed under vacuum. The crude product was 
dissolved in DCM (20 mL) and the solution was filtered to remove any solid 
impurities. The solvent was removed under vacuum, to yield bis(3,5-diethyl-4-
isocyanatophenyl)methane as a white solid (1.59 g, 4.39 mmol, 34 %). This compound 
was used without further purification, for the synthesis of compound 1. The 
characterisation data for this compound were consistent with previous literature.14  
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1H NMR (CDCl3, 400 MHz): δ 6.91 (s, 4H, b), 3.90 (s, 2H, a), 2.70 (q, J = 7.6 Hz, 8H, 
c), 1.26 (t, J = 7.6 Hz, 12H, d). 
13C{1H}or NMR (CDCl3, 101 MHz): δ 138.93 (C=O), 138.53 (ArC), 127.99 (ArC), 
126.97 (ArC), 123.81 (ArC), 41.15 (Ar-CH2-Ar), 25.73 (Ar-CH2-CH3), 14.27 (Ar-
CH2-CH3). 
m/z ESI-MS (MeCN): retention time 4.05 min 363.4 [M+H]+. The [M+H]+ peak is 
very low intensity and there are much larger peaks corresponding to the fragment 
molecule in which one isocyanate group has broken down to an amine: 337.4 [M+H]+. 
Synthesis and characterisation of Compound 1 
 
Racemic mexiletine hydrochloride (1.45 g, 6.7 mmol) was suspended in chloroform 
(100 mL) and dissolved upon the addition of excess triethylamine (1 mL). Bis(3,5-
diethyl-4-isocyanatophenyl)methane (1.00 g, 3.06 mmol) was added, and the solution 
was heated to reflux and stirred for 24 hours. The crude product was collected by 
filtration, suspended in water (100 mL) and sonicated for 10 minutes to remove water 
soluble impurities. The precipitate was collected by filtration, washed with water 
(100 mL) and chloroform (50 mL), and dried under vacuum to yield compound 1 as a 
white solid (1.90 g, 2.63 mmol, 86 %).  
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Compound 1 had limited solubility in all common NMR solvents. In cases where 
sufficient compound dissolved to produce a high-resolution 1H NMR spectrum, the 
sample gelled (Figure 5.2) and as a result, some multiplicity information was lost due 
to significant peak broadening. For these reasons, it was not possible to obtain a 
solution-state 13C NMR spectrum of this molecule, and CP MAS SS NMR was used 
instead.  
1H NMR (CDCl3, 400 MHz): 7.05-6.87 (m, 10H, b, k, l), 5.65 (s br, 2H, e), 4.78 
(apparent t, J = 7.6 Hz, 2H, f)†, 4.28-4.17 (m, 2H, g/HX), 3.92 (s, 2H, a), 3.72-3.60 (m, 
4H, i/HA,B), 2.61 (s br, 8H, c), 2.03 (apparent d, J = 4.3 Hz, 12H, j)†, 1.36 (apparent 
dd, J = 6.7, 5.1 Hz, 6H, h)†, 1.16 (t, J = 7.6 Hz, 12H, d).  
† Compound 1 was synthesised using a racemic starting material and the product is 
therefore a mixture of meso and rac diastereoisomers. As a result, peaks in the 1H 
NMR spectrum corresponding to environments ‘f’, ‘j’ and ‘h’ have a higher apparent 
multiplicity due to the overlapping of signals from each diastereoisomer.  
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Due to the lower resolution of solid-state NMR, many peaks in the 13C spectrum 
overlap, and the spectrum is also complicated by the presence of multiple 
diastereoisomers. Tentative peak assignments are given, based on the spectra of other 
mexiletine-terminated gelators.  
13C NMR (CP-MAS SS NMR, 101 MHz): 158.00 (C=O), 154.58 (ArC), 141.05 (ArC), 
132.58 (ArC), 130.81 (ArC), 129.78 (ArC), 127.81 (ArC), 125.89 (ArC), 123.91 
(ArC), 76.10 (Ar-O-CH2), 45.73 (NH-CH-CH3), 42.74 (Ar-CH2-Ar), 24.30 (AR-CH2-
CH3), 23.20 (O-Ar-CH3), 15.88 (NH-CH-CH3), 13.47 (Ar-CH2-CH3).  
m/z ESI-MS (MeCN): retention time 3.91 min, 721.7 [M+H]+. 
Elemental Analysis: Calc. (%): C 74.96, H 8.39, N 7.77; Found (%): C 74.74, H 8.32, 
N 7.69. 
 
Figure 5.2: A gelled NMR sample of compound 1 in CDCl3.  
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Synthesis and characterisation of Compound 2 
 
Racemic mexiletine hydrochloride (1.42 g, 6.6 mmol) was suspended in chloroform 
(80 mL) and dissolved upon the addition of excess triethylamine (1 mL). 1,3-Bis(1-
isocyanato-1-methylethyl)benzene (0.69 mL, 3 mmol) was added and the solution was 
stirred at room temperature for 24 hours. The solvent was removed under vacuum and 
the crude product was sonicated for 10 minutes in water (100 mL) and then acetonitrile 
(50 mL), to yield compound 2 as a white solid (1.31 g, 2.18 mmol, 73 %). 
 
1H NMR (DMSO-d6, 599 MHz): δ 7.33 – 7.29 (m, 1H, c), 7.17 – 7.10 (m, 3H, a, b), 
6.97 (d, J = 7.5 Hz, 4H, k), 6.87 (t, J = 7.5 Hz, 2H, l), 6.28 (s, 2H, e), 5.94 (d, J = 8.2 
Hz, 2H, f), 3.86 – 3.78 (m, 2H, g/HX)†, 3.58 (ABq, JAB = -9.5 Hz, JAX = 1.61 Hz, 2H, 
i/HA)†, 3.56 (ABq, JAB = -9.5, JBX = 0.2 Hz, 2H, i/HB)†, 2.19 (s, 12H, j), 1.48 (apparent 
t, J = 5.6 Hz, 12H, d)*, 1.19 (d, J = 6.7 Hz, 6H, h).  
† See Figure 5.3 for further details of the assignment of these peaks. 
*See Figure 5.4 for further details of the assignment of these peaks. 
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13C {1H} NMR (DMSO-d6, 151 MHz,) δ 157.00 (C7), 155.52 (C12), 148.86 (C2), 
130.80 (C11), 129.17 (C13), 127.69 (C1), 124.10 (C14), 122.77 (C3), 121.71 (C4), 
75.15 (C10), 54.72 (C5), 45.34 (C8), 30.67 (C6)*, 30.61 (C6)*, 30.52 (C6)*, 30.46 
(C6)*, 18.52 (C9), 16.32 (C15).  
*See Figure 5.4 for further details of the assignment of these peaks. 
m/z ESI-MS (MeCN): retention time 3.40 min, 603.9 [M+H]+, 1205.8 [2M+H]+. 
Elemental Analysis: Calc. (%): C 71.73, H 8.36, N 9.29; Found (%): C 71.32, H 8.24, 
N 9.29. 
Protons ‘i’ and ‘g’ make up an ABX system as shown in Figure 5.3. The signals 
corresponding to HA and HB (environment i) could be assigned as two AB quartets 
however, the difference in chemical shift between the two signals is very small, so the 
central peak overlaps, and the signal contains 7 lines instead of 8. The pure shift signal 
for protons ‘i’ is an apparent triplet, in which the central peak is an artefact that 
indicates strong coupling between the two geminal protons. The proton signal 
corresponding to HX (environment g) is further complicated by coupling to protons 
‘h’, so the multiplicity of this peak could not be assigned.  
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Figure 5.3: Section of the 1H NMR spectrum of compound 2 showing the ABX system: protons in 
environments ‘i’ and ‘g’ 
Compound 2 was synthesised using a racemic starting material and the product is 
therefore a mixture of meso and rac diastereoisomers. As a result, protons ‘d’ produce 
4 separate NMR signals: one from each methyl group in the two diastereoisomers. The 
two central peaks in this signal overlap, so the signal appears as a triplet in both the 
pure shift and 1H NMR spectra. Four distinct signals are however visible in the carbon 
spectrum of these methyl groups (Figure 5.4). 
 
Figure 5.4: Sections of the pure shift, 1H NMR and 13C NMR spectra of compound 2, corresponding 
to protons in environment ‘d’. 
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Synthesis and characterisation of Compound 3 
 
Racemic mexiletine hydrochloride (3.22 g, 13.2 mmol) was suspended in 
acetonitrile (200 mL) and dissolved upon the addition of excess triethylamine (5 mL). 
1,3,5-Benzenetricarbonyl trichloride (1.00 g, 3.77 mmol) was added, the reaction was 
heated to reflux and stirred for 24 hours. The solvent was removed under vacuum and 
the crude product was dissolved in DCM (300 mL), washed with water (3 x 200 mL) 
and recrystallised from THF/diethyl ether to yield compound 3 as a white solid (1.04g, 
1.5 mmol, 40 %). 
 
1H NMR (DMSO-d6, 599 MHz): δ 8.66 (d, J = 8.1 Hz, 3H, b), 8.44 (apparent d, J = 
3.2 Hz, 3H, a)†, 6.97 (d, J = 7.5 Hz, 6H, g), 6.87 (t, J = 7.5 Hz, 3H, h), 4.47 – 4.37 (m, 
3H, c)†, 3.81 – 3.71 (m, 6H, e)†, 2.18 (s, 18H, f), 1.34 (d, J = 6.9 Hz, 9H, d). 
† See Figure 5.5 for further details on the assignment of these peaks. 
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13C{1H} NMR (DMSO-d6, 151 MHz): δ 165.71 (C3)*, 165.69 (C3)*, 165.67 (C3)*, 
155.53 (C8), 135.49 (C2)*, 135.47 (C2)*, 130.74 (C7), 129.20 (C9), 129.16 (C1), 
124.18 (C10), 74.37 (C6), 46.08 (C4), 17.61 (C5), 16.33 (C11). 
* See Figure 5.6 for further details of the assignment of these peaks  
m/z ESI-MS (MeOH): retention time 4.18 min, 694.4 [M+H]+, 716.4 [M+Na]+, 732.3 
[M+K]+, 1409.7 [2M+Na]+, 1425.5 [2M+K]+. 
Elemental Analysis: Calc. (%): C 72.70, H 7.41, N 6.06; Found (%): C 72.28, H 7.31, 
N 5.95. 
Compound 3 was synthesised using a racemic starting material and the product is 
therefore a mixture of eight stereoisomers. Six of these are diastereoisomers that 
produce unique NMR signals. The presence of multiple diastereoisomers leads to 
overlapping signals in the pure shift spectrum and a higher apparent multiplicity of 
signals in the proton spectrum, such as the apparent doublet at 8.44 ppm corresponding 
to protons ‘a’ (Figure 5.5). Similarly, overlapping signals from multiple isomers mean 
that the ABX system, corresponding to protons ‘c’ and ‘e’, cannot be fully resolved. 
However, the typical pattern of repeating AB quartets can be observed in the multiplet 
at 3.81-3.71 ppm. The pure shift signal for the two geminal protons, ‘e’, also contains 
several artefact peaks that are indicate strong coupling between the two protons 
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(Figure 5.5). The presence of multiple diastereoisomers is also evident in the carbon 
spectrum, where there are multiple peaks corresponding to carbon environments 2 and 
3 (Figure 5.6).  
 
Figure 5.5: Sections of 1H and pure shift NMR spectra of compound 2 showing the effects of multiple 
stereoisomers on environments ‘a’, ‘c’ and ‘e’. 
 
Figure 5.6: Sections of the 13C NMR spectrum of compound 3 showing signals from environments 2 
and 3 in multiple diastereoisomers. 
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Detailed gel screening procedure 
The gelation behaviour of compounds 1, 2 and 3 were investigated in a wide range 
of solvents. A 2 % w/v solution was produced by dissolving 10 mg of the gelator in 
0.5 mL of the required solvent by heating the mixture with a heat gun, in a sealed glass 
vial. The solution was left to cool to room temperature in an insulating wooden block 
and was monitored visually for gelation and crystal growth.  
5.6  Chapter 5: Supramolecular Gelation as the First Stage in 
 Ostwald’s Rule 
Synthesis and characterisation of I-TPI 
 
I-TPI was synthesised according to the literature method.15 Benzil (0.42 g, 2 mmol), 
4-iodobenzaldehyde (0.46 g, 2 mmol) and ammonium acetate (1.54 g, 20 mmol) were 
suspended in acetic acid (10 mL) in a 20 mL microwave reaction vessel containing a 
PTFE stirrer bar. Using a microwave, the vessel was heated for 5 min at 180 °C and 
then allowed to cool to room temperature. The mixture was added dropwise to a 
concentrated ammonium hydroxide solution at 0 °C. The resulting white precipitate 
was collected, washed with water, and dried in an oven, yielding I-TPI as a white solid 
(844.5 mg, 92 %). Characterisation data from 1H NMR, 13C{1H} NMR spectroscopy 
and mass spectrometry conformed to the previous literature.16, 17  
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1H NMR (400 MHz, DMSO-d6) δ 12.78 (s, 1H, NH), 7.95 – 7.78 (m, 4H, ArH), 7.66 
– 7.04 (m, 11H, ArH).  
13C{1H} NMR (101 MHz, DMSO) δ 145.11, 137.95, 137.81, 135.47, 131.38, 130.31, 
129.13, 129.07, 128.89, 128.67, 128.33, 127.60, 127.56, 127.08, 94.89.  
m/z ESI-MS 423.2 [M+H]. 
Elemental Analysis: Calc. (%) C 59.73 H 3.58 N 6.63; Found (%) C 59.91 H 3.51 N 
6.75.  
Detailed gel screening procedure 
The gelation behaviour of I-TPI was investigated in a wide range of solvents. A 
2 % w/v solution was produced by combining 10 mg of I-TPI and 0.5 mL of methanol 
in a sealed glass vial and heating with a heat gun until the solid dissolved. The solution 
was left to cool to room temperature in an insulating wooden block and monitored 
visually for gelation and crystal growth.  
For gels containing solid additives, samples were prepared by combining 10 mg of 
I-TPI with the required mass of additive and dissolving in 0.5 mL methanol before 
cooling to room temperature. Gelation of solvent mixtures was also investigated, and 
in this case the 0.5 mL mixture contained mostly methanol, with 5-70 μL of another 
solvent. 
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6. Concluding Remarks 
6.1  Conclusion 
This work exemplifies a modern pharmaceutical polymorph screen; using novel 
crystallisation methods and analytical tools to capture a wider polymorph landscape 
than traditional, solution-phase screens. Two APIs were studied in this work: 
mexiletine hydrochloride, an anti-arrhythmic drug, which was reported to have six 
polymorphs in the literature1-4, and diatrizoic acid, an X-ray contrast agent, of which 
two hydrates, nine solvates and three anhydrous polymorphs have been reported to 
date.5  
First, a polymorph screen of mexiletine hydrochloride was carried out using 
traditional crystallisation methods including cooling, evaporation, anti-solvent 
precipitation and sublimation. Comparing the X-ray diffraction data for each form 
showed that there are actually seven solid forms of mexiletine: an enantiotropic pair 
of anhydrous polymorphs that are stable at different temperatures, one anhydrous 
metastable form, three families of isostructural channel solvates and one further 
solvate, which requires further study to fully understand its structure. Solid-state NMR 
was used to characterise the highly disordered solvent that was loosely bound within 
the channels, leading to the identification of eleven modifications of the Type A and 
B solvate families. Computational crystal structure prediction identified a low-energy, 
high-density predicted form, which may be accessible using high-pressure 
crystallography. When a single crystal of Form 2, which has the same molecular 
conformation as the predicted form, was compressed to 3.56 GPa, a novel unit cell 
was observed. Interestingly, this unit cell was different to the predicted form. These 
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results demonstrate the powerful combination of computational and experimental 
tools in determining the polymorph landscape of an API. 
Gel-phase crystallisation was used to further expand the polymorph screen of 
mexiletine hydrochloride. Three novel, drug-mimetic supramolecular gelators were 
synthesised by attaching the free base of the drug to a central gel-forming group. Once 
self-assembled, the surface of the gel fibres is functionalised with drug-mimetic units, 
to act as a template for the nucleation and growth of high-energy solid forms. 
Crystallisation within the two bis-urea gels led to significant changes in solid form, 
including new routes to known Forms 2, 3 and a Type A solvate, and the crystallisation 
of two new Type A solvates. Crystallisation within this gel is the only known route to 
crystallise the high temperature stable Form 2 at room temperature, which 
demonstrates the profound ability of this gel network to stabilise high-energy solid 
forms. In several cases, gelation was switched off when a change in polymorphism 
was observed, which suggests that strong interactions between the drug and gelator 
are a key driving force for the crystallisation of novel polymorphs in this system.6 
A second gel-phase crystallisation study showed that structural mimicry is not the 
only mechanism by which a gelator can interact with a drug molecule and influence 
the outcome of a crystallisation. When diatrizoic acid (DTA) was crystallised within 
an iodo-triphenyl imidazole (I-TPI) gel, two solid forms were produced, following the 
same two-step crystallisation process as the gelator itself. In accordance with 
Ostwald’s rule of stages, the gel formed first and then, a highly metastable solvate 
containing DTA and I-TPI grew within it. Over time, the gel broke down and the 
crystals transformed into a more stable salt solvate, also containing DTA and I-TPI. 
This pattern reflects the crystallisation behaviour of the gelator, in which a metastable 
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methanol solvate grows within the gel, and then transforms into a more stable 
methanol solvate after the gel has broken down. The spontaneous crystallisation of 
these gels suggests that supramolecular gelation should be considered an early stage 
in the crystallisation regime of the gelator, rather than an entirely separate process. 
The two-step crystallisation behaviour was transferred to the API, which suggests that 
the polymorph landscape of the gelator can influence the crystallising drug, and this 
may provide a new avenue of inquiry in the design of supramolecular gelators for gel-
phase crystallisation of pharmaceuticals. 
6.2  Further Work 
To expand the polymorph screen of mexiletine hydrochloride, further 
crystallisations should be carried out to record a higher precision crystal structure of a 
Type B solvate. This task proved extremely difficult due to the highly disordered 
solvent contained within the channels and the tendency of mexiletine to crystallise in 
a needle-like habit. To overcome these problems, a precise crystallisation procedure 
could be developed by calculating the solubility curve of mexiletine in a solvent 
known to form a Type B solvate, and using that data to ensure that all variables are 
tightly controlled, so that very few nuclei are produced and they are allowed to grow 
slowly into a high-quality single crystal. A programmable temperature controller such 
as the Polar Bear crystallisation reactor would be an ideal tool for this work.7 A 
single-crystal structure should also be collected of the Type D nitrobenzene solvate 
discussed in Chapter 3. Although this form is much easier to crystallise in high quality 
than the Type B solvates, the data collection will most likely require synchrotron 
radiation because it crystallises as small needles.  
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The mexiletine polymorph screen provides a template for further investigations into 
the polymorph landscape of this drug in unusual solvents and under non-ambient 
conditions. To extend this work, cooling, evaporation, and anti-solvent crystallisations 
should be carried out in the rest of the solvents that were used for gel screening. These 
results will act as a control for further gel-phase crystallisation experiments and are 
also likely to identify new polymorphs of mexiletine, given the extremely prolific 
solvate formation observed in this work. Particular attention should be paid to finding 
new members of the Type C and D solvate families, as there are likely to be more than 
the two forms identified in Chapter 3. Any new forms could be characterised and 
compared to the known forms, using the techniques described in Chapter 2. Further 
experiments should also be undertaken to understand the polymorphism of mexiletine 
at high pressure, to fully characterise the high-pressure form identified by a unit cell 
in this work, and to try and find the high-density form that was predicted 
computationally. As the high-pressure unit cell was not consistent with the predicted 
form, there is clearly a high potential for further work in this area, which may include 
compressing crystals of known forms, or recrystalising mexiletine from a solution at 
high pressure.8 
Further investigation into the gel-phase crystallisation of mexiletine hydrochloride 
would involve crystallisations within gels of the three gelators discussed in this work, 
in all remaining solvents. The design of new gelators should focus on bis-ureas 
because they displayed significantly more versatile gelation behaviour than the tris-
amide. The two linking groups used in this work are widely known to produce 
effective gelators and it would therefore be prudent to focus future efforts on 
developing new end groups. There have been several recent works describing drug 
mimetic end-groups9-11 and so new mechanisms of creating a drug-gel interaction 
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should also be considered. Gelators that bind the counterion of a pharmaceutical salt, 
instead of the drug itself, would be a key development in this area as the same gelator 
could interact with a large group of drugs, which would drastically increase the scope 
of this technique. Classical supramolecular chemistry such as ion binding12, 13 and 
supramolecular synthons14 should provide the basis for the design of these end-groups. 
To extend this work using mexiletine hydrochloride, a salt screen could be carried out 
to find other salt forms that might be easy targets for new gelators.  
As gelation was not discovered in any previous polymorph screens of other TPI 
derivatives,15 it is likely that the gelation of I-TPI is unique within this family of 
molecules and so further study of I-TPI as a gelator is not recommended. Instead, this 
study highlights the importance of understanding the polymorph landscape of new 
gelators. Further investigations are required to establish whether gelator 
polymorphism can be exploited to influence the crystallisation of a substrate within 
the gel, as observed with I-TPI. 
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7. Appendices 
7.1  Full crystallographic information for the novel polymorphs of 
 mexiletine hydrochloride 
Table 7.1: Crystallographic information for Form 2 of mexiletine hydrochloride. 
 
 
 
 
 
 
 
 
 
 
 
Crystallisation conditions Sublimation at 150 °C 
Empirical formula C11H18ClNO 
Formula weight 215.71 
Temperature/K 120 
Crystal system orthorhombic 
Space group Pccn 
a/Å 17.8741(14) 
b/Å 18.6782(15) 
c/Å 7.3464(7) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2452.6(4) 
Z 8 
ρcalc g/cm3 1.168 
μ /mm-1 0.283 
F(000) 928.0 
Crystal size/mm3 0.602 × 0.077 × 0.066 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.558 to 52.956 
Index ranges -22 ≤ h ≤ 22, -23 ≤ k ≤ 23, -9 ≤ l ≤ 9 
Reflections collected 39104 
Independent reflections 2530 [Rint = 0.1043, Rsigma = 0.0434] 
Data/restraints/parameters 2530/114/227 
Goodness-of-fit on F2 1.177 
Final R indexes [I>=2σ (I)] R1 = 0.0817, wR2 = 0.1617 
Final R indexes [all data] R1 = 0.1076, wR2 = 0.1712 
Largest diff. peak/hole / e Å-3 0.38/-0.25 
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Table 7.2: Crystallographic information for the Type A solvent-free form of mexiletine hydrochloride. 
Crystallisation conditions 
Slow cooling from a supersaturated 
solution in DCM 
Empirical formula C11H18ClNO 
Formula weight 215.71 
Temperature/K 100.0 
Crystal system orthorhombic 
Space group Pbcn 
a/Å 20.8570(2) 
b/Å 17.3783(18) 
c/Å 7.5648(8) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2741.9(5) 
Z 8 
ρcalc g/cm3 1.045 
μ /mm-1 0.234 
F(000) 928.0 
Crystal size/mm3 0.08 × 0.01 × 0.01 
Radiation synchrotron (λ = 0.6889) 
2Θ range for data collection/° 2.956 to 54.994 
Index ranges -27 ≤ h ≤ 27, -23 ≤ k ≤ 23, -10 ≤ l ≤ 10 
Reflections collected 22800 
Independent reflections 3462 [Rint = 0.1137, Rsigma = 0.1464] 
Data/restraints/parameters 3462/0/142 
Goodness-of-fit on F2 1.031 
Final R indexes [I>=2σ (I)] R1 = 0.0808, wR2 = 0.2112 
Final R indexes [all data] R1 = 0.1071, wR2 = 0.2346 
Largest diff. peak/hole / e Å-3 0.87/-0.22 
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Table 7.3: Crystallographic information for the Type A methanol solvate of mexiletine hydrochloride. 
Crystallisation conditions 
Slow cooling from a supersaturated 
solution in methanol 
Empirical formula C12H22ClNO2 
Formula weight 247.76 
Temperature/K 120.0 
Crystal system orthorhombic 
Space group Pbcn 
a/Å 20.2427(7) 
b/Å 18.7675(6) 
c/Å 7.5502(2) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2868.4(15) 
Z 8 
ρcalc g/cm3 1.147 
μ /mm-1 2.263 
F(000) 1072.0 
Crystal size/mm3 0.33 × 0.12 × 0.1 
Radiation CuKα (λ = 1.54178) 
2Θ range for data collection/° 6.42 to 144.98 
Index ranges -24 ≤ h ≤ 21, -23 ≤ k ≤ 23, -9 ≤ l ≤ 9 
Reflections collected 31273 
Independent reflections 2817 [Rint = 0.0300, Rsigma = 0.0141] 
Data/restraints/parameters 2817/0/150 
Goodness-of-fit on F2 1.072 
Final R indexes [I>=2σ (I)] R1 = 0.0357, wR2 = 0.0972 
Final R indexes [all data] R1 = 0.0385, wR2 = 0.0993 
Largest diff. peak/hole / e Å-3 0.41/-0.38 
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Table 7.4: Crystallographic information for the Type A diethyl ether solvate of mexiletine 
hydrochloride. 
  
Crystallisation conditions 
Vapour diffusion of diethyl ether into a 
saturated solution in DMF 
Empirical formula C11H18ClNO 
Formula weight 215.71 
Temperature/K 120 
Crystal system orthorhombic 
Space group Pbcn 
a/Å 21.125(2) 
b/Å 17.3581(16) 
c/Å 7.5625(7) 
α/° 90 
β/° 90 
γ/° 90 
Volume/Å3 2773.1(4) 
Z 8 
ρcalc g/cm3 1.033 
μ /mm-1 0.250 
F(000) 928.0 
Crystal size/mm3 0.286 × 0.149 × 0.075 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.694 to 50 
Index ranges -25 ≤ h ≤ 25, -20 ≤ k ≤ 20, -8 ≤ l ≤ 8 
Reflections collected 40312 
Independent reflections 2442 [Rint = 0.0562, Rsigma = 0.0269] 
Data/restraints/parameters 2442/0/146 
Goodness-of-fit on F2 1.112 
Final R indexes [I>=2σ (I)] R1 = 0.0397, wR2 = 0.0953 
Final R indexes [all data] R1 = 0.0514, wR2 = 0.1004 
Largest diff. peak/hole / e Å-3 0.21/-0.18 
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Table 7.5: Crystallographic information for the Type A octane solvates of mexiletine hydrochloride. 
Crystallisation conditions 
Vapour diffusion of octane 
into a saturated solution in 
1PrOH 
Vapour diffusion of octane 
into a saturated solution in 
2BuOH 
Empirical formula C11H18ClNO C11H18ClNO 
Formula weight 215.71 215.71 
Temperature/K 120 120 
Crystal system orthorhombic orthorhombic 
Space group Pbcn Pbcn 
a/Å 21.9358(13) 21.9241(14) 
b/Å 17.1061(10) 17.1098(11) 
c/Å 7.5214(5) 7.5198(5) 
α/° 90 90 
β/° 90 90 
γ/° 90 90 
Volume/Å3 2822.3(3) 2820.8(3) 
Z 8 8 
ρcalc g/cm3 1.015 1.016 
μ /mm-1 0.246 0.246 
F(000) 928.0 928.0 
Crystal size/mm3 0.579 × 0.164 × 0.091 0.474 × 0.136 × 0.074 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.762 to 56.56 4.762 to 53.998 
Index ranges 
-29 ≤ h ≤ 29, -22 ≤ k ≤ 22, -
10 ≤ l ≤ 10 
-28 ≤ h ≤ 28, -21 ≤ k ≤ 21, -
9 ≤ l ≤ 9 
Reflections collected 51696 35849 
Independent reflections 
3495 [Rint = 0.1460, 
Rsigma = 0.0701] 
3082 [Rint = 0.1071, 
Rsigma = 0.0548] 
Data/restraints/parameters 3495/0/131 3082/0/188 
Goodness-of-fit on F2 1.033 1.036 
Final R indexes [I>=2σ (I)] R1 = 0.0543, wR2 = 0.1222 R1 = 0.0458, wR2 = 0.0963 
Final R indexes [all data] R1 = 0.0864, wR2 = 0.1345 R1 = 0.0795, wR2 = 0.1079 
Largest diff. peak/hole / e Å-3 0.31/-0.28 0.22/-0.23 
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Table 7.6: Crystallographic information for the Type A hexane solvates of mexiletine hydrochloride. 
Crystallisation conditions 
Vapour diffusion of hexane 
into a saturated solution in 
2PrOH 
Vapour diffusion of hexane 
into a saturated solution in 
DCM 
Empirical formula C11H18ClNO C11H18ClNO 
Formula weight 215.71 215.71 
Temperature/K 120 120 
Crystal system orthorhombic orthorhombic 
Space group Pbcn Pbcn 
a/Å 21.8754(17) 21.4560(3) 
b/Å 17.2112(13) 17.3330(2) 
c/Å 7.5109(6) 7.5478(11) 
α/° 90 90 
β/° 90 90 
γ/° 90 90 
Volume/Å3 2827.9(4) 2807.0(7) 
Z 8 8 
ρcalc g/cm3 1.013 1.021 
μ /mm-1 0.246 0.247 
F(000) 928.0 928.0 
Crystal size/mm3 0.425 × 0.147 × 0.062 0.47 × 0.12 × 0.045 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.734 to 48.814 4.7 to 61.112 
Index ranges 
-25 ≤ h ≤ 25, -20 ≤ k ≤ 20, -
8 ≤ l ≤ 8 
-30 ≤ h ≤ 30, -24 ≤ k ≤ 24, -
10 ≤ l ≤ 10 
Reflections collected 39413 44762 
Independent reflections 
2331 [Rint = 0.1388, 
Rsigma = 0.0569] 
4298 [Rint = 0.1687, 
Rsigma = 0.1095] 
Data/restraints/parameters 2331/0/131 4298/0/131 
Goodness-of-fit on F2 1.059 1.034 
Final R indexes [I>=2σ (I)] R1 = 0.0468, wR2 = 0.1015 R1 = 0.0970, wR2 = 0.2423 
Final R indexes [all data] R1 = 0.0715, wR2 = 0.1098 R1 = 0.1721, wR2 = 0.2763 
Largest diff. peak/hole / e Å-3 0.27/-0.21 0.38/-0.64 
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Table 7.7: Crystallographic information for the Type C 1,2,4-trichlorobenzene solvate of mexiletine. 
Crystallisation conditions 
Slow cooling from a supersaturated 
solution in 1,2,4-trichlorobenzene 
Empirical formula C50H75Cl7N4O4 
Formula weight 1044.29 
Temperature/K 100.0 
Crystal system monoclinic 
Space group P21/c 
a/Å 7.538(3) 
b/Å 20.972(9) 
c/Å 18.043(8) 
α/° 90 
β/° 93.725(7) 
γ/° 90 
Volume/Å3 2846.0(2) 
Z 2 
ρcalc g/cm3 1.219 
μ /mm-1 0.362 
F(000) 1108.0 
Crystal size/mm3 0.14 × 0.015 × 0.005 
Radiation Synchrotron (λ = 0.6889) 
2Θ range for data collection/° 2.89 to 42.986 
Index ranges -8 ≤ h ≤ 8, -22 ≤ k ≤ 22, -19 ≤ l ≤ 19 
Reflections collected 20500 
Independent reflections 3584 [Rint = 0.1746, Rsigma = 0.2670] 
Data/restraints/parameters 3584/3/277 
Goodness-of-fit on F2 0.867 
Final R indexes [I>=2σ (I)] R1 = 0.0873, wR2 = 0.2208 
Final R indexes [all data] R1 = 0.1593, wR2 = 0.3023 
Largest diff. peak/hole / e Å-3 0.35/-0.20 
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Table 7.8: Crystallographic information for the co-crystal solvate containing mexiletine 
hydrochloride, iodine, and DCM. 
  
Crystallisation conditions 
Vapour diffusion of hexane into an equimolar 
solution of mexiletine and iodine in DCM 
Empirical formula C11.5H19Cl2INO 
Formula weight 385.08 
Temperature/K 120.0 
Crystal system triclinic 
Space group P-1 
a/Å 8.7220(9) 
b/Å 13.6572(14) 
c/Å 14.6845(14) 
α/° 70.816(4) 
β/° 76.280(4) 
γ/° 78.824(4) 
Volume/Å3 1592.1(3) 
Z 4 
ρcalc g/cm3 1.607 
μ /mm-1 2.332 
F(000) 760.0 
Crystal size/mm3 0.793 × 0.055 × 0.042 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.846 to 54.994 
Index ranges -11 ≤ h ≤ 11, -17 ≤ k ≤ 17, -19 ≤ l ≤ 19 
Reflections collected 29037 
Independent reflections 7310 [Rint = 0.1083, Rsigma = 0.1221] 
Data/restraints/parameters 7310/7/341 
Goodness-of-fit on F2 1.037 
Final R indexes [I>=2σ (I)] R1 = 0.0590, wR2 = 0.1378 
Final R indexes [all data] R1 = 0.1173, wR2 = 0.1575 
Largest diff. peak/hole / e Å-3 1.62/-1.61 
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7.2  Full crystallographic information for the novel polymorphs of 
I-TPI 
Table 7.9: Crystallographic information for Form SI of I-TPI. 
 
 
Crystallisation conditions 
Slow cooling from a supersaturated 
solution in methanol 
Empirical formula C22H19IN2O 
Formula weight 454.29 
Temperature/K 120 
Crystal system monoclinic 
Space group P21/c 
a/Å 12.6617(9) 
b/Å 12.6076(11) 
c/Å 12.7502(10) 
α/° 90 
β/° 109.050(19) 
γ/° 90 
Volume/Å3 1923.9(3) 
Z 4 
ρcalc g/cm3 1.568 
μ /mm-1 1.677 
F(000) 904.0 
Crystal size/mm3 0.325 × 0.316 × 0.224 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.676 to 51.996 
Index ranges -15 ≤ h ≤ 14, -15 ≤ k ≤ 15, -15 ≤ l ≤ 15 
Reflections collected 22392 
Independent reflections 3769 [Rint = 0.0459, Rsigma = 0.0299] 
Data/restraints/parameters 3769/0/237 
Goodness-of-fit on F2 1.075 
Final R indexes [I>=2σ (I)] R1 = 0.0244, wR2 = 0.0548 
Final R indexes [all data] R1 = 0.0351, wR2 = 0.0601 
Largest diff. peak/hole / e Å-3 0.53/-0.65 
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Table 7.10: Crystallographic information for Form SII of I-TPI. 
 
  
Crystallisation conditions 
Grown from a 2 % w/v gel of I-TPI 
in methanol 
Empirical formula C22H19IN2O 
Formula weight 454.29 
Temperature/K 120.0 
Crystal system monoclinic 
Space group P21/c 
a/Å 6.0855(4) 
b/Å 11.5907(8) 
c/Å 27.2602(16) 
α/° 90 
β/° 92.094(19) 
γ/° 90 
Volume/Å3 1921.5(2) 
Z 4 
ρcalc g/cm3 1.570 
μ /mm-1 1.679 
F(000) 904.0 
Crystal size/mm3 0.211 × 0.068 × 0.062 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.614 to 53.562 
Index ranges -7 ≤ h ≤ 7, -14 ≤ k ≤ 14, -34 ≤ l ≤ 34 
Reflections collected 27504 
Independent reflections 4115 [Rint = 0.0971, Rsigma = 0.0767] 
Data/restraints/parameters 4115/0/311 
Goodness-of-fit on F2 1.080 
Final R indexes [I>=2σ (I)] R1 = 0.0558, wR2 = 0.0817 
Final R indexes [all data] R1 = 0.1094, wR2 = 0.0940 
Largest diff. peak/hole / e Å-3 0.60/-0.89 
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Table 7.11: Crystallographic information for Form SIII of I-TPI. 
 
Crystallisation conditions 
A solution of 10 mg I-TPI, 10 μL H2O and 
0.49 mL MeOH, containing paper fibres as 
nucleation points was stored at room 
temperature in a sealed vial, for one week 
Empirical formula C22H19IN2O 
Formula weight 454.29 
Temperature/K 120.0 
Crystal system monoclinic 
Space group P21 
a/Å 14.6682(12) 
b/Å 12.0909(10) 
c/Å 17.3887(14) 
α/° 90 
β/° 110.237(3) 
γ/° 90 
Volume/Å3 2893.5(4) 
Z 6 
ρcalc g/cm3 1.564 
μ /mm-1 1.673 
F(000) 1356.0 
Crystal size/mm3 0.448 × 0.137 × 0.05 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.192 to 56 
Index ranges -19 ≤ h ≤ 19, -15 ≤ k ≤ 15, -22 ≤ l ≤ 22 
Reflections collected 52934 
Independent reflections 13959 [Rint = 0.1016, Rsigma = 0.1164] 
Data/restraints/parameters 13959/7/707 
Goodness-of-fit on F2 1.029 
Final R indexes [I>=2σ (I)] R1 = 0.0643, wR2 = 0.1294 
Final R indexes [all data] R1 = 0.1161, wR2 = 0.1459 
Largest diff. peak/hole / e Å-3 0.92/-0.95 
Flack parameter 0.04(3) 
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Table 7.12: Crystallographic information for Form V of I-TPI. 
 
Crystallisation conditions 
A solution of 10 mg I-TPI, 2 mg 1,4-
diiodobenzene and 0.5 ml methanol was 
stored in a sealed vial at 50 °C for one week 
Empirical formula C21H15IN2 
Formula weight 422.25 
Temperature/K 120.0 
Crystal system monoclinic 
Space group P21 
a/Å 8.9217(7) 
b/Å 32.728(2) 
c/Å 11.9118(9) 
α/° 90 
β/° 94.579(3) 
γ/° 90 
Volume/Å3 3467.0(5) 
Z 8 
ρcalc g/cm3 1.618 
μ /mm-1 1.851 
F(000) 1664.0 
Crystal size/mm3 0.585 × 0.19 × 0.146 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.238 to 57.998 
Index ranges -12 ≤ h ≤ 12, -44 ≤ k ≤ 44, -16 ≤ l ≤ 16 
Reflections collected 69654 
Independent reflections 18393 [Rint = 0.0656, Rsigma = 0.0630] 
Data/restraints/parameters 18393/73/866 
Goodness-of-fit on F2 1.048 
Final R indexes [I>=2σ (I)] R1 = 0.0546, wR2 = 0.1232 
Final R indexes [all data] R1 = 0.0667, wR2 = 0.1296 
Largest diff. peak/hole / e Å-3 1.27/-1.23 
Flack parameter 0.24(3) 
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Table 7.13: Crystallographic information for Form VI of I-TPI. 
 
 
Crystallisation conditions Sublimation at 250 °C 
Empirical formula C21H15IN2 
Formula weight 422.25 
Temperature/K 120 
Crystal system triclinic 
Space group P-1 
a/Å 8.9006(8) 
b/Å 11.9043(11) 
c/Å 33.334(3) 
α/° 81.404(3) 
β/° 82.994(3) 
γ/° 85.467(3) 
Volume/Å3 3459.5(5) 
Z 8 
ρcalc g/cm3 1.621 
μ /mm-1 1.855 
F(000) 1664.0 
Crystal size/mm3 0.979 × 0.078 × 0.058 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 3.97 to 58 
Index ranges -12 ≤ h ≤ 12, -16 ≤ k ≤ 16, -45 ≤ l ≤ 45 
Reflections collected 63290 
Independent reflections 18359 [Rint = 0.1075, Rsigma = 0.1339] 
Data/restraints/parameters 18359/21/866 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0785, wR2 = 0.1705 
Final R indexes [all data] R1 = 0.1333, wR2 = 0.1903 
Largest diff. peak/hole / e Å-3 5.24/-1.29 
